10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-33135

Regional Health Properties, Inc.

(Exact name of registrant as specified in its charter)

Georgia	81-5166048
(State or other jurisdiction of incorporation)	(I.R.S. Employer Identification Number)

1050 Crown Pointe Parkway, Suite 720 Atlanta GA 30338

(Address of principal executive offices)

(678) 869-5116

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	RHE	NYSE American
Series A Redeemable Preferred Stock, no par value	RHE-PA	NYSE American

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

As of November 14, 2023 the registrant had 1,883,028 shares of common stock, no par value, outstanding.

Regional Health Properties, Inc.

Form 10-Q

Table of Contents

		Page Number
Part I.	FINANCIAL INFORMATION
Item 1.	Financial Statements (unaudited)	3
	Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022	3
	Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022	4
	Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2023 and 2022	5
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022	6
	Notes to Unaudited Consolidated Financial Statements	8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	29
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	38
Item 4.	Controls and Procedures	38
Part II.	OTHER INFORMATION
Item 1.	Legal Proceedings	38
Item 1A.	Risk Factors	38
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	41
Item 3.	Defaults upon Senior Securities	41
Item 4.	Mine Safety Disclosures	41
Item 5.	Other Information	41
Item 6.	Exhibits	41
Signatures		44

2

Part I. Financial Information

Item 1. Financial Statements

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Amounts in 000's)

	September 30, 2023			December 31, 2022
	(Unaudited)
ASSETS
Property and equipment, net	$	45,806		$	46,611
Cash		1,427			843
Restricted cash		3,208			3,066
Accounts receivable, net of allowances of $1,579 and $1,298		2,035			6,289
Prepaid expenses and other		903			746
Notes receivable		1,060			1,099
Intangible assets - bed licenses		2,471			2,471
Intangible assets - lease rights, net		92			110
Right-of-use operating lease assets		2,588			2,848
Goodwill		1,585			1,585
Lease deposits and other deposits		4			—
Straight-line rent receivable		2,830			2,912
Total assets	$	64,009		$	68,580
LIABILITIES AND EQUITY
Senior debt, net	$	44,208		$	45,163
Bonds, net		5,989			6,120
Other debt, net		1,181			895
Accounts payable		2,783			3,293
Accrued expenses		4,806			5,036
Operating lease obligation		2,948			3,226
Other liabilities		1,707			1,131
Total liabilities		63,622			64,864
Stockholders' equity:
Common stock and additional paid-in capital, no par value; 55,000 shares authorized; 1,894 and 1,793 shares issued and 1,883 and 1,784 shares outstanding at September 30, 2023 and December 31, 2022, respectively		63,023			62,702
Preferred stock, no par value; 5,000 shares authorized (including amounts authorized for Series A and Series B); shares issued and outstanding designated as follows:
Preferred stock, Series A, no par value; 560 shares authorized, issued and outstanding at September 30, 2023, with a redemption amount $426 at September 30, 2023; 5,000 shares authorized, 2,812 shares issued and outstanding at December 31, 2022, with a redemption amount of $70,288		426			62,423
Preferred stock, Series B, no par value; 2,812 shares authorized; 2,252 shares issued and outstanding at September 30, 2023, with a redemption amount $18,602 at September 30, 2023; no shares authorized, issued and outstanding at December 31, 2022		18,602			—
Accumulated deficit		(81,664	)		(121,409	)
Total stockholders' equity		387			3,716
Total liabilities and stockholders' equity	$	64,009		$	68,580

See accompanying notes to unaudited consolidated financial statements.

3

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in 000's, except per share data)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Revenues:
Patient care revenues	$	2,136		$	7,769		$	6,577		$	14,650
Rental revenues		1,739			3,000			5,170			10,326
Management fees		263			255			788			774
Other revenues		—			6			107			20
Total revenues		4,138			11,030			12,642			25,770
Expenses:
Patient care expense		2,313			7,476			7,010			14,040
Facility rent expense		149			1,451			446			4,725
Cost of management fees		156			140			442			459
Depreciation and amortization		526			600			1,738			1,819
General and administrative expense		972			1,378			3,190			3,432
Doubtful accounts expense		229			1,515			269			3,742
Other operating expenses		197			441			511			1,409
Total expenses		4,542			13,001			13,606			29,626
Loss from operations		(404	)		(1,971	)		(964	)		(3,856	)
Other (income) expense:
Interest expense, net		708			564			2,066			1,855
Other (income) expense, net		(139	)		(2,164	)		620			(1,088	)
Total other (income) expense, net		569			(1,600	)		2,686			767
Net loss	$	(973	)	$	(371	)	$	(3,650	)	$	(4,623	)
Preferred stock dividends - undeclared		—			(2,249	)		—			(6,748	)
Preferred stock dividends - gain on extinguishment		—			—			43,395			—
Net profit (loss) attributable to Regional Health Properties, Inc. common stockholders	$	(973	)	$	(2,620	)	$	39,745		$	(11,371	)
Net profit (loss) per share of common stock attributable to Regional Health Properties, Inc.
Basic:	$	(0.52	)	$	(1.48	)	$	21.18		$	(6.40	)
Diluted:	$	(0.52	)	$	(1.48	)	$	21.18		$	(6.40	)
Weighted average shares of common stock outstanding:
Basic:		1,883,028			1,768,720			1,876,138			1,775,637
Diluted:		1,883,028			1,768,720			1,876,138			1,775,637

See accompanying notes to unaudited consolidated financial statements.

4

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Amounts in 000's)

(Unaudited)

	Shares of Common Stock Outstanding		Shares of Preferred Stock A			Shares of Preferred Stock B		Shares of Treasury Stock			Common stock and additional paid-in capital		Preferred stock A, no par value			Preferred stock B, no par value		Accumulated Deficit			Total
Balance, December 31, 2022		1,784		2,812			—		(9	)	$	62,702	$	62,423		$	—	$	(121,409	)	$	3,716
Restricted stock issuance		99		—			—		—			—		—			—		—			—
Stock-based compensation		—		—			—		—			81		—			—		—			81
Net loss		—		—			—		—			—		—			—		(1,992	)		(1,992	)
Balances, March 31, 2023		1,883		2,812			—		(9	)	$	62,783	$	62,423		$	—	$	(123,401	)	$	1,805
Extinguishment of Series A Preferred Stock				(2,252	)		—		—			—		(61,997	)		—		—			(61,997	)
Exchange of Series A to Series B		—		—			2,252		—			—		—			18,602		43,395			61,997
Stock-based compensation		—		—			—		—			155		—			—		—			155
Forfeitures of stock-based awards				—			—		(2	)		—		—			—		—			—
Net loss		—		—			—		—			—		—			—		(685	)		(685	)
Balances, June 30, 2023		1,883		560			2,252		(11	)	$	62,938	$	426		$	18,602	$	(80,691	)	$	1,275
Stock-based compensation		—		—			—		—			85		—			—		—			85
Net loss		—		—			—		—			—		—			—		(973	)		(973	)
Balances, September 30, 2023		1,883		560			2,252		(11	)	$	63,023	$	426		$	18,602	$	(81,664	)	$	387

	Shares of Common Stock Outstanding			Shares of Preferred Stock A		Shares of Preferred Stock B		Shares of Treasury Stock			Common Stock and Additional Paid-in Capital			Preferred stock A, no par value		Preferred stock B, no par value		Accumulated Deficit			Total
Balances, December 31, 2021		1,775			2,812		—		(1	)	$	62,515		$	62,423	$	—	$	(114,542	)	$	10,396
Restricted stock issuance		24			—		—		—			—			—		—		—			—
Stock-based compensation		—			—		—		—			111			—		—		—			111
Exercise of restricted share awards net settlement option		—			—		—		(8	)		(46	)		—		—		—			(46	)
Net loss		—			—		—		—			—			—		—		(2,927	)		(2,927	)
Balances, March 31, 2022		1,799			2,812		—		(9	)	$	62,580		$	62,423	$	—	$	(117,469	)	$	7,534
Forfeitures of stock-based awards		(30	)		—		—		—			4			—		—		—			4
Net loss		—			—		—		—			—			—		—		(1,325	)		(1,325	)
Balances, June 30, 2022		1,769			2,812		—		(9	)	$	62,584		$	62,423	$	—	$	(118,794	)	$	6,213
Stock-based compensation		—			—		—		—			58			—		—		—			58
Net loss		—			—		—		—			—			—		—		(371	)		(371	)
Balances, September 30, 2022		1,769			2,812		—		(9	)	$	62,642		$	62,423	$	—	$	(119,165	)	$	5,900

See accompanying notes to unaudited consolidated financial statements.

5

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in 000's)

(Unaudited)

	Nine Months Ended September 30,
	2023			2022
Cash flows from operating activities:
Net loss	$	(3,650	)	$	(4,623	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization		1,738			1,819
Stock-based compensation expense		321			173
Rent expense (less than) in excess of cash paid		(18	)		126
Rent revenue less than (in excess) of cash received		(298	)		(1,410	)
Amortization of deferred financing costs, debt discounts and premiums		56			67
Bad debt expense		269			3,742
Changes in operating assets and liabilities:
Accounts receivable		4,053			(4,349	)
Prepaid expenses and other assets		1,157			533
Lease deposits and other deposits		(4	)		—
Accounts payable and accrued expenses		(739	)		2,013
Other liabilities		575			(262	)
Net cash provided by (used in) operating activities		3,460			(2,171	)
Cash flows from investing activities:
Purchase of property and equipment		(916	)		(183	)
Net cash used in investing activities		(916	)		(183	)
Cash flows from financing activities:
Payment of senior debt		(988	)		(1,219	)
Payment of other debt		(813	)		(882	)
Debt extinguishment and issuance costs		(17	)		—
Proceeds from other debt		—			50
Repurchase of common stock		—			(46	)
Net cash used in financing activities		(1,818	)		(2,097	)
Net change in cash and restricted cash		726			(4,451	)
Cash and restricted cash, beginning		3,909			9,848
Cash and restricted cash, ending	$	4,635		$	5,397

6

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in 000's)

(Unaudited)

	Nine Months Ended September 30,
	2023		2022
Supplemental disclosure of cash flow information:
Cash interest paid	$	2,004	$	1,797
Supplemental disclosure of non-cash activities:
Vendor-financed insurance	$	962	$	1,078
Exchange of preferred stock Series A to Series B	$	18,602	$	—
Gain on extinguishment of preferred stock	$	43,395	$	—
Account receivable converted to note receivable	$	312	$	—

See accompanying notes to unaudited consolidated financial statements.

7

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

September 30, 2023

NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Regional Health Properties, Inc.'s (the "Company" or "Regional Health") predecessor was incorporated in Ohio on August 14, 1991, under the name Passport Retirement, Inc. In 1995, Passport Retirement, Inc. acquired substantially all of the assets and liabilities of AdCare Health Systems, Inc. and changed its name to AdCare Health Systems, Inc. ("AdCare"). AdCare completed its initial public offering in November 2006, relocated its executive offices and accounting operations to Georgia in 2012, and changed its state of incorporation from Ohio to Georgia in December 2013. Regional Health Properties, Inc. is a self-managed real estate investment company that invests primarily in real estate purposed for long-term care and senior housing. Our business primarily consists of leasing such facilities to third-party tenants, which operate the facilities. The Company has two primary reporting segments: (i) Real Estate Services, which consists of the leasing and subleasing of long-term care and senior living facilities to third-party tenants, including the Company's management of three facilities on behalf of third-party owners; and (ii) Healthcare Services, which consists of the operation of the Meadowood and Glenvue facilities. Effective August 3, 2023, the Company’s 12.5% Series B Cumulative Redeemable Preferred Shares (the “Series B Preferred Stock”) is quoted on the OTC Markets Group, Inc.’s OTCQB Venture Market under the symbol “RHEPB”.

Basis of Presentation

The accompanying consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles ("GAAP") in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"). The accompanying consolidated financial statements are unaudited and should be read in conjunction with the 2022 audited consolidated financial statements and notes thereto, which are included in our 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on April 14, 2023 ("Annual Report").

In the opinion of management, the unaudited consolidated financial statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company's financial position and the results of its operations and cash flows for such periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.

Reclassifications

Certain reclassifications have been made to the amounts in prior periods in order to conform to the current period's presentation. A reclassification has been made to the stock balances on the consolidated statement of stockholders’ equity in prior periods in order to conform to the current period's presentation.

Principles of Consolidations

The consolidated financial statements include the Company's majority owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated through consolidation.

Variable Interest Entities

The Company has a loan receivable with Peach Health, a sublessee. Such agreement creates a variable interest in the Peach Health sublessee that may absorb some or all of the expected losses of the entity. The Company does not consolidate the operating activities of the Peach Health sublessee as the Company does not have the power to direct the activities that most significantly impact the entity's economic performance.

8

Revenue Recognition and Allowances

Patient Care Revenue. ASC Topic 606, Revenue from Contracts with Customers requires a company to recognize revenue when the company transfers control of promised goods and services to a customer. Revenue is recognized in an amount that reflects the consideration to which a company expects to receive in exchange for such goods and services. Revenue from our Healthcare Services business segment is derived from services rendered to patients in the Meadowood and Glenvue facilities. The Company receives payments from the following sources for services rendered in our facilities: (i) the federal government under the Medicare program administered by the U.S. Department of Health and Human Services Centers for Medicare and Medicaid Services ("CMS"); (ii) state governments under their respective Medicaid and similar programs; (iii) commercial insurers; and (iv) individual patients and clients. The vast majority of the revenue the Company recognizes is from government sources. The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and other price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. The Company recognizes revenue at the amount that reflects the consideration the Company expects to receive in exchange for the services provided. These amounts are due from residents or third-party payors and include variable consideration for retroactive adjustments from estimated reimbursements, if any, under reimbursement programs. Performance obligations are determined based on the nature of the services provided. Revenue is recognized as performance obligations are satisfied. Estimated uncollectable amounts due from patients are generally considered implicit price concessions that are a direct reduction to net operating revenues.

Triple-Net Leased Properties. The Company recognizes rental revenue in accordance with ASC 842, Leases. The Company's triple-net leases provide for periodic and determinable increases in rent. The Company recognizes rental revenues under these leases on a straight-line basis over the applicable lease term when collectability is probable. Recognizing rental income on a straight-line basis generally results in recognized revenues during the first half of a lease term exceeding the cash amounts contractually due from our tenants, creating a straight-line rent receivable that is included in the straight-line rent receivable on our consolidated balance sheets. In the event the Company cannot reasonably estimate the future collection of rent from one or more tenant(s) of the Company's facilities, rental income for the affected facilities is recognized only upon cash collection, and any accumulated straight-line rent receivable is expensed in the period in which the Company deems rent collection to no longer be probable.

Management Fee Revenues and Other Revenues. The Company recognizes management fee revenues as services are provided. The Company has one contract to manage three facilities (the "Management Contract"), with payment for each month of service generally received in full on a monthly basis. The maximum penalty for service contract nonperformance under the Management Contract is $50,000 per year, payable after the end of the year. Further, the Company recognizes interest income from loans and investments, using the effective interest method when collectability is probable. The Company applies the effective interest method on a loan-by-loan basis. On June 30, 2023, the Company received a notice of termination, pursuant to which the Management Contract will terminate on December 31, 2023.

Allowances. The Company assesses the collectability of its rent receivables, including straight-line rent receivables, working capital loans to tenants and patient reimbursement. The Company bases its assessment of the collectability of rent receivables and working capital loans to tenants on several factors, including payment history, the financial strength of the tenant and any guarantors, the value of the underlying collateral, and current economic conditions. If the Company's evaluation of these factors indicates it is probable that the Company will be unable to receive the rent payments or payments on a working capital loan, then the Company provides a reserve against the recognized straight-line rent receivable asset or working capital loan for the portion that we estimate may not be recovered. Payments received on impaired loans are applied against the allowance. If the Company changes its assumptions or estimates regarding the collectability of future rent payments, then the Company may adjust its reserve to the rental or interest revenue recognized in the period the Company makes such change. See Note 6 – Leases. Regarding patient reimbursements, the Company assesses the patient receivable based on payor type and age of the receivable amongst several other factors. The Company has reserved for approximately 1.5% of our patient care revenue based on the historical performance and industry practices.

As of September 30, 2023 and December 31, 2022, the Company reserved for approximately $1.6 million and $1.3 million, respectively, of uncollected receivables. Accounts receivable, net of allowance, totaled $2.0 million at September 30, 2023 and $6.3 million at December 31, 2022.

9

The following table presents the Company's Accounts receivable, net of allowance for the periods presented:

(Amounts in 000’s)	September 30, 2023			December 31, 2022
Gross receivables
Real Estate Services	$	908		$	1,094
Healthcare Services		2,706			6,493
Subtotal		3,614			7,587
Allowance
Real Estate Services		(338	)		(338	)
Healthcare Services		(1,241	)		(960	)
Subtotal		(1,579	)		(1,298	)
Accounts receivable, net of allowance	$	2,035		$	6,289

Prepaid Expenses and Other

As of September 30, 2023 and December 31, 2022, the Company had approximately $0.9 million and $0.7 million , respectively, in prepaid expenses and other; the $0.2 million increase is related to insurance for the Meadowood and Glenvue facility operations, while the other amounts are predominantly for directors' and officers' insurance, NYSE American annual fees, and mortgage insurance premiums.

Accounts Payable

The following table presents the Company's Accounts payable for the periods presented:

(Amounts in 000’s)	September 30, 2023		December 31, 2022
Accounts payable
Real Estate Services	$	1,052	$	797
Healthcare Services		1,731		2,496
Total Accounts payable	$	2,783	$	3,293

Other Expense, net

The Company retained a law firm to evaluate and assist with possible opportunities to improve the Company's capital structure. For the three months ended September 30, 2023 and September 30, 2022, these costs were $0.3 million and $0.2 million, respectively. For the nine months ended September 30, 2023 and September 30, 2022, these costs were $0.8 million and $1.1 million, respectively.

Leases and Leasehold Improvements

The Company leases certain facilities and equipment in the normal course of business. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating lease or finance lease. As of September 30, 2023, all of the Company's leased facilities are accounted for as operating leases. For operating leases that contain scheduled rent increases, the Company records rent expense on a straight-line basis over the term of the lease. Leasehold improvements are amortized over the shorter of the useful life of the asset or the lease term.

The Company recognizes both right of use assets and lease liabilities for leases in which we lease land, real property, or other equipment. We assess any new contracts or modification of contracts in accordance with ASC 842, Leases to determine the existence of a lease and its classification.

We report revenues and expenses for real estate taxes and insurance where the lessee has not made those payments directly to a third-party in accordance with its respective leases with us. Additionally, we expense certain leasing costs, other than leasing commissions, as they are incurred. The present value of minimum lease payments was calculated on each lease, using a discount rate that approximated our incremental borrowing rate and the current lease term. See Note 6– Leases for more information on the Company's operating leases.

10

Insurance

We maintain general liability, professional liability, and other insurance policies in amounts and with coverage and deductibles we believe are appropriate, based on the nature and risks of our business, historical experience, availability, and industry standards, including for the operations at the Glenvue and Meadowood facilities. Our current policies provide for deductibles for each claim and contain various exclusions from coverage. The Company has self-insured against professional and general liability claims related to its healthcare operations that were discontinued during 2014 and 2015 in connection with its transition from an owner and operator of healthcare properties to a healthcare property holding and leasing company (the "Transition"). For further information, see Note 11 – Commitments and Contingencies, and Note 13 – Commitments and Contingencies, to the consolidated financial statements for the year ended December 31, 2022 for more information. The Company evaluates quarterly the adequacy of its self-insurance reserve based on a number of factors, including: (i) the number of actions pending and the relief sought; (ii) analyses provided by defense counsel, medical experts or other information which comes to light during discovery; (iii) the legal fees and other expenses anticipated to be incurred in defending the actions; (iv) the status and likely success of any mediation or settlement discussions, including estimated settlement amounts and legal fees and other expenses anticipated to be incurred in such settlement, as applicable; and (v) the venues in which the actions have been filed or will be adjudicated. The Company believes that most of the professional and general liability actions are defensible and intends to defend them through final judgment unless settlement is more advantageous to the Company. Accordingly, the self-insurance reserve reflects the Company's estimate of settlement amounts for the pending actions, if applicable, and legal costs of settling or litigating the pending actions, as applicable. Because the self-insurance reserve is based on estimates, the amount of the self-insurance reserve may not be sufficient to cover the settlement amounts actually incurred in settling the pending actions, or the legal costs actually incurred in settling or litigating the pending actions. See Note 7 – Accrued Expenses. In addition, the Company maintains certain other insurance programs, including commercial general liability, property, casualty, directors' and officers' liability, crime, and employment practices liability.

Discontinued Operations

Prior to December 2015, the Company’s business focused primarily on owning and operating skilled nursing facilities ("SNF") and managing such facilities for unaffiliated owners with whom the Company had management contracts. These operations were discontinued and transitioned to the leasing model of business.

As of September 30, 2023 and December 21, 2022 the Company determined remaining escheatment liabilities for discontinued operations are $0.8 million and are included in accrued expenses.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the respective period. Diluted earnings per share is similar to basic net loss per share except that the net loss is adjusted by the impact of the weighted-average number of shares of common stock outstanding including potentially dilutive securities (such as options, warrants and non-vested common stock) when such securities are not anti-dilutive. Potentially dilutive securities from options, warrants and unvested restricted shares are calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all options and warrants with exercise prices exceeding the average market value are used to repurchase common stock at market value. The incremental shares remaining after the proceeds are exhausted represent the potentially dilutive effect of the securities.

Securities outstanding that were excluded from the computation, because they would have been anti-dilutive were as follows:

	September 30,
(Share amounts in 000’s)	2023		2022
Stock options		37		13
Warrants - employee		32		34
Warrants - non employee		1		5
Total anti-dilutive securities		70		52

11

The weighted average contractual terms in years for these securities as of September 30, 2023, with no intrinsic value, are 6.3 years for the stock options and 1.2 years for the warrants.

New Accounting Pronouncements Issued But Not Yet Effective

In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842): Common Control Arrangements (Topic 842) amendments, which requires entities to determine whether related party arrangements between entities under common control are leases. The amendments also address the accounting treatment of leasehold improvements associated with common control leases. They require the lessee to amortize leasehold improvements over the useful life of the improvements to the common control group, regardless of the lease term, as long as the lessee controls the use of the underlying asset. If the lessee no longer controls the use of the asset, the leasehold improvements are accounted for as a transfer between entities under common control through an adjustment to equity. These improvements are also subject to impairment guidance in Topic 360, Property, Plant, and Equipment. The amendment is effective for public entities beginning after December 15, 2023. The Company is currently evaluating the impact of ASU 2023-01 on its financial statements.

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company's financial statements.

NOTE 2. LIQUIDITY

Overview

The Company intends to pursue measures to grow its operations, streamline its cost infrastructure and otherwise increase liquidity, including: (i) refinancing or repaying debt to reduce interest costs and mandatory principal repayments, with such repayment to be funded through potentially expanding borrowing arrangements with certain lenders; (ii) increasing future lease revenue through acquisitions and investments in existing properties; (iii) modifying the terms of existing leases; (iv) replacing certain tenants who default on their lease payment terms; and (v) reducing other and general and administrative expenses.

Management anticipates access to several sources of liquidity, including cash on hand, cash flows from operations, and debt refinancing, during the twelve months following the date of this filing. At September 30, 2023, the Company had $1.4 million in unrestricted cash.

During the nine months ended September 30, 2023, the Company's cash provided by operating activities was $3.5 million primarily due to collection of the Employee Retention Tax Credit. The Company is seeking collection of the past due rent. In addition, management is working to expedite the time it takes to collect and receive aged patient receivables. Cash flow from operations in the future will be based on the operational performance of the facilities under the company's management, Glenvue and Meadowood, as well as continued uncertainty of the COVID-19 pandemic and its impact on the Company's business, financial condition and results of operations.

Series A Preferred Stock Exchange Offer

In connection with the completion of the Exchange Offer and the implementation of the Series A Charter Amendments and the Series B Charter Amendments, the liquidation preference of the Series A Preferred Stock was reduced, accumulated and unpaid dividends on the Series A Preferred Stock were eliminated and future dividends on the Series A Preferred Stock were eliminated. As a result, $50.4 million in accumulated and unpaid dividends on the Series A Preferred Stock were eliminated and, as of September 30, 2023, there are no accumulated and unpaid dividends on the Series A Preferred Stock. For further information regarding the Exchange Offer, Series A Charter Amendments and Series B Charter Amendments, see Note 9 – Common and Preferred Stock.

Debt

As of September 30, 2023, the Company had $51.4 million in indebtedness, net of $1.1 million deferred financing costs and unamortized discounts. The Company anticipates net principal repayments of approximately $2.3 million during the next

12

twelve-month period, approximately $1.5 million of routine debt service amortization, $0.7 million of insurance financing amortization, and a $0.1 million payment of bond debt.

Debt Extinguishment

On December 30, 2022, the Company extended the maturity date on approximately $0.5 million other debt from August 25, 2023 to August 25, 2025 (the "Key Bank Exit Notes"). For further information, see Note 8 – Notes Payable and Other Debt.

On October 21, 2022, the Company, through wholly-owned subsidiaries, consummated a U.S. Department of Housing and Urban Development ("HUD") refinancing of its senior mortgages on three SNFs in Ohio. Funding was provided by Newpoint Real Estate Capital LLC ("Newpoint") pursuant to three HUD guaranteed secured Healthcare Facility Notes (the "HUD Notes"). Proceeds from the HUD Notes were used to pay off existing HUD guaranteed secured mortgages and pay transaction costs. Newpoint is the servicer on other loans extended to the Company.

Consequently, the Company recorded a net loss of approximately $0.4 million on extinguishment of debt during the year ended December 31, 2022, consisting of a $0.2 million prepayment penalty and $0.2 million of expensed deferred financing fees associated with the extinguishment of the Eaglewood Care Center, The Pavilion Care Center, and Hearth & Care of Greenfield loans.

The aggregate principal amount of the three HUD Notes is $7.6 million, and the interest rate on the three HUD Notes is 3.97% fixed for the full term of each HUD Note. The Northwood HUD Note has a principal amount of $4.9 million and matures on November 1, 2052. The Greenfield HUD Note has a principal amount of $1.9 million and matures on November 1, 2050. The Pavilion HUD Note has a principal amount of $0.8 million and matures on December 1, 2039. Payments of principal and interest on the HUD Notes commenced on October 1, 2022. Each HUD Note is secured by a Healthcare Deed to Secure Debt, Security Agreement and Assignment of Rents covering the facilities. Newpoint may declare the loans, accrued interest and any other amounts immediately due and payable upon certain customary events of default.

Debt Covenant Compliance

At September 30, 2023, the Company was in compliance with the various financial and administrative covenants related to all of the Company's credit facilities.

Changes in Operational Liquidity

COVID-19. Many of our operators have reported incurring significant cost increases as a result of the COVID-19 pandemic. We believe these increases primarily stem from elevated labor costs, including increased use of overtime and bonus pay, as well as a significant increase in both the cost and usage of personal protective equipment, testing equipment, processes and supplies. In terms of occupancy levels, many of our operators have reported experiencing declines, in part due to the elimination or suspension of elective hospital procedures, fewer discharges from hospitals to SNFs, and higher hospital readmittances from SNFs. The COVID-19 pandemic may also lead to temporary closures of nursing facilities operated by our tenants, impairing our tenants’ ability to make their rental payments to us pursuant to their respective lease agreements.

Portfolio Stabilization Measures. In the past, our operators did not provide lease guarantees from affiliated entities. Given this, certain operators have terminated their leases in light of operational difficulties caused by the COVID-19 pandemic. While the Company is a self-managed real estate investment company that invests in real estate, when business conditions require, the Company undertakes portfolio stabilization measures. The table below summarizes the lease terminations related to existing properties as of September 30, 2023 since the onset of the COVID-19 pandemic and the Company’s resulting portfolio stabilization measures:

Date	Facility Name	Former Operator	Current Operator
April 2022	Meadowood	C.R. Management	Regional Health (managed by Cavalier Senior Living Operations)
August 2022	Glenvue	C.R. Management	Regional Health

13

For more information, see Note 1 – Organization and Significant Accounting Policies, Note 6 – Leases and Note 12 – Segment Results.

Capital Requirements. The operation of the facilities listed above will require additional working capital, which is partially offset by cash flow received from the operation of these facilities. Since January, 2021, the Company's Accounts Receivable, net of allowance and Accounts Payable for the Healthcare Services segment have grown to $1.8 million and $1.7 million, respectfully.

On December 30, 2022, the Company and Spring Valley, LLC (“Spring Valley”) entered into a Lease Termination Agreement (the “Lease Termination Agreement”) relating to the lease of the following eight nursing facilities: the Powder Springs facility, the Thomasville facility, the Jeffersonville facility, the Lumber City facility, the LaGrange facility, the Tara facility, the Oceanside facility and the Savannah Beach facility (collectively, the “Facilities”). The Lease Termination Agreement terminated the lease effective December 7, 2022 (the “Lease Termination Date”). Since the termination, management has been focusing on collecting the Accounts Receivable and paying the Accounts Payable associated with the referenced facilities.

Evaluation of the Company's Ability to Continue as a Going Concern

Under the accounting guidance related to the presentation of financial statements, the Company is required to evaluate, on a quarterly basis, whether or not the Company's current financial condition, including its sources of liquidity at the date that the consolidated financial statements are issued, will enable the Company to meet its obligations as they come due arising within one year of the date of the issuance of the Company's consolidated financial statements and to make a determination as to whether or not it is probable, under the application of this accounting guidance, that the Company will be able to continue as a going concern. The Company's consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

In applying applicable accounting guidance, management considered the Company's current financial condition and liquidity sources, including current funds available, forecasted future cash flows, the Company's obligations due over the next twelve months, and the Company's recurring business operating expenses.

The Company concluded that it is probable that the Company will be able to meet its obligations arising within one year of the date of issuance of these consolidated financial statements within the parameters set forth in the accounting guidance.

NOTE 3. CASH AND RESTRICTED CASH

The following presents the Company's cash and restricted cash:

(Amounts in 000’s)	September 30, 2023		December 31, 2022
Cash	$	1,427	$	843
Restricted cash:
Cash collateral	$	118	$	135
HUD and other replacement reserves		2,138		2,155
Escrow deposits		635		459
Restricted investments for debt obligations		317		317
Total restricted cash		3,208		3,066
Total cash and restricted cash	$	4,635	$	3,909

Cash collateral—In securing mortgage financing from certain lending institutions, the Company and certain of its wholly-owned subsidiaries are required to deposit cash to be held as collateral in accordance with the terms of such loan agreements.

HUD and other replacement reserves—The regulatory agreements entered into in connection with the financing secured through HUD require monthly escrow deposits for replacement and improvement of the HUD project assets.

14

Escrow deposits—In connection with financing secured through the Company's lenders, several wholly-owned subsidiaries of the Company are required to make monthly escrow deposits for taxes and insurance.

Restricted cash for debt obligations—In compliance with certain financing and insurance agreements, the Company and certain wholly-owned subsidiaries of the Company are required to deposit cash held as collateral by the lender or in escrow with certain designated financial institutions.

NOTE 4. PROPERTY AND EQUIPMENT

The following table sets forth the Company's property and equipment:

(Amounts in 000’s)	Estimated Useful Lives (Years)		September 30, 2023			December 31, 2022
Buildings and improvements	5-40		$	64,429		$	63,746
Equipment and computer related	2-10			1,615			1,807
Land (1)		—		2,774			2,774
Property and equipment				68,818			68,327
Less: accumulated depreciation and amortization				(23,012	)		(21,716	)
Property and equipment, net			$	45,806		$	46,611

(1)Includes $0.1 million of land improvements with an average estimated useful remaining life of approximately 5.3 years.

The following table summarizes total depreciation and amortization expense three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Amounts in 000’s)	2023		2022		2023		2022
Depreciation	$	416	$	490	$	1,409	$	1,490
Amortization		110		110		329		329
Total depreciation and amortization expense	$	526	$	600	$	1,738	$	1,819

NOTE 5. INTANGIBLE ASSETS AND GOODWILL

Intangible assets and Goodwill consist of the following:

(Amounts in 000’s)	Bed licenses (included in property and equipment) (1)			Bed Licenses - Separable (2)		Lease Rights			Total			Goodwill (2)
Balances, December 31, 2022
Gross	$	14,276		$	2,471	$	206		$	16,953		$	1,585
Accumulated amortization		(4,583	)		—		(96	)		(4,678	)		—
Net carrying amount	$	9,693		$	2,471	$	110		$	12,275		$	1,585
Balances, September 30, 2023
Gross		14,276			2,471		206			16,953			1,585
Accumulated amortization		(4,894	)		—		(114	)		(5,008	)		—
Net carrying amount	$	9,382		$	2,471	$	92		$	11,945		$	1,585

(1)Non-separable bed licenses are included in property and equipment as is the related accumulated amortization expense (see Note 4 – Property and Equipment).

(2)The Company does not amortize indefinite-lived intangibles, which consist of separable bed licenses and goodwill.

15

The following table summarizes amortization expense for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Amounts in 000’s)	2023		2022		2023		2022
Bed licenses	$	104	$	104	$	311	$	311
Lease rights		6		6		18		18
Total amortization expense	$	110	$	110	$	329	$	329

Expected amortization expense for the years ending December 31, for all definite-lived intangibles, for each of the next five years and thereafter is as follows:

(Amounts in 000’s)	Bed Licenses		Lease Rights
2023 (3 months remaining)	$	103	$	6
2024		414		24
2025		414		24
2026		414		24
2027		414		14
Thereafter		7,623		-
Total expected amortization expense	$	9,382	$	92

NOTE 6. LEASES

Facility and Office Lessee

As of September 30, 2023, the Company leased one SNF under a non-cancelable operating lease, which had rent escalation clauses and provisions for payments of real estate taxes, insurance, and maintenance costs. The Company also leased certain office space located in Suwanee, Georgia through the termination date of June 30, 2023. Effective July 1, 2023, the Company signed a sublease for 2,000 sq ft of office space in Dunwoody, GA. The sublease expires on July 31, 2025.

The remaining lease term for this one facility and our office lease is approximately 5.6 years and 1.8 years, respectively. As of September 30, 2023, the Company was in compliance with all operating lease financial covenants.

Future Minimum Lease Payments

Future minimum lease payments for the twelve months ending December 31, for each of the next five years and thereafter is as follows:

(Amounts in 000’s)	Future rental payments		Accretion of lease liability (1)			Operating lease obligation
2023 (3 months remaining)	$	156	$	(2	)	$	154
2024		633		(39	)		594
2025		645		(85	)		560
2026		658		(131	)		527
2027		671		(174	)		497
Thereafter		914		(298	)		616
Total	$	3,677	$	(729	)	$	2,948

(1)Weighted average discount rate 3.85%.

Facilities Lessor

On August 11, 2023, the Company and its former tenant, SL SNF, LLC, entered into a lease amendment (the “Amendment”) regarding the Southland facility. The amendment reduces the monthly rent to $43,000 effective April 1, 2023 and includes a $312,000 promissory note (the “Promissory Note”). The lease termination date under the amendment is October 31, 2024. Under the terms of the Promissory Note, the principal sum plus all accrued interest, accruing on the unpaid principal balance at

16

a rate of 8% per annum, is due and payable on December 1, 2024, with minimum monthly payments of principal and interest of $18,353 per month beginning on July 1, 2023. As on September 30, 2023, no promissory note payments have been received from SL SNF, LLC.

As of September 30, 2023, the Company was the lessor of 9 of its 11 owned facilities, and the sublessor of one facility. These leases are triple net basis leases, meaning that the lessee (i.e., the third-party tenant of the property) is obligated for all costs of operating the property, including insurance, taxes and facility maintenance, as well as the lease or sublease payments to the Company. The weighted average remaining lease term for our 10 owned and subleased out facilities is approximately 5.5 years.

Future Minimum Lease Receivables

Future minimum lease receivables for the twelve months ending December 31, for each of the next five years and thereafter is as follows:

	(Amounts in 000's)
2023 (3 months remaining)	$	1,577
2024		6,187
2025		6,034
2026		5,362
2027		5,445
Thereafter		11,605
Total	$	36,210

For further details regarding the Company's leased and subleased facilities to third-party operators, including a full summary of the Company's leases to third-parties and which comprise the future minimum lease receivables of the Company, see Note 6 - Leases and Leasing Transactions in Part II, Item 8, Financial Statements and Supplementary Data, included in the Annual Report.

NOTE 7. ACCRUED EXPENSES

Accrued expenses consist of the following:

(Amounts in 000’s)	September 30, 2023		December 31, 2022
Accrued employee benefits and payroll-related	$	328	$	539
Real estate and other taxes (1)		2,891		2,428
Self-insured reserve		62		80
Accrued interest		222		210
Unearned rental revenue		-		43
Medicaid overpayment - Healthcare Services		56		169
Insurance escrow		79		—
Other accrued expenses		1,168		1,567
Total accrued expenses	$	4,806	$	5,036

(1)September 30, 2023 includes approximately $2.5 million of franchise tax accruals for the Healthcare Services segment. December 31, 2022 includes approximately $2.2 million of franchise tax accruals for the Healthcare Services segment.

17

NOTE 8. NOTES PAYABLE AND OTHER DEBT

See Note 8 – Notes Payable and Other Debt in Part II, Item 8, Financial Statements and Supplementary Data, included in the Annual Report for a detailed description of all the Company's debt facilities.

Notes payable and other debt consists of the following:

(Amounts in 000’s)	September 30, 2023			December 31, 2022
Senior debt—guaranteed by HUD	$	29,183		$	29,782
Senior debt—guaranteed by USDA (1)		7,332			7,526
Senior debt—guaranteed by SBA(2)		562			580
Senior debt—bonds		6,117			6,253
Senior debt—other mortgage indebtedness		8,089			8,266
Other debt		1,181			895
Subtotal		52,464			53,302
Deferred financing costs		(971	)		(1,005	)
Unamortized discount on bonds		(115	)		(119	)
Notes payable and other debt	$	51,378		$	52,178

(1)U.S. Department of Agriculture ("USDA")

(2)U.S. Small Business Administration ("SBA")

The following is a detailed listing of the debt facilities that comprise each of the above categories:

(Amounts in 000’s)
Facility	Lender	Maturity	Interest Rate (1)			September 30, 2023		December 31, 2022
Senior debt - guaranteed by HUD (2)
The Pavilion Care Center	Newpoint Capital	12/01/2039	Fixed	3.97	%	$	810	$	835
Hearth and Care of Greenfield	Newpoint Capital	8/01/2050	Fixed	3.97	%		1,919		1,949
Woodland Manor	Newpoint Capital	11/01/2052	Fixed	3.97	%		4,913		4,980
Glenvue	Newpoint Capital	10/01/2044	Fixed	3.75	%		7,134		7,297
Autumn Breeze	KeyBank	01/01/2045	Fixed	3.65	%		6,203		6,344
Georgetown	Newpoint Capital	10/01/2046	Fixed	2.98	%		3,144		3,214
Sumter Valley	KeyBank	01/01/2047	Fixed	3.70	%		5,061		5,163
Total						$	29,184	$	29,782
Senior debt - guaranteed by USDA (3)
Mountain Trace (4)	Community B&T	12/24/2036	Prime + 1.75%	10.00	%	$	3,575	$	3,680
Southland (5)	Cadence Bank, NA	07/27/2036	Prime + 1.50%	9.75	%		3,757		3,846
Total						$	7,332	$	7,526
Senior debt - guaranteed by SBA
Southland(6)	Cadence Bank, NA	07/27/2036	Prime + 2.25%	10.50	%	$	562	$	580
Total						$	562	$	580

(1)Represents cash interest rates as of September 30, 2023 as adjusted for interest rate floor limitations, if applicable. The rates exclude amortization of deferred financing costs, which range from 0.09% to 0.53% per annum.

18

(2)For the seven SNFs, the Company has term loans with financial institutions that are insured 100% by HUD. The loans are secured by, among other things, an assignment of all rents paid under any existing or future leases and rental agreements with respect to the underlying facility. The loans contain customary events of default, including fraud or material misrepresentations or material omission, the commencement of a forfeiture action or proceeding, failure to make required payments, and failure to perform or comply with certain agreements. Upon the occurrence of certain events of default, the lenders may, after receiving the prior written approval of HUD, terminate the loans and all amounts under the loans will become immediately due and payable. In connection with entering into each loan, the Company entered into a healthcare regulatory agreement and a promissory note, each containing customary terms and conditions. Pursuant to the CARES Act, up to three months of debt service payments for six of the credit facilities can be made from our restricted cash reserves.

(3)For the two SNFs, the Company has term loans with financial institutions that are insured 70% to 80% by the USDA. The loans have an annual renewal fee for the USDA guarantee of 0.25% of the guaranteed portion. The loans had prepayment penalties of 1%, capped at 1% for the remainder of the first 10 years of the term and 0% thereafter.

(4)Pursuant to the CARES Act, the monthly principal and interest payments due May 1, 2020 through August 1, 2020 for the Mountain Trace Facility loan were deferred. Monthly payments that commenced on September 1, 2020 were being applied to current interest, then deferred interest until the deferred interest was paid in full on April 1, 2021. Payments have been re-amortized over the extended term of the loan.

(5)Pursuant to the CARES Act, the monthly principal and interest payments due May 1, 2020 through October 1, 2020 for the loan for that certain 126-bed SNF commonly known as Southland, located in Dublin, Georgia, were deferred as a part of the USDA Payment Program. Monthly payments recommenced on November 1, 2020 with payments through February 2021 being applied to principal and interest. Monthly payments that commenced on March 1, 2021 are being applied to current interest, then deferred interest until the deferred interest is paid in full, payments will be re-amortized over the extended term of the loan.

(6)For the one SNF, commonly known as Southland, the Company has a term loan with a financial institution, which is 75% insured by the SBA. The SBA funded two monthly debt payments during the three months ended March 31, 2021 and six payments commencing on March 1, 2020 and ending on August 1, 2020.

(Amounts in 000’s)
Facility	Lender	Maturity	Interest Rate (1)			September 30, 2023		December 31, 2022
Senior debt - bonds
Eaglewood Bonds Series A	City of Springfield, Ohio	05/01/2042	Fixed	7.65	%	$	6,117	$	6,253

(1)Represents cash interest rates as of September 30, 2023. The rates exclude amortization of deferred financing of approximately 0.1% per annum.

(Amounts in 000’s)
Facility	Lender	Maturity	Interest Rate (1)			September 30, 2023		December 31, 2022
Senior debt - other mortgage indebtedness
Meadowood (2)	Exchange Bank of Alabama	10/01/2026	Fixed	4.50	%	$	3,279	$	3,319
Coosa (3)	Exchange Bank of Alabama	10/10/2026	Fixed	3.95	%		4,810		4,946
Total						$	8,089	$	8,266

(1)Represents cash interest rates as of September 30, 2023 as adjusted for interest rate floor limitations, if applicable. The rates exclude amortization of deferred financing costs of 0.34% per annum.

(2)On October 1, 2021, the Exchange Bank of Alabama and the Company extended the maturity date of the Meadowood Credit Facility which is secured by the Meadowood Facility and the assets of Coosa, and which is guaranteed by Regional Health Properties, Inc., from May 1, 2022 to October 1, 2026.

(3)On September 30, 2021, the Company refinanced the MCB Coosa Loan secured by the Coosa Facility, incurring approximately $0.1 million in new fees. The Coosa Credit Facility, guaranteed by Regional Health Properties, Inc. includes customary terms, including events of default with an associated annual 5% default interest rate, and is secured by the Coosa Facility and the assets of Meadowood. Upon the occurrence of certain events of default, the lenders may terminate the Coosa Credit Facility and the Meadowood Credit Facility and all amounts due under both credit facilities will become immediately due and payable. The Coosa Credit Facility has prepayment penalties of 5% in the first year, 4% in the second year and 1% thereafter.

19

(Amounts in 000’s)
Lender	Maturity	Interest Rate			September 30, 2023		December 31, 2022
Other debt
First Insurance Funding (1)	Various 2023	Fixed	3.19	%	$	658	$	357
Key Bank (2)	08/25/2025	Fixed	0.00	%		495		495
Marlin Capital Solutions	06/1/2027	Fixed	5.00	%		28		43
Total					$	1,181	$	895

(1)Annual Insurance financing primarily for the Company's directors and officers insurance and professional liability for the facilities where the company is the licensed operator.

(2)On December 30, 2022, Key Bank and the Company extended the maturity date from August 25, 2023 to August 25, 2025.

Debt Covenant Compliance

As of September 30, 2023, the Company had 16 credit related instruments outstanding that include various financial and administrative covenant requirements. Covenant requirements include, but are not limited to, fixed charge coverage ratios, debt service coverage ratios, minimum earnings before interest, taxes, depreciation, and amortization or earnings before interest, taxes, depreciation, amortization, and restructuring or rent costs, and current ratios. Certain financial covenant requirements are based on consolidated financial measurements whereas others are based on measurements at the subsidiary level (i.e., facility, multiple facilities or a combination of subsidiaries). The subsidiary level requirements are as follows: (i) financial covenants measured against subsidiaries of the Company; and (ii) financial covenants measured against third-party operator performance. Some covenants are based on annual financial metric measurements, whereas others are based on monthly and quarterly financial metric measurements. The Company routinely tracks and monitors its compliance with its covenant requirements.

As of September 30, 2023, the Company was in compliance with the various financial and administrative covenants under the Company's outstanding credit related instruments.

Scheduled Maturities

The schedule below summarizes the scheduled gross maturities as of September 30, 2023 for each of the next five years and thereafter.

For the Twelve Months Ended December 31,	(Amounts in 000’s)
2023 (3 months remaining)	$	660
2024		2,046
2025		2,269
2026		8,746
2027		1,562
Thereafter		37,181
Subtotal	$	52,464
Less: unamortized discounts		(115	)
Less: deferred financing costs, net		(971	)
Total notes and other debt	$	51,378

NOTE 9. COMMON AND PREFERRED STOCK

On June 27, 2023, the Company convened a special meeting (the “Special Meeting”) of the holders of its 10.875% Series A Cumulative Redeemable Preferred Shares (the “Series A Preferred Stock”) and the holders of its common stock (the “Common Stock”) and Series E Redeemable Preferred Shares (the “Series E Preferred Stock”). The Special Meeting was called to consider the proposals set forth in the Company’s definitive proxy statement/prospectus filed with the SEC on May 25, 2023 (as supplemented or amended, the “Proxy Statement/Prospectus”) in connection with the Company’s offer to exchange (the “Exchange Offer”) any and all outstanding shares of the Series A Preferred Stock for newly issued shares of the Company’s Series B Preferred Stock. The expiration date (the “Expiration Date”) for the Exchange Offer was 11:59 p.m., New York City time, on June 27, 2023.

All of the proposals presented at the Special Meeting were approved by the requisite votes of the applicable shareholders of the Company, including:

20

•certain amendments to the Company’s Amended and Restated Articles of Incorporation (as in effect prior to such amendments, the “Prior Charter”) with respect to the Series A Preferred Stock to significantly reduce the rights of holders of Series A Preferred Stock (the “Series A Charter Amendments” and, such proposal, the “Preferred Series A Charter Amendment Proposal”); and

•(i) a temporary amendment of the Prior Charter to increase the authorized number of shares of preferred stock to 6,000,000 shares and, following the consummation of the Exchange Offer, the subsequent amendment of the Prior Charter to decrease the authorized number of shares of preferred stock to 5,000,000 shares and (ii) the authorization, creation and designation by the Board of Directors of the Company (the “Board”), from the authorized but undesignated shares of preferred stock, of the Series B Preferred Stock (the “Series B Charter Amendments” and, such proposal, the “Series B Preferred Stock Proposal”); and

•certain amendments to the Prior Charter relating to (i) the Series A Charter Amendments and (ii) the temporary amendment of the Prior Charter to increase the authorized number of shares of the Company to 61,000,000 shares, consisting of 55,000,000 shares of common stock and 6,000,000 shares of preferred stock, and, following the consummation of the Exchange Offer, the subsequent amendment of the Prior Charter to decrease the authorized number of shares of the Company to 60,000,000 shares, consisting of 55,000,000 shares of common stock and 5,000,000 shares of preferred stock (such proposal, the “Common Charter Amendment Proposal”).

On June 30, 2023, the Company closed the Exchange Offer. Continental Stock Transfer & Trust Company, the exchange agent in connection with the Exchange Offer, notified the Company that 2,252,272 shares of Series A Preferred Stock had been properly tendered (and not validly withdrawn) in the Exchange Offer, representing approximately 80.1% of the then outstanding shares of Series A Preferred Stock. All of the shares of Series A Preferred Stock properly tendered (and not validly withdrawn) prior to the Expiration Date pursuant to the Exchange Offer were accepted by the Company and were retired. On June 30, 2023, in exchange for each such share of Series A Preferred Stock, participating holders of Series A Preferred Stock received one share of Series B Preferred Stock, resulting in the issuance of 2,252,272 shares of Series B Preferred Stock. 559,263 shares of Series A Preferred Stock did not participate in the Exchange Offer and remain outstanding.

On July 3, 2023, in connection with the closing of the Exchange Offer, the Company filed Amended and Restated Articles of Incorporation (the “Charter”) with the Secretary of State of the State of Georgia.

Common Stock

As of September 30, 2023, the Company had 55,000,000 shares of Common Stock authorized and 1,893,908 shares issued and 1,883,028 shares outstanding. There were no dividends declared or paid on the common stock during the three and nine months ended September 30, 2023 and 2022.

Preferred Stock

As of September 30, 2023 , the Company had 5,000,000 shares of Preferred Stock authorized and 2,811,535 shares issued and outstanding.

Series A Preferred Stock

On June 27, 2023, certain Preferred Series A Charter Amendments were approved at the Special Meeting to (i) reduce the liquidation preference of the Series A Preferred Stock to $5.00 per share, (ii) eliminate accumulated and unpaid dividends on the Series A Preferred Stock, (iii) eliminate future dividends on the Series A Preferred Stock, (iv) eliminate penalty events and the right of holders of Series A Preferred Stock to elect directors upon the occurrence of a penalty event, (v) reduce the redemption price of the Series A Preferred Stock in the event of an optional redemption to $5.00 per share, (vi) reduce the redemption price of the Series A Preferred Stock in the event of a “change of control” to $5.00 per share and (vii) change the voting rights of holders of Series A Preferred Stock when voting as a single class with any other class or series of stock to one vote per $5.00 liquidation preference.

The Company has accounted for the Series A Charter Amendments to the rights, preferences, and privileges of the Series A Preferred Stock as an extinguishment of the Series A Preferred Stock and issuance of new Series B Preferred Stock due to the significance of the modifications to the substantive contractual terms and the associated fundamental changes to the nature of the Series A Preferred Stock. Accordingly, the Company recorded an aggregate gain of $43.4 million within stockholders’ equity equal to the difference between the fair value of the new shares of Series B Preferred Stock issued and the carrying amount of the shares of Series A Preferred Stock extinguished. The gain on extinguishment is reflected in the calculation of net

21

income (loss) available to common stockholders in accordance with FASB ASC Topic 260, Earnings per Share. The fair value of the Series A Preferred Stock was $0.76 per share based on a probability-weighted average of the expected return method.

On June 30, 2023, in connection with the closing of the Exchange Offer, 2,252,272 shares of Series A Preferred Stock were retired and exchanged for 2,252,272 shares of Series B Preferred Stock.

As of September 30, 2023, the Company had 559,263 shares of Series A Preferred Stock issued and outstanding, and the accumulated and unpaid dividends on the Series A Preferred Stock in the amount of $50.4 million were forfeited as part of the extinguishment. No dividends were declared or paid on the Series A Preferred Stock for the three and nine months ended September 30, 2023 and 2022.

Series B Preferred Stock

The terms and provisions of the Series B Preferred Stock include, among other things: (i) no stated maturity and not being subject to any sinking fund or mandatory redemption, except following a change of control and the cumulative redemption provisions, (ii) ranks senior to our common stock, our Series A Preferred Stock and any other shares of our stock that we may issue in the future, the terms of which specifically provide that such stock ranks junior to the Series B Preferred Stock, in each case with respect to payment of dividends and amounts upon the occurrence of a liquidation event, (iii) dividend rate is 12.5% per annum of the liquidation preference of the Series B Preferred Stock in effect on the first calendar day of the applicable dividend period, (iv) initial dividend period will commence July 1, 2027, (v) liquidation preference is initially be $10.00 per share and will increase over time, pursuant to the terms set forth in the Charter, to $25.00 per share upon the fourth anniversary date of the original issuance date, provided that once there are 200,000 or fewer shares of the Series B Preferred Stock outstanding, the liquidation preference will be reduced to $5.00 per share; and (vi) the Company must redeem, repurchase or otherwise acquire certain amount of shares of Series B Preferred Stock through the fourth anniversary of the original date of issuance as provided in the Charter. The fair value of the Series B Preferred Stock was $8.26 per share based on a probability-weighted average of the expected return method.

As of September 30, 2023, the Company had 2,252,272 shares of Series B Preferred Stock issued and outstanding. No dividends were declared or paid on the Series B Preferred Stock for the three and nine months ended September 30, 2023 and 2022.

Series E Preferred Stock

On February 13, 2023, the Board declared a dividend of one one-thousandth of a share of Series E Preferred Stock for each outstanding share of common stock, payable on February 28, 2023 to shareholders of record at 5:00 p.m. Eastern Time on February 27, 2023 (the “Dividend Record Date”). The Articles of Amendment Establishing Series E Redeemable Preferred Shares were filed with the Secretary of State of the State of Georgia and became effective on February 14, 2023. The Series E Preferred Stock was distributed on February 28, 2023 to shareholders of record on the Dividend Record Date.

All shares of Series E Preferred Stock were redeemed in connection with the Special Meeting. The Series E Preferred Stock designation has been eliminated from the Charter and, as of September 30, 2023, there are no shares of Series E Preferred Stock issued and outstanding.

NOTE 10. STOCK BASED COMPENSATION

Stock Incentive Plans

On November 4, 2020, the Board adopted, the Regional Health Properties, Inc. 2020 Equity Incentive Plan (the "2020 Plan"). The Company's shareholders approved the 2020 Plan on December 16, 2020 at the 2020 Annual Meeting of Shareholders of the Company. The maximum number of shares of common stock authorized for issuance under the 2020 Plan is 250,000 shares, subject to certain adjustments. No awards may be made under the 2020 Plan after the 10th anniversary of the date of shareholder approval of the 2020 Plan, and no incentive stock options may be granted after the 10th anniversary of the date of Board approval of the 2020 Plan. As of September 30, 2023, the number of securities remaining available for future issuance under the 2020 Plan is 52,805.

The 2020 Plan replaced the AdCare Health Systems, Inc. 2011 Stock Incentive Plan, as amended (the "2011 Plan"), which was assumed by Regional Health pursuant to the Merger. The 2011 Plan was originally due to expire on March 28, 2021 and provided for a maximum of 168,950 shares of common stock to be issued. No additional awards may be granted under the 2011 Plan.

22

The shares of common stock underlying any awards granted under the 2020 Plan or the 2011 Plan that are forfeited, canceled, or otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2020 Plan. However, shares: (i) tendered or held back upon exercise of a stock option or other award under the 2020 Plan to cover the exercise price or tax withholding; and (ii) subject to a stock appreciation right that are not issued in connection with the stock settlement of the stock appreciation right upon exercise thereof, will not be added back to the shares of common stock available for issuance under the 2020 Plan. In addition, shares of common stock repurchased by the Company on the open market will not be added back to the shares of common stock available for issuance under the 2020 Plan.

For the three and nine months ended September 30, 2023 and 2022, the Company recognized stock-based compensation expense as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Amounts in 000’s)	2023		2022		2023		2022
Employee compensation:
Stock compensation expense	$	85	$	58	$	321	$	227
Forfeitures of stock based awards		—		—		—		(54	)
Total employee stock-based compensation expense	$	85	$	58	$	321	$	173

As of September 30, 2023, the remaining stock-based compensation expense that is expected to be recognized in future periods is $0.3 million.

Restricted Stock

The following table summarizes the Company's restricted stock activity for the nine months ended September 30, 2023:

	Number of Shares (000's)			Weighted Avg. Grant Date (per Share) Fair Value
Unvested, December 31, 2022		51		$	8.99
Granted		99		$	3.61
Vested		(26	)	$	9.06
Unvested, September 30, 2023		124		$	4.68

The remaining unvested shares at September 30, 2023 will vest over the next 2.0 years with $0.3 million in compensation expense recognized over this period.

Common Stock Options

The following summarizes the Company's employee and non-employee stock option activity for the nine months ended September 30, 2023:

	Number of Shares (000's)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (000's)
Outstanding, December 31, 2022		13	$	47.53		1.6	$	—
Granted		24	$	3.32
Outstanding and Vested, September 30, 2023		37	$	18.63		6.3	$	—

The aggregate intrinsic value of options outstanding and vested was calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock as of September 30, 2023. The fair value of the common stock is the closing stock price of the Company's Common Stock.

23

The following summary information reflects stock options outstanding, vested, and related details as of September 30, 2023:

	Stock Options Outstanding						Stock Options Exercisable
Exercise Price	Number of Shares (000's)		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price		Shares Vested, September 30, 2023 (000,s)		Weighted Average Exercise Price
$3.32		24		9.3	$	3.32		24	$	3.32
$46.80 - $48.72		13		0.9	$	47.42		13	$	47.42
Total		37		6.3	$	18.63		37	$	18.63

Common Stock Warrants

The following summarizes the Company's employee and non-employee common stock warrant activity for the nine months ended September 30, 2023:

	Outstanding and Exercisable
	Number of Shares (000's)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)
Outstanding and Vested, December 31, 2022		35		$	53.31		1.9
Expired		(2	)	$	70.80
Outstanding and Vested, September 30, 2023		33		$	52.38		1.2

The Company has no unrecognized compensation expense related to common stock warrants as of September 30, 2023.

NOTE 11. COMMITMENTS AND CONTINGENCIES

Regulatory Matters

Laws and regulations governing federal Medicare and state Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from certain governmental programs. As of September 30, 2023, all of the Company's facilities operated by Regional or leased and subleased to third-party operators and managed for third-parties are certified by CMS and are operational. See Note 6 - Leases.

Legal Matters

The Company is a party to various legal actions and administrative proceedings and is subject to various claims arising in the ordinary course of business, including claims that the services the Company provided during the time it operated SNFs resulted in injury or death to the patients of the Company's facilities and claims related to professional and general negligence, employment, staffing requirements and commercial matters. Although the Company intends to vigorously defend itself in these matters, there is no assurance that the outcomes of these matters will not have a material adverse effect on the Company's business, results of operations and financial condition.

The Company previously operated, and the Company and its tenants now operate, in an industry that is highly regulated. As such, in the ordinary course of business, the Company and its tenants are continuously subject to state and federal regulatory scrutiny, supervision and control. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition, the Company believes that there has been, and will continue to be, an increase in governmental investigations of long-term care providers, particularly in the area of Medicare and Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in legal proceedings or governmental investigations against or involving the Company or its tenants, whether currently asserted or

24

arising in the future, could have a material adverse effect on the Company's business, results of operations and financial condition.

Professional and General Liability Claims

Claims on behalf of the Company's Former Patients prior to the Transition

As of September 30, 2023, the Company is a defendant in one professional and general liability action commenced on behalf of one of our former patients who received care at one of our facilities prior to the Transition. The plaintiff in this action alleges negligence due to failure to provide adequate and competent staff resulting in injuries, pain and suffering, mental anguish and malnutrition and seeks unspecified actual and compensatory damages, and unspecified punitive damages. This action is covered by insurance, except that any punitive damages awarded would be excluded from coverage. The case is set to go to trial on October 23, 2023.

Claims on behalf of the Company's Former Patients After the Transition

On May 2, 2023, Plaintiff Danielle Taylor, as Guardian and Conservator of Lynette Taylor filed suit against Tara Operator, LLC alleging negligent care and treatment of Ms. Taylor during her residence at Thunderbolt from June 12, 2021 through September 13, 2021. Specifically, Plaintiff’s claims relate to wound care management Ms. Taylor received while a resident at Thunderbolt. Plaintiff further alleges the Thunderbolt staff failed to develop reasonable interventions for Ms. Taylor’s care after wound development, failed to properly document her wounds, failed to maintain a consistent turning schedule or offloading of pressure, and failed to modify her care plan accordingly. According to Plaintiff, these failures resulted in Ms. Taylor needing bilateral, above the knee amputations of both legs. Plaintiff’s Complaint asserts the following causes of action: failure to exercise a reasonable degree of care and skill and breach of contract. Defendant responded with its Answer on June 28, 2023 and discovery is ongoing.

On July 10, 2023, Plaintiff Sharon Hendricks filed suit against Tara Operator, LLC; ADK Georgia, LLC; Spring Valley, LLC; 3223 Falligant Avenue Associates, LP; Mansell Court Associates, LLC; and Wellington Healthcare Services II, LP alleging negligent care and treatment of Ms. Jones during her residence at Thunderbolt from July 12, 2021 through July 29, 2021. Specifically, Plaintiff’s claims relate to a fall Ms. Jones had on July 17, 2021 while at Thunderbolt. Plaintiff further alleges the Thunderbolt staff failed to administer medications as ordered, failed to initiate appropriate seizure protocols, and failed to properly update Ms. Jones’ care plan after the aforementioned fall. Plaintiff’s Complaint asserts the following causes of action: violation of 42 CFR 483.1; violation of OCGA 31-8-100; violation of federal and state statutes and regulations in the operation of a nursing home; professional negligence, ordinary negligence, negligent management and operation; breach of contract; failure to provide sufficient and properly trained staff; imputed liability; estate tort claims; joint enterprise; wrongful death; and punitive damages.

Claims on behalf of the Company's Prior or Current Tenant's Former Patients after the Transition

As of September 30, 2023, the Company is a defendant in an aggregate of 9 additional professional and general liability actions. These 9 additional professional and general liability actions were commenced on behalf of former patients of our current or prior tenants. These actions generally seek unspecified compensatory and punitive damages for former patients who were allegedly injured or died due to professional negligence or understaffing at the applicable facility operated by our tenants. These actions all relate to events which occurred after the Company transitioned the operations of the facilities in question to a third-party operator (and of which four such actions relate to events which occurred after the Company sold such facilities) and are subject to such operators' indemnification obligations in favor of the Company. There is no assurance that our tenants will have sufficient assets, income, access to financing and insurance coverage to enable them to satisfy their respective indemnification obligations.

During the nine months ended September 30, 2023, the following professional and general liability actions (included in the 10 actions mentioned above) related to our current or former tenant's former patients were filed against the Company.

The resident’s daughter filed suit on behalf of Mr. Shellman on February 14, 2023 asserting claims of professional and ordinary negligence as well the alleged breach of various state and federal regulations. The lawsuit relates to Mr. Shellman’s residence at Glenvue nursing facility which was operated by C.R. of Glenvue, LLC which is also named as a defendant. Plaintiff’s counsel has agreed to extend the deadline for Glenvue H&R Property Holdings, LLC to respond to the lawsuit up to and including May 15, 2023 to enable him to review the response filed by C.R. of Glenvue, LLC and determine whether or not Plaintiff will agree to the dismissal of Glenvue H&R Property Holdings, LLC. If plaintiff does not agree, we intend to serve Plaintiff with a notice

25

that Glenvue H&R Property Holdings, LLC constitutes an excluded party pursuant to O.C.G.A. 31-7-3.3. Should Plaintiff still not agree to the dismissal of Glenvue H&R Property Holdings, LLC, we will file a motion for summary judgment seeking judgment in its favor. The Court may require Glenvue H&R Property Holdings, LLC to participate in discovery prior to ruling on this motion. In the event that occurs, Glenvue H&R Property Holdings, LLC can seek the recovery of its attorneys fees and expenses pursuant to the above-referenced excluded party statute.

The family of Mable Polite filed suit on March 15, 2023 asserting claims of professional and ordinary negligence as well the alleged breach of various state and federal regulations. The lawsuit relates to Ms. Polite’s residence at the Thunderbolt nursing facility from March 19, 2020 to March 20, 2021. Plaintiff has also asserted claims against 3223 Falligant Avenue Associates, LP and other Wellington related entities. 3223 Falligant Avenue was the operator and licensee of the facility for the first part of Ms. Polite’s residence prior to Tara Operator becoming the operator. Based upon the date the suit was filed, there is an argument that certain claimed acts of negligence are barred by the limitations period. Ms. Polite’s daughter signed an arbitration agreement on her admission to Thunderbolt but we are not in possession of a power of attorney or other documentation authorizing her to execute this agreement. Nonetheless, Tara Operator will file its answer to the Complaint (due April 14) via special appearance to reserve the right to seek arbitration should a power of attorney be located.

Dismissed Claims on behalf of the Company's Prior or Current Tenant's Former Patients after the Transition

In February 2023, the Company was dismissed from the case involving Ronald and Sarah Ross against our prior operator Symmetry Healthcare Management.

The Company established a self-insurance reserve for its professional and general liability claims, included within Accrued expenses on the Company's consolidated balance sheets of $0.1 million and $0.2 million as of September 30, 2023 and December 31, 2022, respectively. Additionally, as of September 30, 2023 and December 31, 2022, $0.1 million and $0.1 million, respectively, was reserved for settlement amounts in Accounts payable on the Company's consolidated balance sheets. For additional information regarding the Company's self-insurance reserve, see Note 13 – Commitments and Contingencies in Part II, Item 8, Financial Statements and Supplementary Data, included in the Annual Report.

NOTE 12. SEGMENT RESULTS

The Company has two primary reporting segments: (i) Real Estate Services, which consists of the leasing and subleasing of long-term care and senior living facilities to third-party tenants, including the Company's management of three facilities on behalf of third-party owners; and (ii) Healthcare Services, which consists of the operation of the Meadowood and Glenvue facilities.

The Company reports segment information based on the "management approach" defined in ASC 280, Segment Reporting. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments.

The table below presents the results of operations for our reporting segments for the periods presented.

26

	Three Months Ended September 30,									Three Months Ended September 30,
	2023			2023			2023			2022			2022			2022
(Amounts in 000’s)	Real Estate Services			Healthcare Services			Total			Real Estate Services			Healthcare Services			Total
Revenues:
Patient care revenues	$	—		$	2,136		$	2,136		$	—		$	7,769		$	7,769
Rental revenues		1,739			—			1,739			3,000			—			3,000
Management fees		263			—			263			255			—			255
Other revenues		—			—			—			6			—			6
Total revenues		2,002			2,136			4,138			3,261			7,769			11,030
Expenses:
Patient care expense		—			2,313			2,313			—			7,476			7,476
Facility rent expense		149			—			149			923			528			1,451
Cost of management fees		156			—			156			140			—			140
Depreciation and amortization		472			54			526			590			10			600
General and administrative expense		950			22			972			975			403			1,378
Doubtful accounts expense		—			229			229			1,515			—			1,515
Other operating expenses		54			143			197			(80	)		521			441
Total expenses		1,781			2,761			4,542			4,063			8,938			13,001
Income (loss) from operations		221			(625	)		(404	)		(802	)		(1,169	)		(1,971	)
Other (income) expense:
Interest expense, net		669			39			708			633			(69	)		564
Other (income) expense, net		(541	)		402			(139	)		(2,164	)		—			(2,164	)
Total other (income) expense, net		128			441			569			(1,531	)		(69	)		(1,600	)
Net income (loss)	$	93		$	(1,066	)	$	(973	)	$	729		$	(1,100	)	$	(371	)

	Nine Months Ended September 30,									Nine Months Ended September 30,
	2023			2023			2023			2022			2022			2022
(Amounts in 000’s)	Real Estate Services			Healthcare Services			Total			Real Estate Services			Healthcare Services			Total
Revenues:
Patient care revenues	$	—		$	6,577		$	6,577		$	—		$	14,650		$	14,650
Rental revenues		5,170			—			5,170			10,326			—			10,326
Management fees		788			—			788			774			—			774
Other revenues		107			—			107			20			—			20
Total revenues		6,065			6,577			12,642			11,120			14,650			25,770
Expenses:
Patient care expense		—			7,010			7,010			—			14,040			14,040
Facility rent expense		446			—			446			3,899			826			4,725
Cost of management fees		442			—			442			459			—			459
Depreciation and amortization		1,578			160			1,738			1,796			23			1,819
General and administrative expense		2,970			220			3,190			2,660			772			3,432
Doubtful accounts expense		—			269			269			3,742			—			3,742
Other operating expenses		225			286			511			555			854			1,409
Total expenses		5,661			7,945			13,606			13,111			16,515			29,626
Income (loss) from operations		404			(1,368	)		(964	)		(1,991	)		(1,865	)		(3,856	)
Other (income) expense:
Interest expense, net		1,947			119			2,066			1,898			(43	)		1,855
Other (income) expense, net		—			620			620			(1,088	)		—			(1,088	)
Total other (income) expense, net		1,947			739			2,686			810			(43	)		767
Net income (loss)	$	(1,543	)	$	(2,107	)	$	(3,650	)	$	(2,801	)	$	(1,822	)	$	(4,623	)

Total assets for the Real Estate Services segment and Healthcare Services segment were $57.0 million and $7.0 million, respectively, as of September 30, 2023. Total assets for the Real Estate Services segment and Healthcare Services segment were $63.5 million and $5.6 million, respectively, as of December 31, 2022.

27

NOTE 13. SUBSEQUENT EVENTS

We evaluate subsequent events that occur after our consolidated balance sheet date but before our consolidated financial statements are issued. We have evaluated subsequent events occurring after September 30, 2023, and based on our evaluation have identified the subsequent events described below.

On October 13, 2023, the lawsuit against the Company filed by one of our former patients prior to the transition referenced in Note 11 settled for an undisclosed sum within insurance policy limits. In addition, the Company's motion for summary judgment presented on October 23, 2023 was granted, and the Company was dismissed from the lawsuit with prejudice on November 3, 2023.

28

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our consolidated financial statements and the related notes included therein and our Annual Report on Form 10-K for the year ended December 31, 2022, where certain terms have been defined.

This Management’s Discussion and Analysis of Financial Condition and Results of Operations includes forward-looking statements. We base these forward-looking statements on our current plans, expectations and beliefs about future events. There are risks, including the factors discussed in “Risk Factors” in Part II, Item 1A and elsewhere in this Quarterly Report, that our actual experience will differ materially from these expectations. For more information, see “Forward-Looking Statements” below.

In this Quarterly Report, except as the context suggests otherwise, “Company,” “Regional Health Properties, Inc.,” “Regional Health,” “we,” “our,” “ours,” and “us” refer to Regional Health Properties, Inc. and its subsidiaries and predecessors.

Forward Looking Statements

This Quarterly Report and certain information incorporated herein by reference contain forward-looking statements and information within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, and management's plans and objectives. In addition, certain statements included in this Quarterly Report, in the Company's future filings with the SEC, in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements. Words such as "may," "could," "should," "would," "believe," "expect," "anticipate," "estimate," "intend," "seek," "plan," "project," "continue," "predict," "will," and other words or expressions of similar meaning are intended by us to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company's current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made.

All forward-looking statements are subject to the risks and uncertainties inherent in predicting the future. The Company's actual results may differ materially from those projected, stated or implied in these forward-looking statements as a result of many factors, including the Company's critical accounting policies and risks and uncertainties related to, but not limited to, the operating results of the Company's tenants, the overall industry environment, the Company's financial condition, and the impact of the COVID-19 pandemic on the Company's business. These and other risks and uncertainties are described in more detail in the Annual Report and in Part II, Item 1A "Risk Factors" of this Quarterly Report, as well as other reports that the Company files with the SEC.

Forward-looking statements speak only as of the date they are made and should not be relied upon as representing the Company's views as of any subsequent date. The Company undertakes no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by applicable laws, and you are urged to review and consider disclosures that the Company makes in this Quarterly Report and other reports that the Company files with the SEC that discuss factors germane to the Company's business.

Overview

Regional Health Properties, Inc., a Georgia corporation, is a self-managed real estate investment company that invests primarily in real estate purposed for long-term care and senior housing. We operate through two reportable segments: Real Estate and Healthcare Services. Our Real Estate segment consists of real estate investments in skilled nursing and senior housing facilities. We fund our real estate investments primarily through: (1) operational cash flow, (2) mortgages, and (3) sale of equity securities. Our Healthcare Services segment is comprised of an entity set up to operate our facilities as needed under our Portfolio Stabilization measures.

While the Company is a self-managed real estate investment company, the Company, when business conditions require, may undertake portfolio stabilization measures, such as operating a previously leased facility. For more information see "Recent Developments" below and Note 2 - Liquidity - Changes in Operational Liquidity - Portfolio Stabilization Measures and Note 6 - Leases to the Company's consolidated financial statements, which are included in Part I. Item 1 hereto.

29

Effective August 3, 2023, the Company’s 12.5% Series B Cumulative Redeemable Preferred Shares (the “Series B Preferred Stock”) is quoted on the OTC Markets Group, Inc.’s OTCQB Venture Market under the symbol “RHEPB”.

Real Estate Portfolio

As of September 30, 2023, we had investments of approximately $66.5 million in eleven health care real estate properties and one leased property. We currently own eleven properties, consisting of nine skilled nursing facilities (“SNFs”) and two multi-service facilities. Nine facilities are pursuant to triple-net leases, one is managed by an external manager, and one is managed internally by the Company. The Company has one leased facility that is subleased pursuant to a triple-net lease.

Skilled nursing facilities. SNFs provide services that include daily nursing, therapeutic rehabilitation, social services, activities, housekeeping, nutrition, medication management and administrative services for individuals requiring certain assistance for activities in daily living. A typical skilled nursing facility includes mostly one and two bed units, each equipped with a private or shared bathroom and community dining facilities.

Multi-Service Campuses. Multi-service campuses generally include some combination of co-located skilled nursing, independent living, assisted living and/or memory care units all housed at a single location and operated as a continuum of care.

Portfolio

The following table provides summary information regarding the number of facilities and related licensed beds/units as of September 30, 2023:

Location	Skilled Nursing Facilities	Multi Service Properties	Total Properties
Alabama	1	1	2
Georgia	3	-	3
North Carolina	1	-	1
Ohio	2	1	3
South Carolina	2	-	2
	9	2	11
Location	Skilled Nursing Beds/Units	Multi Service Beds/Units	Total Beds/Units
Alabama	124	90	214
Georgia	395	-	395
North Carolina	106	-	106
Ohio	112	194	306
South Carolina	180	-	180
	917	284	1,201
Location	Skilled Nursing Investment	Multi Service Investment	Total Investment
Alabama	$9,613,199	$4,884,514	$14,497,713
Georgia	24,475,283	-	24,475,283
North Carolina	7,224,953	-	7,224,953
Ohio	3,872,791	6,716,420	10,589,211
South Carolina	9,733,024	-	9,733,024
	$54,919,250	$11,600,934	$66,520,184

30

The following table provides summary information regarding the number of facilities and related licensed beds/units by operator affiliation as of September 30, 2023:

Operator Affiliation	Number of Facilities (1)		Beds / Units
C.R. Management 2 3 5 6		2		233
Aspire Regional Partners		3		306
Oak Hollow Health Care Management 7		2		180
Beacon Health Management 4		1		126
Vero Health Management		1		106
Cavalier Senior Living		1		90
RHP Operations		1		160
Subtotal		11		1,201

(1)Represents the number of facilities leased or subleased to separate tenants, of which each tenant is an affiliate of the entity named in the table above.

(2)In April 2022, the Company entered into an Operations Transfer and Surrender Agreement by and between Meadowood Operations, LLC and C.R. of Meadowood, LLC.

(3)In May 2022, the Company entered into an Operations Transfer and Surrender Agreement by and between LaGrange Operations, LLC and C.R. of LaGrange, LLC.

(4)In May 2022, the Company entered into an Operations Transfer and Surrender Agreement by and between Lumber City Operations, LLC and LC SNF, LLC.

(5)In July 2022, the Company entered into an Operations Transfer and Surrender Agreement by and between Thomasville Operations, LLC and C.R. of Thomasville, LLC.

(6)In August 2022, the Company entered into an Operations Transfer Agreement and Surrender Agreement by and between Glenvue Operations, LLC and C.R. of Glenvue, LLC.

(7)In October, 2022, the parent company of Symmetry entered into an Operations Transfer Agreement with Oak Hallow Health Management, LLC to transition the two facilities in South Carolina.

For a more detailed discussion of the above information, see Note 6 - Leases to the consolidated financial statements included in Part I, Item 1 herein. Additionally, see "Portfolio of Healthcare Investments" included in Part I, Item 1 "Business" in the Annual Report.

Portfolio Occupancy Rates

The following table provides summary information regarding our portfolio facility-level occupancy rates for the periods shown:

Operating Metric	December 31, 2022			March 31, 2023			June 30, 2023			September 30, 2023
Occupancy (%)		65.7	%		66.4	%		66.8	%		66.9	%

(1)Excludes three managed facilities in Ohio.

(2)Due to the Company exiting the Foster lease in December 2022, historical data no longer includes Thomasville, Powder Springs, Tara, LaGrange, Twiggs, Oceanside, and Savannah Beach.

(3)Meadowood's current and historical calculations have been changed from 161 licensed beds to 90 beds. This change reflects the actual total beds available by the business.

31

Lease Expiration

The following table provides summary information regarding our lease expirations for the years shown as of December 31,:

		Licensed Beds					Annual Lease Revenue (2)
	Number of Facilities	Count		Percent (%)			Amount ($) '000's (1)		Percent (%)
2023	1	50			4.8	%	$	44		0.7	%
2024	1	126			11.9	%		-		0.0	%
2025	1	109			10.4	%		910		15.4	%
2026	0	0			0.0	%		-		0.0	%
2027	0	0			0.0	%		-		0.0	%
2028	4	355			33.8	%		2,352		39.8	%
2029	1	106			10.1	%		538		9.1	%
Thereafter	3	304			29.0	%		2,066		35.0	%
Total	11		1,050		100.0	%	$	5,911		100.0	%

(1)Straight-line rent.

(2)See Note 6 - Leases to the consolidated financial statements included in Part I, Item 1 herein for a discussion of lease terminations.

Results of Operations

The following table sets forth, for the periods indicated, an unaudited statement of operations items and the amounts and percentages of change of these items. The results of operations for any particular period are not necessarily indicative of results for any future period. The following data should be read in conjunction with our consolidated financial statements and the notes thereto, which are included herein.

	Three Months Ended September 30,									Nine Months Ended September 30,
(Amounts in 000’s)	2023			2022			Percent Change			2023			2022			Percent Change
Revenues:
Patient care revenues	$	2,136		$	7,769			(72.5	)%	$	6,577		$	14,650			(55.1	)%
Rental revenues		1,739			3,000			(42.0	)%		5,170			10,326			(49.9	)%
Management fees		263			255			3.1	%		788			774			1.8	%
Other revenues		—			6			(100.0	)%		107			20			435.0	%
Total revenues		4,138			11,030			(62.5	)%		12,642			25,770			(50.9	)%
Expenses:
Patient care expense		2,313			7,476			(69.1	)%		7,010			14,040			(50.1	)%
Facility rent expense		149			1,451			(89.7	)%		446			4,725			(90.6	)%
Cost of management fees		156			140			11.4	%		442			459			(3.7	)%
Depreciation and amortization		526			600			(12.3	)%		1,738			1,819			(4.5	)%
General and administrative expense		972			1,378			(29.5	)%		3,190			3,432			(7.1	)%
Doubtful accounts expense		229			1,515			(84.9	)%		269			3,742			(92.8	)%
Other operating expenses		197			441			(55.3	)%		511			1,409			(63.7	)%
Total expenses		4,542			13,001			(65.1	)%		13,606			29,626			(54.1	)%
Loss from operations		(404	)		(1,971	)		(79.5	)%		(964	)		(3,856	)		(75.0	)%
Other (income) expense:
Interest expense, net		708			564			25.5	%		2,066			1,855			11.4	%
Other (income) expense, net		(139	)		(2,164	)		(93.6	)%		620			(1,088	)		(157.0	)%
Total other (income) expense, net		569			(1,600	)		(135.6	)%		2,686			767			250.2	%
Net loss	$	(973	)	$	(371	)		162.3	%	$	(3,650	)	$	(4,623	)		(21.0	)%

Three Months Ended September 30, 2023 and 2022

Patient care revenues—Patient care revenues for the Healthcare Services segment, as a result of the Company operating the Meadowood and Glenvue Facilities, were $2.1 million for the three months ended September 30, 2023, compared to $7.8

32

million for the same period in 2022. The 72.5% decrease is primarily due to the change in the facilities that were operated in the period compared to the prior period.

Rental revenues—Rental revenue for our Real Estate Services segment decreased by approximately $1.3 million to $1.7 million for the three months ended September 30, 2023, compared with $3.0 million for the same period in 2022. The 42.0% decrease is due to less rent collected from a reduction in the number of facilities subleased.

Patient care expense—Patient care expense was $2.3 million for the three months ended September 30, 2023 compared with $7.5 million for the same period in 2022. The current period expense decrease of $5.2 million was primarily due to the change in the facilities we are operating.

Facility rent expense—Facility rent of $0.1 million for the three months ended September 30, 2023 decreased 89.7% from $1.5 million for the same period in 2022 due to the termination of the Foster Lease.

Depreciation and amortization—Depreciation and amortization was $0.5 million for the three months ended September 30, 2023, compared to $0.6 million for the same period in 2022.

General and administrative expenses—General and administrative expenses were $1.0 million for the three months ended September 30, 2023 compared with $1.4 million for the same period in 2022. The decrease was due to an increase in audit expenses and director's fees offset by a decrease in management fees due to the termination of the Foster Lease.

	Three Months Ended September 30,
(Amounts in 000’s)	2023		2022		Percent Change
General and administrative expenses:
Real Estate Services	$	950	$	975		(2.6	)%
Healthcare Services		22		403		(94.5	)%
Total	$	972	$	1,378		(29.5	)%

Doubtful accounts expense—The current period expense of $229.0 thousand for the three months ended September 30, 2023 compared with $1.5 million for the same period in 2022 is primarily due to the reduction in the number of facilities caused by the termination of the Foster Lease.

Other operating expenses—Other operating expenses decreased by $0.2 million to $0.2 million for the three months ended September 30, 2023, compared with $0.4 million for the same period in 2022. The decrease was due to professional and legal services related to operator transition transactions along with decreased expenses related to the termination of the Foster Lease.

	Three Months Ended September 30,
(Amounts in 000’s)	2023		2022			Percent Change
Other operating expenses:
Real Estate Services	$	54	$	(80	)		(167.8	)%
Healthcare Services		143		521			(72.6	)%
Total	$	197	$	441			(55.3	)%

Other (income) expense, net—Other (income) expense increased by $2.1 million to ($0.1) million for the three months ended September 30, 2023, compared with ($2.2) million for the same period in 2022. These other expenses are related to professional and legal services incurred for evaluation and assistance with possible opportunities that improve the company's capital structure. For three months ended September 30, 2022, these other expenses were offset by the $2.4 million gain recognized related to the write-down of certain accounts payable balances for unclaimed property.

Nine Months Ended September 30, 2023 and 2022

Patient care revenues—Patient care revenues for the Healthcare Services segment, as a result of the Company operating the Meadowood and Glenvue Facilities, were $6.6 million for the nine months ended September 30, 2023, compared to $14.7 million for the same period in 2022. The 55.1% decrease is primarily due to the change in the facilities that were operated in the period compared to the prior period.

33

Rental revenues—Rental revenue for our Real Estate Services segment decreased by approximately $5.1 million to $5.2 million for the nine months ended September 30, 2023, compared with $10.3 million for the same period in 2022. The 49.9% decrease is due to less rent collected from a reduction in the number of facilities subleased.

Patient care expense—Patient care expense was $7.0 million for the nine months ended September 30, 2023, compared with $14.0 million for the same period in 2022. The current period expense decrease of $7.0 million was primarily due to the change in the number of facilities we are operating.

Facility rent expense—Facility rent expense of $0.4 million for the nine months ended September 30, 2023 decreased 90.6% from $4.7 million for the same period in 2022 due to the termination of the Foster Lease.

Depreciation and amortization—Depreciation and amortization was $1.7 million for the nine months ended September 30, 2023, compared to $1.8 million for the same period in 2022.

General and administrative expenses—General and administrative expenses were $3.2 million for the nine months ended September 30, 2023, compared with $3.4 million for the same period in 2022. The decrease was due to a slight increase in audit expenses and director's fees offset by a decrease in management fees due to the termination of the Foster Lease.

	Nine Months Ended September 30,
(Amounts in 000’s)	2023		2022		Percent Change
General and administrative expenses:
Real Estate Services	$	2,970	$	2,660		11.7	%
Healthcare Services		220		772		(71.5	)%
Total	$	3,190	$	3,432		(7.1	)%

Doubtful accounts expense—Doubtful accounts expense was $0.3 million for nine months ended September 30, 2023, compared to $3.7 million for the same period in 2022. The decrease is primarily due to the change in the number of facilities we are operating.

Other operating expenses—Other operating expenses decreased by approximately $0.9 million to $0.5 million for the nine months ended September 30, 2023, compared with $1.4 million for the same period in 2022. The decrease was due to professional and legal services related to operator transition transactions along with decreased expenses related to the termination of the Foster Lease.

	Nine Months Ended September 30,
(Amounts in 000’s)	2023		2022		Percent Change
Other operating expenses:
Real Estate Services	$	225	$	555		(59.5	)%
Healthcare Services		286		854		(66.5	)%
Total	$	511	$	1,409		(63.7	)%

Other (income) expense, net—Other (income) expense, net increase by approximately $1.7 million, to $0.6 million for the nine months ended September 30, 2023, compared to ($1.1) million for the same period in 2022 . These expenses are related to professional and legal services incurred for evaluation and assistance with possible opportunities that improve the company's capital structure. In addition, we incurred $0.2 million for professional services used to obtain the Employee Retention Tax Credit ("ERTC"). For the nine months ended September 30, 2022, these other expenses were offset by the $2.4 million gain recognized related to the write-down of certain accounts payable balances for unclaimed property.

Liquidity and Capital Resources

Overview

The Company intends to pursue measures to grow its operations, streamline its cost infrastructure and otherwise increase liquidity, including: (i) refinancing or repaying debt to reduce interest costs and mandatory principal repayments, with such repayment to be funded through potentially expanding borrowing arrangements with certain lenders; (ii) increasing future lease

34

revenue through acquisitions and investments in existing properties; (iii) modifying the terms of existing leases; (iv) replacing certain tenants who default on their lease payment terms; and (v) reducing other and general and administrative expenses.

Management anticipates access to several sources of liquidity, including cash on hand, cash flows from operations, and debt refinancing during the twelve months following the date of this filing. At September 30, 2023, the Company had $1.4 million in unrestricted cash.

During the nine months ended September 30, 2023, the Company's net cash provided by operating activities was $3.5 million primarily due to collection of patient care receivables, the ERTC, and rent receivables. Management anticipates collecting a portion of the past due rent after the filing date and is currently negotiating various methods to collect the remaining unpaid rent.

As of September 30, 2023, the Company recorded an estimated allowance of $1.6 million against a gross accounts receivable of $3.6 million.

As of September 30, 2023, the Company had $51.4 million in indebtedness, net of $1.1 million deferred financing, and unamortized discounts. The Company anticipates net principal repayments of approximately $2.3 million during the next twelve-month period, approximately $1.5 million of routine debt service amortization, $0.7 million of insurance financing amortization, and a $0.1 million payment of bond debt.

Debt Modification

On December 30, 2022, the Company extended the maturity date on approximately $0.5 million other debt from August 25, 2023 to August 25, 2025 (known as the "KeyBank Exit Notes"). For further information, see Note 8 – Notes Payable and Other Debt to the consolidated financial statements included in Part I, Item 1 herein.

The Company is current with all of its Notes payable and other debt as described in Note 8 – Notes Payable and Other Debt to the consolidated financial statements included in Part I, Item 1 herein.

In 2020, the Company began exploring alternatives to retire or refinance the Series A Preferred Stock through privately negotiated transactions, open market repurchases, redemptions, exchange offers, tender offers, or otherwise. Costs associated with these efforts have been expensed as incurred in Other (income) expense, net and were $0.6 million and $1.3 million for the nine months ended September 30, 2023 and September 30, 2022, respectively.

In connection with the completion of the Exchange Offer and the implementation of the Series A Charter Amendments and the Series B Charter Amendments, the liquidation preference of the Series A Preferred Stock was reduced, accumulated and unpaid dividends on the Series A Preferred Stock were eliminated and future dividends on the Series A Preferred Stock were eliminated. As a result, $50.4 million in accumulated and unpaid dividends on the Series A Preferred Stock were eliminated and, as of September 30, 2023, there are no accumulated and unpaid dividends on the Series A Preferred Stock. For further information regarding the Exchange Offer, Series A Charter Amendments and Series B Charter Amendments, see Note 2 – Liquidity and Note 9 – Common and Preferred Stock to the consolidated financial statements included in Part I, Item 1 herein.

Debt Covenant Compliance

As of September 30, 2023, the Company was in compliance with the various financial and administrative covenants under the Company's outstanding credit related instruments.

Evaluation of the Company's Ability to Continue as a Going Concern

Under the accounting guidance related to the presentation of financial statements, the Company is required to evaluate, on a quarterly basis, whether or not the Company's current financial condition, including its sources of liquidity at the date that the consolidated financial statements are issued, will enable the Company to meet its obligations as they come due arising within one year of the date of the issuance of the Company's consolidated financial statements and to make a determination as to whether or not it is probable, under the application of this accounting guidance, that the Company will be able to continue as a going concern. The Company's consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In applying applicable accounting guidance, management considered the Company's current financial condition and liquidity sources, including current funds available, forecasted future cash flows, the Company's obligations due over the next twelve months, and the Company's recurring business operating expenses.

35

The Company concludes that it is probable that the Company will be able to meet its obligations arising within one year of the date of issuance of these consolidated financial statements within the parameters set forth in the accounting guidance.

For additional information regarding the Company's liquidity, see Note 2 – Liquidity and Note 8 – Notes Payable and other debt, to the consolidated financial statements included in Part I, Item 1 herein.

Cash Flows

The following table presents selected data from our consolidated statements of cash flows for the periods presented:

	Nine Months Ended September 30,
(Amounts in 000’s)	2023			2022
Net cash provided by (used in) operating activities	$	3,460		$	(2,171	)
Net cash used in investing activities		(916	)		(183	)
Net cash used in financing activities		(1,818	)		(2,097	)
Net change in cash and restricted cash		726			(4,451	)
Cash and restricted cash at beginning of period		3,909			9,848
Cash and restricted cash, ending	$	4,635		$	5,397

Nine Months Ended September 30, 2023

Net cash provided by operating activities—was approximately $3.5 million. The positive cash flow from operating activities were largely due to collection of the ERTC, collection of patient care receivables, and rent receivables.

Net cash used in investing activities—was approximately $0.9 million. The negative cash flow was mainly from reclassified capital expenditures, new equipment, and finished capital expense projects.

Net cash used in financing activities—was approximately $1.8 million. The cash was used to make routine payments totaling $1.8 million for our debt obligations.

Nine Months Ended September 30, 2022

Net cash used by operating activities — was approximately $2.2 million. The negative cash flow from operating activities was primarily caused by nonpayment of rent from Beacon and Symmetry and changes in working capital requirements, mostly due to accounts receivable increase of $3.3 million, for the facilities we operate.

Net cash used in investing activities — was approximately $0.2 million. This capital expenditure was for computer hardware, software and furniture and fixtures for the Tara Facility.

Net cash used in financing activities—was approximately $2.1 million. The cash was used to make routine payments totaling $1.2 million for our debt obligations and $0.9 million for Other debt.

Off-Balance Sheet Arrangements

Guarantee

The Company subleased five facilities located in Ohio to the Aspire Sublessees, formerly affiliated with MSTC Development Inc., pursuant to the Aspire Subleases, whereby the Aspire Sublessees took possession of, and commenced operating, the Aspire Facilities as subtenant. The Company agreed to indemnify Aspire against any and all liabilities imposed on them as arising from the former operator, capped at $8.0 million. The Company has assessed the fair value of the indemnity agreements as not material to the financial statements at September 30, 2023. For further information see Note 6 – Leases, to the consolidated financial statements included in Part I, Item 1 herein and also and Note 6 – Leases included in Part II, Item 8 of the Annual Report.

Critical Accounting Policies

We prepare our financial statements in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Article 8 of Regulation S-X. The preparation of these financial statements requires us to make

36

estimates and judgments that affect the reported amount of assets, liabilities, revenues and expenses. On an ongoing basis, we review our judgments and estimates, including, but not limited to, those related to doubtful accounts, income taxes, stock compensation, intangible assets and loss contingencies. We base our estimates on historical experience, business knowledge and on various other assumptions that we believe to be reasonable under the circumstances at the time. Actual results may vary from our estimates. These estimates are evaluated by management and revised as circumstances change.

For a discussion of our critical accounting policies, see Note 1 – Organization and Significant Accounting Policies to the consolidated financial statements included in Part I, Item 1 herein.

37

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Disclosure in response to Item 3 of Form 10-Q is not required to be provided by smaller reporting companies.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report (the "Evaluation Date"). Based on such evaluation, principal executive officer and principal financial officer have concluded that, as of the Evaluation Date, our disclosure controls and procedures are not effective.

Our management believes a material weakness exists in our internal controls over financial reporting as of September 30, 2023 because we lack the necessary corporate accounting resources in our financial reporting processing and accounting functions as a result of recent departures of certain accounting and financial reporting personnel. A material weakness is a deficiency or a combination of control deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Our management will seek to remediate the material weakness described above through hiring qualified accounting and financial reporting personnel to replace the personnel who departed.

Changes in Internal Control Over Financial Reporting

There has been no change in the Company's internal controls over financial reporting that occurred during the period covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

Part II. Other Information

Item 1. Legal Proceedings.

The Company is a defendant in various legal actions and administrative proceedings arising in the ordinary course of business, including claims that the services the Company provided during the time it operated skilled nursing facilities resulted in injury or death to patients. Although the Company settles cases from time to time when settlement can be achieved on a reasonable basis, the Company vigorously defends any matter in which it believes the claims lack merit and the Company has a reasonable chance to prevail at trial or in arbitration. Litigation is inherently unpredictable. There is no assurance that the outcomes of these matters will not have a material adverse effect on the Company's financial condition. Although arising in the ordinary course of the Company's business, certain of these matters are described in Note 11 - Commitments and Contingencies to the consolidated financial statements included in Part I, Item 1 herein.

Item 1A. Risk Factors.

For a detailed description of certain risk factors that could affect our business, operations and financial condition, see Part I, Item 1A., Risk Factors, included in the Annual Report, as supplemented and modified by the risk factors set forth below in this Item 1A. The risk factors described in the Annual Report and this Quarterly Report (collectively, the “Risk Factors”) do not describe all risks applicable to our business, and we intend it only as a summary of certain material factors. The Risk Factors should be considered in connection with evaluating the forward-looking statements contained in this Quarterly Report because

38

the Risk Factors could cause the actual results and conditions to differ materially from those projected in forward-looking statements. If any of the risks actually occur, our business, financial condition, or results of operations could be negatively affected. In that case, the trading price of the common stock, the Series A Preferred Stock and the Series B Preferred Stock could decline.

The COVID-19 pandemic and measures intended to prevent its spread could have a material adverse effect on our business, results of operations, cash flows, and financial condition.

On March 11, 2020, the World Health Organization declared the outbreak of the respiratory illness caused by a novel strain of coronavirus, SARS-CoV-2, also known as COVID-19, a global pandemic. The COVID-19 pandemic has led governments and other authorities in the United States to impose measures intended to control its spread, including restrictions on freedom of movement and business operations such as travel bans, border closings, business closures, quarantines and shelter-in-place orders. The COVID-19 pandemic and the measures to protect its spread adversely affected our business in 2022, and we expect it will continue to adversely affect our business in 2023 and beyond, for a variety of reasons, including those discussed below and elsewhere hereunder.

As of December 31, 2022, the Company is aware that each of our facilities has reported one or more positive cases of COVID-19 among the residents and/or operator employee populations. Many of our operators have reported incurring significant cost increases as a result of the COVID-19 pandemic, with dramatic increases for facilities with positive cases. We believe these increases primarily stem from elevated labor costs, including increased use of overtime and bonus pay, as well as a significant increase in both the cost and usage of personal protective equipment, testing equipment, processes and supplies. In terms of occupancy levels, many of our operators have reported experiencing declines, in part due to the elimination or suspension of elective hospital procedures, fewer discharges from hospitals to SNFs, and higher hospital readmittances from SNFs.

The COVID-19 pandemic may also lead to temporary closures of nursing facilities, operated by our tenants, which also may affect our tenants’ ability to make their rental payments to us pursuant to their respective lease agreements. In addition, our tenants’ operations could be further disrupted if any of their employees, or the employees of their vendors, have, or are suspected of having, COVID-19. This has caused, and may cause in the future, our tenants or their vendors to experience staffing shortages, and this could potentially require our tenants and their vendors to close parts of or entire facilities, distribution centers, or other buildings to disinfect any affected areas.

We could also be adversely affected if government authorities impose upon our tenants, or their vendors, certain restrictions due to the COVID-19 pandemic. These restrictions may be in the form of mandatory closures, requested voluntary closures, bans on new admissions, restricted operations, or restrictions on the importation of necessary equipment or supplies which may adversely affect our tenants’ operations and their ability to make rental payments to us moving forward. In addition, family members may elect to keep nursing facility residents at home during the COVID-19 pandemic, thus reducing our tenants’ revenue. Currently, a number of our tenants have stopped admitting new patients due to rising COVID-19 infections resulting in decreased revenues.

As a result of the COVID-19 pandemic, our tenants may face lawsuits for alleged negligence associated with their responses to the emergency. The costs associated with defending, settling, or paying damages from such claims could negatively impact our tenants’ operating budgets and affect their ability to meet their obligations under our leases. Further, we may be subject to increased lawsuits arising out of our alleged actions or the alleged actions of our tenants for which they have agreed to indemnify, defend and hold us harmless. An unfavorable resolution of any such pending or future litigation could materially adversely affect us. The Company is not aware of any such lawsuits against our tenants.

If our tenants are unable to make rental payments to us pursuant to their lease obligations, whether due to the tenants’ decrease in revenues or otherwise, then, in some cases, we may be forced to either attempt to replace tenants or restructure tenants’ long-term rent obligations and may not be able to do so on terms that are as favorable to us as those currently in place.

While the Company has received approximately 95% of its expected monthly rental receipts from tenants for the quarter ended September 30, 2023, there are a number of uncertainties the Company faces as it considers the potential impact of COVID-19 on its business, including the length of census disruption, elevated COVID-19 operating costs related to personal protection equipment, cleaning supplies, virus testing and increased overtime due to staff illness and the extent to which federal and state funding support will offset these incremental costs for our tenants. To the extent government support is not sufficient or timely to offset these impacts, or to the extent these trends continue or accelerate and are not offset by additional government relief that is sufficient or timely, the operating results of our operators are likely to be adversely affected, some may be unwilling or unable to pay their contractual obligations to us in full or on a timely basis, as has occurred with more than one of our operators.

39

We also do not know the number of facilities that will ultimately experience widespread, high-cost outbreaks of COVID-19, and while we have requested reporting of case numbers from our operators and CMS has required additional reporting by operators, we may not receive accurate information on the number of cases, which could result in a delay in reporting. We expect to see continued increased clinical protocols for infection control within facilities and increased monitoring of employees, guests and other individuals entering facilities; however, we do not yet know if future reimbursement rates will be sufficient to cover the increased costs of enhanced infection control and monitoring. The extent of the COVID-19 pandemic’s effect on our and our tenants’ operational and financial performance will depend on future developments, including the ultimate duration, spread and intensity of the outbreak, which may depend on factors such as the development and implementation of an effective vaccine and treatments for COVID-19, government funds and other support for the senior care sector and the efficacy of other policies and measures that may mitigate the impact of the pandemic, all of which are uncertain and difficult to predict. Due to these uncertainties, we are unable at this time to estimate the effect of these factors on our business, but the adverse impact on our business, results of operations, financial condition and cash flows could be material.

In addition, the COVID-19 pandemic led to CMS, the OIG and other regulatory agencies implementing various waivers and flexibilities intended to minimize burdens for healthcare providers and other industry participants that faced the challenges of the COVID-19 pandemic. These included, for example, coverage requirement waivers (e.g., three-day prior hospitalization requirement for SNF stay coverage), exercising administrative discretion in fraud and abuse enforcement, and waivers relating to telehealth and licensure requirements. The national emergency and public health emergency declarations related to the COVID-19 pandemic ended on May 11, 2023. Consequently, many of the waivers and flexibilities that were implemented by CMS, the OIG and other regulatory agencies in response to the COVID-19 pandemic expired on May 11, 2023. We are unable to estimate at this time the impact these developments may have on the Company’s business.

We are currently out of compliance with the continued listing standards of the NYSE American LLC ("NYSE American"). Our failure to resume compliance with the continued listing standards or make continued progress toward compliance consistent with a plan of compliance we intend to submit to NYSE Regulation may result in the delisting of our common stock and Series A Preferred Stock.

Our common stock and Series A Preferred Stock are each listed on the NYSE American. In order to maintain these listings, we must maintain certain share prices, financial and share distribution targets, including maintaining a minimum amount of shareholders’ equity and a minimum number of public shareholders. In addition to these objective standards, NYSE Regulation may delist the securities of any issuer (i) if, in its opinion, the issuer’s financial condition and/or operating results appear unsatisfactory; (ii) if it appears that the extent of public distribution or the aggregate market value of the security has become so reduced as to make continued listing on the NYSE American inadvisable; (iii) if the issuer sells or disposes of principal operating assets or ceases to be an operating company; (iv) if an issuer fails to comply with the NYSE American’s listing requirements; (v) if an issuer’s common stock sells at what NYSE Regulation considers a “low selling price” and the issuer fails to correct this via a reverse split of shares after notification by NYSE Regulation; or (vi) if any other event occurs or any condition exists which makes continued listing on the NYSE American in its opinion, inadvisable.

As part of these continued listing requirements, under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide, which require an issuer to have (i) shareholders’ equity of $2.0 million or more if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years and (ii) shareholders’ equity of $4.0 million or more since if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years, respectively. Our audited consolidated financial statements for the year ended December 31, 2022 reflect shareholders’ equity of approximately $3.7 million and losses from continuing operations and/or net losses in three of its four most recent fiscal years. On May 10, 2023, we received a letter from the NYSE American (the "Initial Deficiency Letter") notifying us that we are not in compliance with Section 1003(a)(ii) of the NYSE American Company Guide. As a result, we became subject to the procedures and requirements of Section 1009 of the NYSE American Company Guide. On June 9, 2023, we submitted a plan to the NYSE American advising of actions we have taken or will take to regain compliance with the continued listing standards by November 10, 2024. On June 29, 2023, we received a letter from the NYSE American (the "Second Deficiency Letter") notifying us that we are not in compliance with Section 1003(a)(i) of the NYSE Company Guide. On August 1, 2023, we received a letter (the “Acceptance Letter”) from the NYSE American notifying us that the plan was accepted. The NYSE American has granted the Company a plan period through November 10, 2024 to regain compliance with the continued listing standards. We have been advised that if we do not make progress consistent with the plan or we fail to regain compliance by the deadline, then the NYSE American may commence delisting procedures.

Although we intend to regain compliance with the continued listing requirements prior to November 10, 2024, we may be unable to do so. If delisting proceedings are commenced, the NYSE American rules permit us to appeal a staff delisting determination. Our common stock and Series A Preferred Stock will continue to be listed and traded on the NYSE American during the plan period, subject to our compliance with the NYSE American’s other applicable continued listing standards. If

40

NYSE American delists our common stock or Series A Preferred Stock, investors may face material adverse consequences, including, but not limited to, a lack of trading market for these securities, reduced liquidity, decreased analyst coverage of these securities, and an inability for us to obtain additional financing to fund our operations.

We may conduct a transaction or transactions prior to November 10, 2024 that could result in significant dilution to our existing shareholders. The transaction(s) could include the private investment in public equity, a public rights offering, a debt restructuring or any combination of these or similar transactions with the intent of maintaining our NYSE American listings. Such transaction(s), if completed, would be dilutive to certain shareholders, could adversely affect the market price of our common stock, Series A Preferred Stock and Series B Preferred Stock, would involve some expense and management distraction from our business and ultimately may not be successful in maintaining our NYSE American listings.

To maintain our NYSE American listings, we may conduct a private investment in public equity, a public rights offering, a debt restructuring or any combination of these or similar transactions prior to November 10, 2024. Although we may not complete any of these transactions, if a transaction occurs, it would be dilutive to certain shareholders and could adversely or favorably affect the market price of our common stock, Series A Preferred Stock and Series B Preferred Stock. Furthermore, any transaction would involve some expense and management distraction from our business, and it is possible that despite the transaction, we may still be unsuccessful in maintaining our NYSE American listings. If NYSE American delists our common stock or Series A Preferred Stock, investors may face material adverse consequences, including, but not limited to, a lack of trading market for these securities, reduced liquidity, decreased analyst coverage of these securities, and an inability for us to obtain additional financing to fund our operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults upon Senior Securities.

In connection with the completion of the Exchange Offer and the implementation of the Series A Charter Amendments and the Series B Charter Amendments, the liquidation preference of the Series A Preferred Stock was reduced, accumulated and unpaid dividends on the Series A Preferred Stock were eliminated and future dividends on the Series A Preferred Stock were eliminated. As a result, $50.4 million in accumulated and unpaid dividends on the Series A Preferred Stock were eliminated and, as of September 30, 2023, there are no accumulated and unpaid dividends on the Series A Preferred Stock. For further information regarding the Exchange Offer, Series A Charter Amendments and Series B Charter Amendments, see Note 2 – Liquidity and Note 9 – Common and Preferred Stock to the consolidated financial statements included in Part I, Item 1 herein.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

The agreements included as exhibits to this Quarterly Report are included to provide information regarding the terms of these agreements and are not intended to provide any other factual or disclosure information about the Company, its business or the other parties to these agreements. These agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the other parties to the applicable agreement and:

•should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;

•have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;

•may apply standards of materiality in a way that is different from what may be viewed as material to investors; and

•were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

41

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time, and should not be relied upon by investors.

42

EXHIBIT INDEX

Exhibit No.	Description	Method of Filing
3.1	Amended and Restated Articles of Incorporation of Regional Health Properties, Inc., effective  July 3, 2023	Incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K filed on July 6, 2023
3.24	Amended and Restated Bylaws of Regional Health Properties, Inc., effective September 21, 2017	Incorporated by reference to Exhibit 3.3 of the Registrant's Current Report on Form 8-K12B filed on October 10, 2017
3.2(a)	Amendment No. 1 to Amended and Restated Bylaws of Regional Health Properties, Inc., effective June 27, 2023	Incorporated by reference to Exhibit 3.6 of the Registrant’s Post-Effective Amendment No. 1 to Registration Statement on Form S-4 (Reg. No. 333-269750) filed on June 28, 2023
4.1	Description of Regional Health Properties, Inc. Capital Stock	Incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K filed on July 6, 2023
31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act	Filed herewith
31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act	Filed herewith
32.1	Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act	Filed herewith
32.2	Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act	Filed herewith
101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.	Filed herewith
101.SCH	Inline XBRL Taxonomy Extension Schema Document	Filed herewith
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document	Filed herewith
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)	Filed herewith

43

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.

		REGIONAL HEALTH PROPERTIES, INC.
		(Registrant)
Date:	November 14, 2023	/s/ Brent Morrison
		Brent Morrison
		Chairman, Chief Executive Officer and Director (Principal Executive Officer)
Date:	November 14, 2023	/s/ Paul O'Sullivan
		Paul O'Sullivan
		Senior Vice President (Principal Financial Officer)

44

EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Brent Morrison, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Regional Health Properties, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 14, 2023	By	/s/ Brent Morrison
		Chairman Chief Executive Officer and President

EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Paul O’Sullivan, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Regional Health Properties, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 14, 2023	By	/s/ Paul O’ Sullivan
		Senior Vice President

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Regional Health Properties, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brent Morrison, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 14, 2023	By:	/s/ Brent Morrison
		Brent Morrison Chairman, Chief Executive Officer and President

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Regional Health Properties, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul O’Sullivan, Senior Vice President of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 14, 2023	By:	/s/ Paul O’Sullivan
		Paul O’Sullivan Senior Vice President

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 14, 2023
Document Information [Line Items]
Entity Registrant Name	REGIONAL HEALTH PROPERTIES, INC.
Entity Central Index Key	0001004724
Document Type	10-Q
Document Period End Date	Sep. 30, 2023
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		1,883,028
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Current Reporting Status	Yes
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	001-33135
Entity Tax Identification Number	81-5166048
Entity Address, Address Line One	1050 Crown Pointe Parkway
Entity Address, Address Line Two	Suite 720
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30338
City Area Code	678
Local Phone Number	869-5116
Entity Incorporation, State or Country Code	GA
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false
Common Stock
Document Information [Line Items]
Trading Symbol	RHE
Security Exchange Name	NYSEAMER
Title of 12(b) Security	Common Stock, no par value
Series A Preferred Stock
Document Information [Line Items]
Trading Symbol	RHE-PA
Security Exchange Name	NYSEAMER
Title of 12(b) Security	Series A Redeemable Preferred Stock, no par value

XML

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
ASSETS
Property and equipment, net	$ 45,806	$ 46,611
Cash	1,427	843
Restricted cash	3,208	3,066
Accounts receivable, net of allowances of $1,579 and $1,298	2,035	6,289
Prepaid expenses and other	903	746
Notes receivable	1,060	1,099
Intangible assets - bed licenses	2,471	2,471
Intangible assets - lease rights, net	92	110
Right-of-use operating lease assets	2,588	2,848
Goodwill	1,585	1,585
Lease deposits and other deposits	4
Straight-line rent receivable	2,830	2,912
Total assets	64,009	68,580
LIABILITIES AND EQUITY
Senior debt, net	44,208	45,163
Bonds, net	5,989	6,120
Other debt, net	1,181	895
Accounts payable	2,783	3,293
Accrued expenses	4,806	5,036
Operating lease obligation	2,948	3,226
Other liabilities	1,707	1,131
Total liabilities	63,622	64,864
Stockholders’ equity:
Common stock and additional paid-in capital, no par value; 55,000 shares authorized; 1,894 and 1,793 shares issued and 1,883 and 1,784 shares outstanding at September 30, 2023 and December 31, 2022, respectively	63,023	62,702
Preferred stock, no par value; 5,000 shares authorized (including amounts authorized for Series A and Series B); shares issued and outstanding designated as follows:
Accumulated deficit	(81,664)	(121,409)
Total stockholders’ equity	387	3,716
Total liabilities and stockholders’ equity	64,009	68,580
Series A Preferred Stock
Preferred stock, no par value; 5,000 shares authorized (including amounts authorized for Series A and Series B); shares issued and outstanding designated as follows:
Preferred stock	426	$ 62,423
Series B Preferred Stock
Preferred stock, no par value; 5,000 shares authorized (including amounts authorized for Series A and Series B); shares issued and outstanding designated as follows:
Preferred stock	$ 18,602

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounts receivable, allowances	$ 1,579	$ 1,298
Common stock and additional paid-in capital, par value	$ 0	$ 0
Common stock and additional paid-in capital, shares authorized	55,000,000	55,000,000
Common stock and additional paid-in capital, shares issued	1,894,000	1,793,000
Common stock and additional paid-in capital, shares outstanding	1,883,028	1,784,000
Series A Preferred Stock
Preferred stock, par value	$ 0	$ 0
Preferred stock, shares authorized	560,000	5,000,000
Preferred stock, shares issued	560,000	2,812,000
Preferred stock, shares outstanding	560,000	2,812,000
Preferred stock, redemption amount	$ 426	$ 70,288
Series B Preferred Stock
Preferred stock, par value	$ 0	$ 0
Preferred stock, shares authorized	2,812,000	0
Preferred stock, shares issued	2,252,272	0
Preferred stock, shares outstanding	2,252,272	0
Preferred stock, redemption amount	$ 18,602
Series A and B Preferred Stock
Preferred stock, par value	$ 0	$ 0
Preferred stock, shares authorized	5,000,000	5,000,000

XML

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Patient care, management fees and other revenues	$ 4,138	$ 11,030	$ 12,642	$ 25,770
Total revenues	4,138	11,030	12,642	25,770
Expenses:
Patient care expense	2,313	7,476	7,010	14,040
Facility rent expense	149	1,451	446	4,725
Cost of management fees	156	140	442	459
Depreciation and amortization	526	600	1,738	1,819
General and administrative expense	972	1,378	3,190	3,432
Doubtful accounts expense	229	1,515	269	3,742
Other operating expenses	197	441	511	1,409
Total expenses	4,542	13,001	13,606	29,626
Loss from operations	(404)	(1,971)	(964)	(3,856)
Other (income) expense:
Interest expense, net	708	564	2,066	1,855
Other (income) expense, net	(139)	(2,164)	620	(1,088)
Total other (income) expense, net	569	(1,600)	2,686	767
Net Loss	(973)	(371)	(3,650)	(4,623)
Preferred stock dividends - undeclared		(2,249)		(6,748)
Preferred stock dividends - gain on extinguishment			43,395
Net profit (loss) attributable to Regional Health Properties, Inc. common stockholders	$ (973)	$ (2,620)	$ 39,745	$ (11,371)
Net profit (loss) per share of common stock attributable to Regional Health Properties, Inc.
Net profit (loss) per share of common stock attributable to Regional Health Properties, Inc., basic	$ (0.52)	$ (1.48)	$ 21.18	$ (6.4)
Net profit (loss) per share of common stock attributable to Regional Health Properties, Inc., diluted	$ (0.52)	$ (1.48)	$ 21.18	$ (6.4)
Weighted average shares of common stock outstanding:
Basic (in shares)	1,883,028	1,768,720	1,876,138	1,775,637
Diluted (in shares)	1,883,028	1,768,720	1,876,138	1,775,637
Patient Care Revenues
Revenues:
Patient care, management fees and other revenues	$ 2,136	$ 7,769	$ 6,577	$ 14,650
Rental Revenue
Revenues:
Patient care, management fees and other revenues	1,739	3,000	5,170	10,326
Management Fees
Revenues:
Patient care, management fees and other revenues	263	255	788	774
Other Revenues
Revenues:
Patient care, management fees and other revenues	$ 0	$ 6	$ 107	$ 20

XML

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Shares of Common Stock Outstanding	Shares of Treasury Stock	Common stock and additional paid-in capital	Accumulated Deficit	Series A Preferred Stock	Series A Preferred Stock Shares of Preferred Stock	Series A Preferred Stock Preferred Stock	Series B Preferred Stock	Series B Preferred Stock Shares of Preferred Stock	Series B Preferred Stock Preferred Stock
Balance at Dec. 31, 2021	$ 10,396			$ 62,515	$ (114,542)			$ 62,423
Balance (in shares) at Dec. 31, 2021		1,775,000	(1,000)
Balance (in shares) at Dec. 31, 2021							2,812,000
Restricted stock issuance (in shares)		24,000
Stock-based compensation	111			111
Exercise of restricted share awards net settlement option	(46)			(46)
Exercise of restricted share awards net settlement option (in shares)			(8,000)
Net loss	(2,927)				(2,927)
Balance at Mar. 31, 2022	7,534			62,580	(117,469)			62,423
Balance (in shares) at Mar. 31, 2022		1,799,000	(9,000)
Balance (in shares) at Mar. 31, 2022							2,812,000
Balance at Dec. 31, 2021	10,396			$ 62,515	(114,542)			62,423
Balance (in shares) at Dec. 31, 2021		1,775,000	(1,000)
Balance (in shares) at Dec. 31, 2021							2,812,000
Net loss	(4,623)
Balance at Sep. 30, 2022	5,900				(119,165)			62,423
Balance (in shares) at Sep. 30, 2022		1,769,000	(9,000)	62,642,000
Balance (in shares) at Sep. 30, 2022							2,812,000
Balance at Mar. 31, 2022	7,534			$ 62,580	(117,469)			62,423
Balance (in shares) at Mar. 31, 2022		1,799,000	(9,000)
Balance (in shares) at Mar. 31, 2022							2,812,000
Forfeitures of stock based awards	4			4
Forfeitures of stock based awards (in shares)		(30,000)
Net loss	(1,325)				(1,325)
Balance at Jun. 30, 2022	6,213			62,584	(118,794)			62,423
Balance (in shares) at Jun. 30, 2022		1,769,000	(9,000)
Balance (in shares) at Jun. 30, 2022							2,812,000
Stock-based compensation	58			$ 58
Net loss	(371)				(371)
Balance at Sep. 30, 2022	5,900				(119,165)			62,423
Balance (in shares) at Sep. 30, 2022		1,769,000	(9,000)	62,642,000
Balance (in shares) at Sep. 30, 2022							2,812,000
Balance at Dec. 31, 2022	$ 3,716			$ 62,702	(121,409)			62,423
Balance (in shares) at Dec. 31, 2022	1,793,000	1,784,000	(9,000)
Balance (in shares) at Dec. 31, 2022						2,812,000	2,812,000		0
Restricted stock issuance (in shares)		99,000
Stock-based compensation	$ 81			81
Net loss	(1,992)				(1,992)
Balance at Mar. 31, 2023	1,805			62,783	(123,401)			62,423
Balance (in shares) at Mar. 31, 2023		1,883,000	(9,000)
Balance (in shares) at Mar. 31, 2023							2,812,000
Balance at Dec. 31, 2022	$ 3,716			62,702	(121,409)			62,423
Balance (in shares) at Dec. 31, 2022	1,793,000	1,784,000	(9,000)
Balance (in shares) at Dec. 31, 2022						2,812,000	2,812,000		0
Net loss	$ (3,650)
Balance at Sep. 30, 2023	$ 387			63,023	(81,664)			426			$ 18,602
Balance (in shares) at Sep. 30, 2023	1,894,000	1,883,000	(11,000)
Balance (in shares) at Sep. 30, 2023						560,000	560,000		2,252,272	2,252,000
Balance at Mar. 31, 2023	$ 1,805			62,783	(123,401)			62,423
Balance (in shares) at Mar. 31, 2023		1,883,000	(9,000)
Balance (in shares) at Mar. 31, 2023							2,812,000
Extinguishment of Series A Preferred Stock (in shares)							(2,252,000)
Extinguishment of Series A Preferred Stock	(61,997)							(61,997)
Exchange of Series A to Series B (in shares)										2,252,000
Exchange of Series A to Series B	61,997				43,395						18,602
Stock-based compensation	155			155
Forfeitures of stock based awards (in shares)			(2,000)
Net loss	(685)				(685)
Balance at Jun. 30, 2023	1,275			62,938	(80,691)			426			18,602
Balance (in shares) at Jun. 30, 2023		1,883,000	(11,000)
Balance (in shares) at Jun. 30, 2023							560,000			2,252,000
Stock-based compensation	85			85
Net loss	(973)				(973)
Balance at Sep. 30, 2023	$ 387			$ 63,023	$ (81,664)			$ 426			$ 18,602
Balance (in shares) at Sep. 30, 2023	1,894,000	1,883,000	(11,000)
Balance (in shares) at Sep. 30, 2023						560,000	560,000		2,252,272	2,252,000

XML

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Series A Preferred Stock
Preferred stock, par value	$ 0	$ 0
Series A Preferred Stock | Preferred Stock
Preferred stock, par value	0		$ 0
Series B Preferred Stock
Preferred stock, par value	0	$ 0
Series B Preferred Stock | Preferred Stock
Preferred stock, par value	$ 0		$ 0

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (3,650)	$ (4,623)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	1,738	1,819
Stock-based compensation expense	321	173
Rent expense (less than) in excess of cash paid	(18)	126
Rent revenue less than (in excess) of cash received	(298)	(1,410)
Amortization of deferred financing costs, debt discounts and premiums	56	67
Bad debt expense	269	3,742
Changes in operating assets and liabilities:
Accounts receivable	4,053	(4,349)
Prepaid expenses and other assets	1,157	533
Lease deposits and other deposits	(4)
Accounts payable and accrued expenses	(739)	2,013
Other liabilities	575	(262)
Net cash provided by (used in) operating activities	3,460	(2,171)
Cash flows from investing activities:
Purchase of property and equipment	(916)	(183)
Net cash used in investing activities	(916)	(183)
Cash flows from financing activities:
Payment of senior debt	(988)	(1,219)
Payment of other debt	(813)	(882)
Debt extinguishment and issuance costs	(17)
Proceeds from other debt		50
Repurchase of common stock		(46)
Net cash used in financing activities	(1,818)	(2,097)
Net change in cash and restricted cash	726	(4,451)
Cash and restricted cash, beginning	3,909	9,848
Cash and restricted cash, ending	4,635	5,397
Supplemental disclosure of cash flow information:
Cash interest paid	2,004	1,797
Supplemental disclosure of non-cash activities:
Vendor-financed insurance	962	$ 1,078
Exchange of preferred stock Series A to Series B	18,602
Gain on extinguishment of preferred stock	43,395
Account receivable converted to note receivable	$ 312

XML

Organization and Significant Accounting Policies

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Organization and Significant Accounting Policies

NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Regional Health Properties, Inc.'s (the "Company" or "Regional Health") predecessor was incorporated in Ohio on August 14, 1991, under the name Passport Retirement, Inc. In 1995, Passport Retirement, Inc. acquired substantially all of the assets and liabilities of AdCare Health Systems, Inc. and changed its name to AdCare Health Systems, Inc. ("AdCare"). AdCare completed its initial public offering in November 2006, relocated its executive offices and accounting operations to Georgia in 2012, and changed its state of incorporation from Ohio to Georgia in December 2013. Regional Health Properties, Inc. is a self-managed real estate investment company that invests primarily in real estate purposed for long-term care and senior housing. Our business primarily consists of leasing such facilities to third-party tenants, which operate the facilities. The Company has two primary reporting segments: (i) Real Estate Services, which consists of the leasing and subleasing of long-term care and senior living facilities to third-party tenants, including the Company's management of three facilities on behalf of third-party owners; and (ii) Healthcare Services, which consists of the operation of the Meadowood and Glenvue facilities. Effective August 3, 2023, the Company’s 12.5% Series B Cumulative Redeemable Preferred Shares (the “Series B Preferred Stock”) is quoted on the OTC Markets Group, Inc.’s OTCQB Venture Market under the symbol “RHEPB”.

Basis of Presentation

The accompanying consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles ("GAAP") in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"). The accompanying consolidated financial statements are unaudited and should be read in conjunction with the 2022 audited consolidated financial statements and notes thereto, which are included in our 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on April 14, 2023 ("Annual Report").

In the opinion of management, the unaudited consolidated financial statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company's financial position and the results of its operations and cash flows for such periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.

Reclassifications

Certain reclassifications have been made to the amounts in prior periods in order to conform to the current period's presentation. A reclassification has been made to the stock balances on the consolidated statement of stockholders’ equity in prior periods in order to conform to the current period's presentation.

Principles of Consolidations

The consolidated financial statements include the Company's majority owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated through consolidation.

Variable Interest Entities

The Company has a loan receivable with Peach Health, a sublessee. Such agreement creates a variable interest in the Peach Health sublessee that may absorb some or all of the expected losses of the entity. The Company does not consolidate the operating activities of the Peach Health sublessee as the Company does not have the power to direct the activities that most significantly impact the entity's economic performance.

Revenue Recognition and Allowances

Patient Care Revenue. ASC Topic 606, Revenue from Contracts with Customers requires a company to recognize revenue when the company transfers control of promised goods and services to a customer. Revenue is recognized in an amount that reflects the consideration to which a company expects to receive in exchange for such goods and services. Revenue from our Healthcare Services business segment is derived from services rendered to patients in the Meadowood and Glenvue facilities. The Company receives payments from the following sources for services rendered in our facilities: (i) the federal government under the Medicare program administered by the U.S. Department of Health and Human Services Centers for Medicare and Medicaid Services ("CMS"); (ii) state governments under their respective Medicaid and similar programs; (iii) commercial insurers; and (iv) individual patients and clients. The vast majority of the revenue the Company recognizes is from government sources. The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and other price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. The Company recognizes revenue at the amount that reflects the consideration the Company expects to receive in exchange for the services provided. These amounts are due from residents or third-party payors and include variable consideration for retroactive adjustments from estimated reimbursements, if any, under reimbursement programs. Performance obligations are determined based on the nature of the services provided. Revenue is recognized as performance obligations are satisfied. Estimated uncollectable amounts due from patients are generally considered implicit price concessions that are a direct reduction to net operating revenues.

Triple-Net Leased Properties. The Company recognizes rental revenue in accordance with ASC 842, Leases. The Company's triple-net leases provide for periodic and determinable increases in rent. The Company recognizes rental revenues under these leases on a straight-line basis over the applicable lease term when collectability is probable. Recognizing rental income on a straight-line basis generally results in recognized revenues during the first half of a lease term exceeding the cash amounts contractually due from our tenants, creating a straight-line rent receivable that is included in the straight-line rent receivable on our consolidated balance sheets. In the event the Company cannot reasonably estimate the future collection of rent from one or more tenant(s) of the Company's facilities, rental income for the affected facilities is recognized only upon cash collection, and any accumulated straight-line rent receivable is expensed in the period in which the Company deems rent collection to no longer be probable.

Management Fee Revenues and Other Revenues. The Company recognizes management fee revenues as services are provided. The Company has one contract to manage three facilities (the "Management Contract"), with payment for each month of service generally received in full on a monthly basis. The maximum penalty for service contract nonperformance under the Management Contract is $50,000 per year, payable after the end of the year. Further, the Company recognizes interest income from loans and investments, using the effective interest method when collectability is probable. The Company applies the effective interest method on a loan-by-loan basis. On June 30, 2023, the Company received a notice of termination, pursuant to which the Management Contract will terminate on December 31, 2023.

Allowances. The Company assesses the collectability of its rent receivables, including straight-line rent receivables, working capital loans to tenants and patient reimbursement. The Company bases its assessment of the collectability of rent receivables and working capital loans to tenants on several factors, including payment history, the financial strength of the tenant and any guarantors, the value of the underlying collateral, and current economic conditions. If the Company's evaluation of these factors indicates it is probable that the Company will be unable to receive the rent payments or payments on a working capital loan, then the Company provides a reserve against the recognized straight-line rent receivable asset or working capital loan for the portion that we estimate may not be recovered. Payments received on impaired loans are applied against the allowance. If the Company changes its assumptions or estimates regarding the collectability of future rent payments, then the Company may adjust its reserve to the rental or interest revenue recognized in the period the Company makes such change. See Note 6 – Leases. Regarding patient reimbursements, the Company assesses the patient receivable based on payor type and age of the receivable amongst several other factors. The Company has reserved for approximately 1.5% of our patient care revenue based on the historical performance and industry practices.

As of September 30, 2023 and December 31, 2022, the Company reserved for approximately $1.6 million and $1.3 million, respectively, of uncollected receivables. Accounts receivable, net of allowance, totaled $2.0 million at September 30, 2023 and $6.3 million at December 31, 2022.

The following table presents the Company's Accounts receivable, net of allowance for the periods presented:

(Amounts in 000’s)	September 30, 2023			December 31, 2022
Gross receivables
Real Estate Services	$	908		$	1,094
Healthcare Services		2,706			6,493
Subtotal		3,614			7,587
Allowance
Real Estate Services		(338	)		(338	)
Healthcare Services		(1,241	)		(960	)
Subtotal		(1,579	)		(1,298	)
Accounts receivable, net of allowance	$	2,035		$	6,289

Prepaid Expenses and Other

As of September 30, 2023 and December 31, 2022, the Company had approximately $0.9 million and $0.7 million , respectively, in prepaid expenses and other; the $0.2 million increase is related to insurance for the Meadowood and Glenvue facility operations, while the other amounts are predominantly for directors' and officers' insurance, NYSE American annual fees, and mortgage insurance premiums.

Accounts Payable

The following table presents the Company's Accounts payable for the periods presented:

(Amounts in 000’s)	September 30, 2023		December 31, 2022
Accounts payable
Real Estate Services	$	1,052	$	797
Healthcare Services		1,731		2,496
Total Accounts payable	$	2,783	$	3,293

Other Expense, net

The Company retained a law firm to evaluate and assist with possible opportunities to improve the Company's capital structure. For the three months ended September 30, 2023 and September 30, 2022, these costs were $0.3 million and $0.2 million, respectively. For the nine months ended September 30, 2023 and September 30, 2022, these costs were $0.8 million and $1.1 million, respectively.

Leases and Leasehold Improvements

The Company leases certain facilities and equipment in the normal course of business. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating lease or finance lease. As of September 30, 2023, all of the Company's leased facilities are accounted for as operating leases. For operating leases that contain scheduled rent increases, the Company records rent expense on a straight-line basis over the term of the lease. Leasehold improvements are amortized over the shorter of the useful life of the asset or the lease term.

The Company recognizes both right of use assets and lease liabilities for leases in which we lease land, real property, or other equipment. We assess any new contracts or modification of contracts in accordance with ASC 842, Leases to determine the existence of a lease and its classification.

We report revenues and expenses for real estate taxes and insurance where the lessee has not made those payments directly to a third-party in accordance with its respective leases with us. Additionally, we expense certain leasing costs, other than leasing commissions, as they are incurred. The present value of minimum lease payments was calculated on each lease, using a discount rate that approximated our incremental borrowing rate and the current lease term. See Note 6– Leases for more information on the Company's operating leases.

Insurance

We maintain general liability, professional liability, and other insurance policies in amounts and with coverage and deductibles we believe are appropriate, based on the nature and risks of our business, historical experience, availability, and industry standards, including for the operations at the Glenvue and Meadowood facilities. Our current policies provide for deductibles for each claim and contain various exclusions from coverage. The Company has self-insured against professional and general liability claims related to its healthcare operations that were discontinued during 2014 and 2015 in connection with its transition from an owner and operator of healthcare properties to a healthcare property holding and leasing company (the "Transition"). For further information, see Note 11 – Commitments and Contingencies, and Note 13 – Commitments and Contingencies, to the consolidated financial statements for the year ended December 31, 2022 for more information. The Company evaluates quarterly the adequacy of its self-insurance reserve based on a number of factors, including: (i) the number of actions pending and the relief sought; (ii) analyses provided by defense counsel, medical experts or other information which comes to light during discovery; (iii) the legal fees and other expenses anticipated to be incurred in defending the actions; (iv) the status and likely success of any mediation or settlement discussions, including estimated settlement amounts and legal fees and other expenses anticipated to be incurred in such settlement, as applicable; and (v) the venues in which the actions have been filed or will be adjudicated. The Company believes that most of the professional and general liability actions are defensible and intends to defend them through final judgment unless settlement is more advantageous to the Company. Accordingly, the self-insurance reserve reflects the Company's estimate of settlement amounts for the pending actions, if applicable, and legal costs of settling or litigating the pending actions, as applicable. Because the self-insurance reserve is based on estimates, the amount of the self-insurance reserve may not be sufficient to cover the settlement amounts actually incurred in settling the pending actions, or the legal costs actually incurred in settling or litigating the pending actions. See Note 7 – Accrued Expenses. In addition, the Company maintains certain other insurance programs, including commercial general liability, property, casualty, directors' and officers' liability, crime, and employment practices liability.

Discontinued Operations

Prior to December 2015, the Company’s business focused primarily on owning and operating skilled nursing facilities ("SNF") and managing such facilities for unaffiliated owners with whom the Company had management contracts. These operations were discontinued and transitioned to the leasing model of business.

As of September 30, 2023 and December 21, 2022 the Company determined remaining escheatment liabilities for discontinued operations are $0.8 million and are included in accrued expenses.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the respective period. Diluted earnings per share is similar to basic net loss per share except that the net loss is adjusted by the impact of the weighted-average number of shares of common stock outstanding including potentially dilutive securities (such as options, warrants and non-vested common stock) when such securities are not anti-dilutive. Potentially dilutive securities from options, warrants and unvested restricted shares are calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all options and warrants with exercise prices exceeding the average market value are used to repurchase common stock at market value. The incremental shares remaining after the proceeds are exhausted represent the potentially dilutive effect of the securities.

Securities outstanding that were excluded from the computation, because they would have been anti-dilutive were as follows:

	September 30,
(Share amounts in 000’s)	2023		2022
Stock options		37		13
Warrants - employee		32		34
Warrants - non employee		1		5
Total anti-dilutive securities		70		52

The weighted average contractual terms in years for these securities as of September 30, 2023, with no intrinsic value, are 6.3 years for the stock options and 1.2 years for the warrants.

New Accounting Pronouncements Issued But Not Yet Effective

In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842): Common Control Arrangements (Topic 842) amendments, which requires entities to determine whether related party arrangements between entities under common control are leases. The amendments also address the accounting treatment of leasehold improvements associated with common control leases. They require the lessee to amortize leasehold improvements over the useful life of the improvements to the common control group, regardless of the lease term, as long as the lessee controls the use of the underlying asset. If the lessee no longer controls the use of the asset, the leasehold improvements are accounted for as a transfer between entities under common control through an adjustment to equity. These improvements are also subject to impairment guidance in Topic 360, Property, Plant, and Equipment. The amendment is effective for public entities beginning after December 15, 2023. The Company is currently evaluating the impact of ASU 2023-01 on its financial statements.

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company's financial statements.

XML

Liquidity

9 Months Ended

Sep. 30, 2023

Liquidity [Abstract]

Liquidity

NOTE 2. LIQUIDITY

Overview

The Company intends to pursue measures to grow its operations, streamline its cost infrastructure and otherwise increase liquidity, including: (i) refinancing or repaying debt to reduce interest costs and mandatory principal repayments, with such repayment to be funded through potentially expanding borrowing arrangements with certain lenders; (ii) increasing future lease revenue through acquisitions and investments in existing properties; (iii) modifying the terms of existing leases; (iv) replacing certain tenants who default on their lease payment terms; and (v) reducing other and general and administrative expenses.

Management anticipates access to several sources of liquidity, including cash on hand, cash flows from operations, and debt refinancing, during the twelve months following the date of this filing. At September 30, 2023, the Company had $1.4 million in unrestricted cash.

During the nine months ended September 30, 2023, the Company's cash provided by operating activities was $3.5 million primarily due to collection of the Employee Retention Tax Credit. The Company is seeking collection of the past due rent. In addition, management is working to expedite the time it takes to collect and receive aged patient receivables. Cash flow from operations in the future will be based on the operational performance of the facilities under the company's management, Glenvue and Meadowood, as well as continued uncertainty of the COVID-19 pandemic and its impact on the Company's business, financial condition and results of operations.

Series A Preferred Stock Exchange Offer

In connection with the completion of the Exchange Offer and the implementation of the Series A Charter Amendments and the Series B Charter Amendments, the liquidation preference of the Series A Preferred Stock was reduced, accumulated and unpaid dividends on the Series A Preferred Stock were eliminated and future dividends on the Series A Preferred Stock were eliminated. As a result, $50.4 million in accumulated and unpaid dividends on the Series A Preferred Stock were eliminated and, as of September 30, 2023, there are no accumulated and unpaid dividends on the Series A Preferred Stock. For further information regarding the Exchange Offer, Series A Charter Amendments and Series B Charter Amendments, see Note 9 – Common and Preferred Stock.

Debt

As of September 30, 2023, the Company had $51.4 million in indebtedness, net of $1.1 million deferred financing costs and unamortized discounts. The Company anticipates net principal repayments of approximately $2.3 million during the next

twelve-month period, approximately $1.5 million of routine debt service amortization, $0.7 million of insurance financing amortization, and a $0.1 million payment of bond debt.

Debt Extinguishment

On December 30, 2022, the Company extended the maturity date on approximately $0.5 million other debt from August 25, 2023 to August 25, 2025 (the "Key Bank Exit Notes"). For further information, see Note 8 – Notes Payable and Other Debt.

On October 21, 2022, the Company, through wholly-owned subsidiaries, consummated a U.S. Department of Housing and Urban Development ("HUD") refinancing of its senior mortgages on three SNFs in Ohio. Funding was provided by Newpoint Real Estate Capital LLC ("Newpoint") pursuant to three HUD guaranteed secured Healthcare Facility Notes (the "HUD Notes"). Proceeds from the HUD Notes were used to pay off existing HUD guaranteed secured mortgages and pay transaction costs. Newpoint is the servicer on other loans extended to the Company.

Consequently, the Company recorded a net loss of approximately $0.4 million on extinguishment of debt during the year ended December 31, 2022, consisting of a $0.2 million prepayment penalty and $0.2 million of expensed deferred financing fees associated with the extinguishment of the Eaglewood Care Center, The Pavilion Care Center, and Hearth & Care of Greenfield loans.

The aggregate principal amount of the three HUD Notes is $7.6 million, and the interest rate on the three HUD Notes is 3.97% fixed for the full term of each HUD Note. The Northwood HUD Note has a principal amount of $4.9 million and matures on November 1, 2052. The Greenfield HUD Note has a principal amount of $1.9 million and matures on November 1, 2050. The Pavilion HUD Note has a principal amount of $0.8 million and matures on December 1, 2039. Payments of principal and interest on the HUD Notes commenced on October 1, 2022. Each HUD Note is secured by a Healthcare Deed to Secure Debt, Security Agreement and Assignment of Rents covering the facilities. Newpoint may declare the loans, accrued interest and any other amounts immediately due and payable upon certain customary events of default.

Debt Covenant Compliance

At September 30, 2023, the Company was in compliance with the various financial and administrative covenants related to all of the Company's credit facilities.

Changes in Operational Liquidity

COVID-19. Many of our operators have reported incurring significant cost increases as a result of the COVID-19 pandemic. We believe these increases primarily stem from elevated labor costs, including increased use of overtime and bonus pay, as well as a significant increase in both the cost and usage of personal protective equipment, testing equipment, processes and supplies. In terms of occupancy levels, many of our operators have reported experiencing declines, in part due to the elimination or suspension of elective hospital procedures, fewer discharges from hospitals to SNFs, and higher hospital readmittances from SNFs. The COVID-19 pandemic may also lead to temporary closures of nursing facilities operated by our tenants, impairing our tenants’ ability to make their rental payments to us pursuant to their respective lease agreements.

Portfolio Stabilization Measures. In the past, our operators did not provide lease guarantees from affiliated entities. Given this, certain operators have terminated their leases in light of operational difficulties caused by the COVID-19 pandemic. While the Company is a self-managed real estate investment company that invests in real estate, when business conditions require, the Company undertakes portfolio stabilization measures. The table below summarizes the lease terminations related to existing properties as of September 30, 2023 since the onset of the COVID-19 pandemic and the Company’s resulting portfolio stabilization measures:

Date	Facility Name	Former Operator	Current Operator
April 2022	Meadowood	C.R. Management	Regional Health (managed by Cavalier Senior Living Operations)
August 2022	Glenvue	C.R. Management	Regional Health

For more information, see Note 1 – Organization and Significant Accounting Policies, Note 6 – Leases and Note 12 – Segment Results.

Capital Requirements. The operation of the facilities listed above will require additional working capital, which is partially offset by cash flow received from the operation of these facilities. Since January, 2021, the Company's Accounts Receivable, net of allowance and Accounts Payable for the Healthcare Services segment have grown to $1.8 million and $1.7 million, respectfully.

On December 30, 2022, the Company and Spring Valley, LLC (“Spring Valley”) entered into a Lease Termination Agreement (the “Lease Termination Agreement”) relating to the lease of the following eight nursing facilities: the Powder Springs facility, the Thomasville facility, the Jeffersonville facility, the Lumber City facility, the LaGrange facility, the Tara facility, the Oceanside facility and the Savannah Beach facility (collectively, the “Facilities”). The Lease Termination Agreement terminated the lease effective December 7, 2022 (the “Lease Termination Date”). Since the termination, management has been focusing on collecting the Accounts Receivable and paying the Accounts Payable associated with the referenced facilities.

Evaluation of the Company's Ability to Continue as a Going Concern

Under the accounting guidance related to the presentation of financial statements, the Company is required to evaluate, on a quarterly basis, whether or not the Company's current financial condition, including its sources of liquidity at the date that the consolidated financial statements are issued, will enable the Company to meet its obligations as they come due arising within one year of the date of the issuance of the Company's consolidated financial statements and to make a determination as to whether or not it is probable, under the application of this accounting guidance, that the Company will be able to continue as a going concern. The Company's consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

In applying applicable accounting guidance, management considered the Company's current financial condition and liquidity sources, including current funds available, forecasted future cash flows, the Company's obligations due over the next twelve months, and the Company's recurring business operating expenses.

The Company concluded that it is probable that the Company will be able to meet its obligations arising within one year of the date of issuance of these consolidated financial statements within the parameters set forth in the accounting guidance.

XML

Cash and Restricted Cash

9 Months Ended

Sep. 30, 2023

Restricted Cash and Investments [Abstract]

Cash and Restricted Cash

NOTE 3. CASH AND RESTRICTED CASH

The following presents the Company's cash and restricted cash:

(Amounts in 000’s)	September 30, 2023		December 31, 2022
Cash	$	1,427	$	843
Restricted cash:
Cash collateral	$	118	$	135
HUD and other replacement reserves		2,138		2,155
Escrow deposits		635		459
Restricted investments for debt obligations		317		317
Total restricted cash		3,208		3,066
Total cash and restricted cash	$	4,635	$	3,909

Cash collateral—In securing mortgage financing from certain lending institutions, the Company and certain of its wholly-owned subsidiaries are required to deposit cash to be held as collateral in accordance with the terms of such loan agreements.

HUD and other replacement reserves—The regulatory agreements entered into in connection with the financing secured through HUD require monthly escrow deposits for replacement and improvement of the HUD project assets.

Escrow deposits—In connection with financing secured through the Company's lenders, several wholly-owned subsidiaries of the Company are required to make monthly escrow deposits for taxes and insurance.

Restricted cash for debt obligations—In compliance with certain financing and insurance agreements, the Company and certain wholly-owned subsidiaries of the Company are required to deposit cash held as collateral by the lender or in escrow with certain designated financial institutions.

XML

Property and Equipment

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Property and Equipment

NOTE 4. PROPERTY AND EQUIPMENT

The following table sets forth the Company's property and equipment:

(Amounts in 000’s)	Estimated Useful Lives (Years)		September 30, 2023			December 31, 2022
Buildings and improvements	5-40		$	64,429		$	63,746
Equipment and computer related	2-10			1,615			1,807
Land (1)		—		2,774			2,774
Property and equipment				68,818			68,327
Less: accumulated depreciation and amortization				(23,012	)		(21,716	)
Property and equipment, net			$	45,806		$	46,611

(1)Includes $0.1 million of land improvements with an average estimated useful remaining life of approximately 5.3 years.

The following table summarizes total depreciation and amortization expense three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Amounts in 000’s)	2023		2022		2023		2022
Depreciation	$	416	$	490	$	1,409	$	1,490
Amortization		110		110		329		329
Total depreciation and amortization expense	$	526	$	600	$	1,738	$	1,819

XML

Intangible Assets and Goodwill

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

NOTE 5. INTANGIBLE ASSETS AND GOODWILL

Intangible assets and Goodwill consist of the following:

(Amounts in 000’s)	Bed licenses (included in property and equipment) (1)			Bed Licenses - Separable (2)		Lease Rights			Total			Goodwill (2)
Balances, December 31, 2022
Gross	$	14,276		$	2,471	$	206		$	16,953		$	1,585
Accumulated amortization		(4,583	)		—		(96	)		(4,678	)		—
Net carrying amount	$	9,693		$	2,471	$	110		$	12,275		$	1,585
Balances, September 30, 2023
Gross		14,276			2,471		206			16,953			1,585
Accumulated amortization		(4,894	)		—		(114	)		(5,008	)		—
Net carrying amount	$	9,382		$	2,471	$	92		$	11,945		$	1,585

(1)Non-separable bed licenses are included in property and equipment as is the related accumulated amortization expense (see Note 4 – Property and Equipment).

(2)The Company does not amortize indefinite-lived intangibles, which consist of separable bed licenses and goodwill.

The following table summarizes amortization expense for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Amounts in 000’s)	2023		2022		2023		2022
Bed licenses	$	104	$	104	$	311	$	311
Lease rights		6		6		18		18
Total amortization expense	$	110	$	110	$	329	$	329

Expected amortization expense for the years ending December 31, for all definite-lived intangibles, for each of the next five years and thereafter is as follows:

(Amounts in 000’s)	Bed Licenses		Lease Rights
2023 (3 months remaining)	$	103	$	6
2024		414		24
2025		414		24
2026		414		24
2027		414		14
Thereafter		7,623		-
Total expected amortization expense	$	9,382	$	92

XML

Leases

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Leases

NOTE 6. LEASES

Facility and Office Lessee

As of September 30, 2023, the Company leased one SNF under a non-cancelable operating lease, which had rent escalation clauses and provisions for payments of real estate taxes, insurance, and maintenance costs. The Company also leased certain office space located in Suwanee, Georgia through the termination date of June 30, 2023. Effective July 1, 2023, the Company signed a sublease for 2,000 sq ft of office space in Dunwoody, GA. The sublease expires on July 31, 2025.

The remaining lease term for this one facility and our office lease is approximately 5.6 years and 1.8 years, respectively. As of September 30, 2023, the Company was in compliance with all operating lease financial covenants.

Future Minimum Lease Payments

Future minimum lease payments for the twelve months ending December 31, for each of the next five years and thereafter is as follows:

(Amounts in 000’s)	Future rental payments		Accretion of lease liability (1)			Operating lease obligation
2023 (3 months remaining)	$	156	$	(2	)	$	154
2024		633		(39	)		594
2025		645		(85	)		560
2026		658		(131	)		527
2027		671		(174	)		497
Thereafter		914		(298	)		616
Total	$	3,677	$	(729	)	$	2,948

(1)Weighted average discount rate 3.85%.

Facilities Lessor

On August 11, 2023, the Company and its former tenant, SL SNF, LLC, entered into a lease amendment (the “Amendment”) regarding the Southland facility. The amendment reduces the monthly rent to $43,000 effective April 1, 2023 and includes a $312,000 promissory note (the “Promissory Note”). The lease termination date under the amendment is October 31, 2024. Under the terms of the Promissory Note, the principal sum plus all accrued interest, accruing on the unpaid principal balance at

a rate of 8% per annum, is due and payable on December 1, 2024, with minimum monthly payments of principal and interest of $18,353 per month beginning on July 1, 2023. As on September 30, 2023, no promissory note payments have been received from SL SNF, LLC.

As of September 30, 2023, the Company was the lessor of 9 of its 11 owned facilities, and the sublessor of one facility. These leases are triple net basis leases, meaning that the lessee (i.e., the third-party tenant of the property) is obligated for all costs of operating the property, including insurance, taxes and facility maintenance, as well as the lease or sublease payments to the Company. The weighted average remaining lease term for our 10 owned and subleased out facilities is approximately 5.5 years.

Future Minimum Lease Receivables

Future minimum lease receivables for the twelve months ending December 31, for each of the next five years and thereafter is as follows:

	(Amounts in 000's)
2023 (3 months remaining)	$	1,577
2024		6,187
2025		6,034
2026		5,362
2027		5,445
Thereafter		11,605
Total	$	36,210

For further details regarding the Company's leased and subleased facilities to third-party operators, including a full summary of the Company's leases to third-parties and which comprise the future minimum lease receivables of the Company, see Note 6 - Leases and Leasing Transactions in Part II, Item 8, Financial Statements and Supplementary Data, included in the Annual Report.

XML

Accrued Expenses

9 Months Ended

Sep. 30, 2023

Payables and Accruals [Abstract]

Accrued Expenses

NOTE 7. ACCRUED EXPENSES

Accrued expenses consist of the following:

(Amounts in 000’s)	September 30, 2023		December 31, 2022
Accrued employee benefits and payroll-related	$	328	$	539
Real estate and other taxes (1)		2,891		2,428
Self-insured reserve		62		80
Accrued interest		222		210
Unearned rental revenue		-		43
Medicaid overpayment - Healthcare Services		56		169
Insurance escrow		79		—
Other accrued expenses		1,168		1,567
Total accrued expenses	$	4,806	$	5,036

(1)September 30, 2023 includes approximately $2.5 million of franchise tax accruals for the Healthcare Services segment. December 31, 2022 includes approximately $2.2 million of franchise tax accruals for the Healthcare Services segment.

XML

Notes Payable and Other Debt

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Notes Payable and Other Debt

NOTE 8. NOTES PAYABLE AND OTHER DEBT

See Note 8 – Notes Payable and Other Debt in Part II, Item 8, Financial Statements and Supplementary Data, included in the Annual Report for a detailed description of all the Company's debt facilities.

Notes payable and other debt consists of the following:

(Amounts in 000’s)	September 30, 2023			December 31, 2022
Senior debt—guaranteed by HUD	$	29,183		$	29,782
Senior debt—guaranteed by USDA (1)		7,332			7,526
Senior debt—guaranteed by SBA(2)		562			580
Senior debt—bonds		6,117			6,253
Senior debt—other mortgage indebtedness		8,089			8,266
Other debt		1,181			895
Subtotal		52,464			53,302
Deferred financing costs		(971	)		(1,005	)
Unamortized discount on bonds		(115	)		(119	)
Notes payable and other debt	$	51,378		$	52,178

(1)U.S. Department of Agriculture ("USDA")

(2)U.S. Small Business Administration ("SBA")

The following is a detailed listing of the debt facilities that comprise each of the above categories:

(Amounts in 000’s)
Facility	Lender	Maturity	Interest Rate (1)			September 30, 2023		December 31, 2022
Senior debt - guaranteed by HUD (2)
The Pavilion Care Center	Newpoint Capital	12/01/2039	Fixed	3.97	%	$	810	$	835
Hearth and Care of Greenfield	Newpoint Capital	8/01/2050	Fixed	3.97	%		1,919		1,949
Woodland Manor	Newpoint Capital	11/01/2052	Fixed	3.97	%		4,913		4,980
Glenvue	Newpoint Capital	10/01/2044	Fixed	3.75	%		7,134		7,297
Autumn Breeze	KeyBank	01/01/2045	Fixed	3.65	%		6,203		6,344
Georgetown	Newpoint Capital	10/01/2046	Fixed	2.98	%		3,144		3,214
Sumter Valley	KeyBank	01/01/2047	Fixed	3.70	%		5,061		5,163
Total						$	29,184	$	29,782
Senior debt - guaranteed by USDA (3)
Mountain Trace (4)	Community B&T	12/24/2036	Prime + 1.75%	10.00	%	$	3,575	$	3,680
Southland (5)	Cadence Bank, NA	07/27/2036	Prime + 1.50%	9.75	%		3,757		3,846
Total						$	7,332	$	7,526
Senior debt - guaranteed by SBA
Southland(6)	Cadence Bank, NA	07/27/2036	Prime + 2.25%	10.50	%	$	562	$	580
Total						$	562	$	580

(1)Represents cash interest rates as of September 30, 2023 as adjusted for interest rate floor limitations, if applicable. The rates exclude amortization of deferred financing costs, which range from 0.09% to 0.53% per annum.

(2)For the seven SNFs, the Company has term loans with financial institutions that are insured 100% by HUD. The loans are secured by, among other things, an assignment of all rents paid under any existing or future leases and rental agreements with respect to the underlying facility. The loans contain customary events of default, including fraud or material misrepresentations or material omission, the commencement of a forfeiture action or proceeding, failure to make required payments, and failure to perform or comply with certain agreements. Upon the occurrence of certain events of default, the lenders may, after receiving the prior written approval of HUD, terminate the loans and all amounts under the loans will become immediately due and payable. In connection with entering into each loan, the Company entered into a healthcare regulatory agreement and a promissory note, each containing customary terms and conditions. Pursuant to the CARES Act, up to three months of debt service payments for six of the credit facilities can be made from our restricted cash reserves.

(3)For the two SNFs, the Company has term loans with financial institutions that are insured 70% to 80% by the USDA. The loans have an annual renewal fee for the USDA guarantee of 0.25% of the guaranteed portion. The loans had prepayment penalties of 1%, capped at 1% for the remainder of the first 10 years of the term and 0% thereafter.

(4)Pursuant to the CARES Act, the monthly principal and interest payments due May 1, 2020 through August 1, 2020 for the Mountain Trace Facility loan were deferred. Monthly payments that commenced on September 1, 2020 were being applied to current interest, then deferred interest until the deferred interest was paid in full on April 1, 2021. Payments have been re-amortized over the extended term of the loan.

(5)Pursuant to the CARES Act, the monthly principal and interest payments due May 1, 2020 through October 1, 2020 for the loan for that certain 126-bed SNF commonly known as Southland, located in Dublin, Georgia, were deferred as a part of the USDA Payment Program. Monthly payments recommenced on November 1, 2020 with payments through February 2021 being applied to principal and interest. Monthly payments that commenced on March 1, 2021 are being applied to current interest, then deferred interest until the deferred interest is paid in full, payments will be re-amortized over the extended term of the loan.

(6)For the one SNF, commonly known as Southland, the Company has a term loan with a financial institution, which is 75% insured by the SBA. The SBA funded two monthly debt payments during the three months ended March 31, 2021 and six payments commencing on March 1, 2020 and ending on August 1, 2020.

(Amounts in 000’s)
Facility	Lender	Maturity	Interest Rate (1)			September 30, 2023		December 31, 2022
Senior debt - bonds
Eaglewood Bonds Series A	City of Springfield, Ohio	05/01/2042	Fixed	7.65	%	$	6,117	$	6,253

(1)Represents cash interest rates as of September 30, 2023. The rates exclude amortization of deferred financing of approximately 0.1% per annum.

(Amounts in 000’s)
Facility	Lender	Maturity	Interest Rate (1)			September 30, 2023		December 31, 2022
Senior debt - other mortgage indebtedness
Meadowood (2)	Exchange Bank of Alabama	10/01/2026	Fixed	4.50	%	$	3,279	$	3,319
Coosa (3)	Exchange Bank of Alabama	10/10/2026	Fixed	3.95	%		4,810		4,946
Total						$	8,089	$	8,266

(1)Represents cash interest rates as of September 30, 2023 as adjusted for interest rate floor limitations, if applicable. The rates exclude amortization of deferred financing costs of 0.34% per annum.

(2)On October 1, 2021, the Exchange Bank of Alabama and the Company extended the maturity date of the Meadowood Credit Facility which is secured by the Meadowood Facility and the assets of Coosa, and which is guaranteed by Regional Health Properties, Inc., from May 1, 2022 to October 1, 2026.

(3)On September 30, 2021, the Company refinanced the MCB Coosa Loan secured by the Coosa Facility, incurring approximately $0.1 million in new fees. The Coosa Credit Facility, guaranteed by Regional Health Properties, Inc. includes customary terms, including events of default with an associated annual 5% default interest rate, and is secured by the Coosa Facility and the assets of Meadowood. Upon the occurrence of certain events of default, the lenders may terminate the Coosa Credit Facility and the Meadowood Credit Facility and all amounts due under both credit facilities will become immediately due and payable. The Coosa Credit Facility has prepayment penalties of 5% in the first year, 4% in the second year and 1% thereafter.

(Amounts in 000’s)
Lender	Maturity	Interest Rate			September 30, 2023		December 31, 2022
Other debt
First Insurance Funding (1)	Various 2023	Fixed	3.19	%	$	658	$	357
Key Bank (2)	08/25/2025	Fixed	0.00	%		495		495
Marlin Capital Solutions	06/1/2027	Fixed	5.00	%		28		43
Total					$	1,181	$	895

(1)Annual Insurance financing primarily for the Company's directors and officers insurance and professional liability for the facilities where the company is the licensed operator.

(2)On December 30, 2022, Key Bank and the Company extended the maturity date from August 25, 2023 to August 25, 2025.

Debt Covenant Compliance

As of September 30, 2023, the Company had 16 credit related instruments outstanding that include various financial and administrative covenant requirements. Covenant requirements include, but are not limited to, fixed charge coverage ratios, debt service coverage ratios, minimum earnings before interest, taxes, depreciation, and amortization or earnings before interest, taxes, depreciation, amortization, and restructuring or rent costs, and current ratios. Certain financial covenant requirements are based on consolidated financial measurements whereas others are based on measurements at the subsidiary level (i.e., facility, multiple facilities or a combination of subsidiaries). The subsidiary level requirements are as follows: (i) financial covenants measured against subsidiaries of the Company; and (ii) financial covenants measured against third-party operator performance. Some covenants are based on annual financial metric measurements, whereas others are based on monthly and quarterly financial metric measurements. The Company routinely tracks and monitors its compliance with its covenant requirements.

As of September 30, 2023, the Company was in compliance with the various financial and administrative covenants under the Company's outstanding credit related instruments.

Scheduled Maturities

The schedule below summarizes the scheduled gross maturities as of September 30, 2023 for each of the next five years and thereafter.

For the Twelve Months Ended December 31,	(Amounts in 000’s)
2023 (3 months remaining)	$	660
2024		2,046
2025		2,269
2026		8,746
2027		1,562
Thereafter		37,181
Subtotal	$	52,464
Less: unamortized discounts		(115	)
Less: deferred financing costs, net		(971	)
Total notes and other debt	$	51,378

XML

Common and Preferred Stock

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Common and Preferred Stock

NOTE 9. COMMON AND PREFERRED STOCK

On June 27, 2023, the Company convened a special meeting (the “Special Meeting”) of the holders of its 10.875% Series A Cumulative Redeemable Preferred Shares (the “Series A Preferred Stock”) and the holders of its common stock (the “Common Stock”) and Series E Redeemable Preferred Shares (the “Series E Preferred Stock”). The Special Meeting was called to consider the proposals set forth in the Company’s definitive proxy statement/prospectus filed with the SEC on May 25, 2023 (as supplemented or amended, the “Proxy Statement/Prospectus”) in connection with the Company’s offer to exchange (the “Exchange Offer”) any and all outstanding shares of the Series A Preferred Stock for newly issued shares of the Company’s Series B Preferred Stock. The expiration date (the “Expiration Date”) for the Exchange Offer was 11:59 p.m., New York City time, on June 27, 2023.

All of the proposals presented at the Special Meeting were approved by the requisite votes of the applicable shareholders of the Company, including:

•certain amendments to the Company’s Amended and Restated Articles of Incorporation (as in effect prior to such amendments, the “Prior Charter”) with respect to the Series A Preferred Stock to significantly reduce the rights of holders of Series A Preferred Stock (the “Series A Charter Amendments” and, such proposal, the “Preferred Series A Charter Amendment Proposal”); and

•(i) a temporary amendment of the Prior Charter to increase the authorized number of shares of preferred stock to 6,000,000 shares and, following the consummation of the Exchange Offer, the subsequent amendment of the Prior Charter to decrease the authorized number of shares of preferred stock to 5,000,000 shares and (ii) the authorization, creation and designation by the Board of Directors of the Company (the “Board”), from the authorized but undesignated shares of preferred stock, of the Series B Preferred Stock (the “Series B Charter Amendments” and, such proposal, the “Series B Preferred Stock Proposal”); and

•certain amendments to the Prior Charter relating to (i) the Series A Charter Amendments and (ii) the temporary amendment of the Prior Charter to increase the authorized number of shares of the Company to 61,000,000 shares, consisting of 55,000,000 shares of common stock and 6,000,000 shares of preferred stock, and, following the consummation of the Exchange Offer, the subsequent amendment of the Prior Charter to decrease the authorized number of shares of the Company to 60,000,000 shares, consisting of 55,000,000 shares of common stock and 5,000,000 shares of preferred stock (such proposal, the “Common Charter Amendment Proposal”).

On June 30, 2023, the Company closed the Exchange Offer. Continental Stock Transfer & Trust Company, the exchange agent in connection with the Exchange Offer, notified the Company that 2,252,272 shares of Series A Preferred Stock had been properly tendered (and not validly withdrawn) in the Exchange Offer, representing approximately 80.1% of the then outstanding shares of Series A Preferred Stock. All of the shares of Series A Preferred Stock properly tendered (and not validly withdrawn) prior to the Expiration Date pursuant to the Exchange Offer were accepted by the Company and were retired. On June 30, 2023, in exchange for each such share of Series A Preferred Stock, participating holders of Series A Preferred Stock received one share of Series B Preferred Stock, resulting in the issuance of 2,252,272 shares of Series B Preferred Stock. 559,263 shares of Series A Preferred Stock did not participate in the Exchange Offer and remain outstanding.

On July 3, 2023, in connection with the closing of the Exchange Offer, the Company filed Amended and Restated Articles of Incorporation (the “Charter”) with the Secretary of State of the State of Georgia.

Common Stock

As of September 30, 2023, the Company had 55,000,000 shares of Common Stock authorized and 1,893,908 shares issued and 1,883,028 shares outstanding. There were no dividends declared or paid on the common stock during the three and nine months ended September 30, 2023 and 2022.

Preferred Stock

As of September 30, 2023 , the Company had 5,000,000 shares of Preferred Stock authorized and 2,811,535 shares issued and outstanding.

Series A Preferred Stock

On June 27, 2023, certain Preferred Series A Charter Amendments were approved at the Special Meeting to (i) reduce the liquidation preference of the Series A Preferred Stock to $5.00 per share, (ii) eliminate accumulated and unpaid dividends on the Series A Preferred Stock, (iii) eliminate future dividends on the Series A Preferred Stock, (iv) eliminate penalty events and the right of holders of Series A Preferred Stock to elect directors upon the occurrence of a penalty event, (v) reduce the redemption price of the Series A Preferred Stock in the event of an optional redemption to $5.00 per share, (vi) reduce the redemption price of the Series A Preferred Stock in the event of a “change of control” to $5.00 per share and (vii) change the voting rights of holders of Series A Preferred Stock when voting as a single class with any other class or series of stock to one vote per $5.00 liquidation preference.

The Company has accounted for the Series A Charter Amendments to the rights, preferences, and privileges of the Series A Preferred Stock as an extinguishment of the Series A Preferred Stock and issuance of new Series B Preferred Stock due to the significance of the modifications to the substantive contractual terms and the associated fundamental changes to the nature of the Series A Preferred Stock. Accordingly, the Company recorded an aggregate gain of $43.4 million within stockholders’ equity equal to the difference between the fair value of the new shares of Series B Preferred Stock issued and the carrying amount of the shares of Series A Preferred Stock extinguished. The gain on extinguishment is reflected in the calculation of net

income (loss) available to common stockholders in accordance with FASB ASC Topic 260, Earnings per Share. The fair value of the Series A Preferred Stock was $0.76 per share based on a probability-weighted average of the expected return method.

On June 30, 2023, in connection with the closing of the Exchange Offer, 2,252,272 shares of Series A Preferred Stock were retired and exchanged for 2,252,272 shares of Series B Preferred Stock.

As of September 30, 2023, the Company had 559,263 shares of Series A Preferred Stock issued and outstanding, and the accumulated and unpaid dividends on the Series A Preferred Stock in the amount of $50.4 million were forfeited as part of the extinguishment. No dividends were declared or paid on the Series A Preferred Stock for the three and nine months ended September 30, 2023 and 2022.

Series B Preferred Stock

The terms and provisions of the Series B Preferred Stock include, among other things: (i) no stated maturity and not being subject to any sinking fund or mandatory redemption, except following a change of control and the cumulative redemption provisions, (ii) ranks senior to our common stock, our Series A Preferred Stock and any other shares of our stock that we may issue in the future, the terms of which specifically provide that such stock ranks junior to the Series B Preferred Stock, in each case with respect to payment of dividends and amounts upon the occurrence of a liquidation event, (iii) dividend rate is 12.5% per annum of the liquidation preference of the Series B Preferred Stock in effect on the first calendar day of the applicable dividend period, (iv) initial dividend period will commence July 1, 2027, (v) liquidation preference is initially be $10.00 per share and will increase over time, pursuant to the terms set forth in the Charter, to $25.00 per share upon the fourth anniversary date of the original issuance date, provided that once there are 200,000 or fewer shares of the Series B Preferred Stock outstanding, the liquidation preference will be reduced to $5.00 per share; and (vi) the Company must redeem, repurchase or otherwise acquire certain amount of shares of Series B Preferred Stock through the fourth anniversary of the original date of issuance as provided in the Charter. The fair value of the Series B Preferred Stock was $8.26 per share based on a probability-weighted average of the expected return method.

As of September 30, 2023, the Company had 2,252,272 shares of Series B Preferred Stock issued and outstanding. No dividends were declared or paid on the Series B Preferred Stock for the three and nine months ended September 30, 2023 and 2022.

Series E Preferred Stock

On February 13, 2023, the Board declared a dividend of one one-thousandth of a share of Series E Preferred Stock for each outstanding share of common stock, payable on February 28, 2023 to shareholders of record at 5:00 p.m. Eastern Time on February 27, 2023 (the “Dividend Record Date”). The Articles of Amendment Establishing Series E Redeemable Preferred Shares were filed with the Secretary of State of the State of Georgia and became effective on February 14, 2023. The Series E Preferred Stock was distributed on February 28, 2023 to shareholders of record on the Dividend Record Date.

All shares of Series E Preferred Stock were redeemed in connection with the Special Meeting. The Series E Preferred Stock designation has been eliminated from the Charter and, as of September 30, 2023, there are no shares of Series E Preferred Stock issued and outstanding.

XML

Stock Based Compensation

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Stock Based Compensation

NOTE 10. STOCK BASED COMPENSATION

Stock Incentive Plans

On November 4, 2020, the Board adopted, the Regional Health Properties, Inc. 2020 Equity Incentive Plan (the "2020 Plan"). The Company's shareholders approved the 2020 Plan on December 16, 2020 at the 2020 Annual Meeting of Shareholders of the Company. The maximum number of shares of common stock authorized for issuance under the 2020 Plan is 250,000 shares, subject to certain adjustments. No awards may be made under the 2020 Plan after the 10th anniversary of the date of shareholder approval of the 2020 Plan, and no incentive stock options may be granted after the 10th anniversary of the date of Board approval of the 2020 Plan. As of September 30, 2023, the number of securities remaining available for future issuance under the 2020 Plan is 52,805.

The 2020 Plan replaced the AdCare Health Systems, Inc. 2011 Stock Incentive Plan, as amended (the "2011 Plan"), which was assumed by Regional Health pursuant to the Merger. The 2011 Plan was originally due to expire on March 28, 2021 and provided for a maximum of 168,950 shares of common stock to be issued. No additional awards may be granted under the 2011 Plan.

The shares of common stock underlying any awards granted under the 2020 Plan or the 2011 Plan that are forfeited, canceled, or otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2020 Plan. However, shares: (i) tendered or held back upon exercise of a stock option or other award under the 2020 Plan to cover the exercise price or tax withholding; and (ii) subject to a stock appreciation right that are not issued in connection with the stock settlement of the stock appreciation right upon exercise thereof, will not be added back to the shares of common stock available for issuance under the 2020 Plan. In addition, shares of common stock repurchased by the Company on the open market will not be added back to the shares of common stock available for issuance under the 2020 Plan.

For the three and nine months ended September 30, 2023 and 2022, the Company recognized stock-based compensation expense as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Amounts in 000’s)	2023		2022		2023		2022
Employee compensation:
Stock compensation expense	$	85	$	58	$	321	$	227
Forfeitures of stock based awards		—		—		—		(54	)
Total employee stock-based compensation expense	$	85	$	58	$	321	$	173

As of September 30, 2023, the remaining stock-based compensation expense that is expected to be recognized in future periods is $0.3 million.

Restricted Stock

The following table summarizes the Company's restricted stock activity for the nine months ended September 30, 2023:

	Number of Shares (000's)			Weighted Avg. Grant Date (per Share) Fair Value
Unvested, December 31, 2022		51		$	8.99
Granted		99		$	3.61
Vested		(26	)	$	9.06
Unvested, September 30, 2023		124		$	4.68

The remaining unvested shares at September 30, 2023 will vest over the next 2.0 years with $0.3 million in compensation expense recognized over this period.

Common Stock Options

The following summarizes the Company's employee and non-employee stock option activity for the nine months ended September 30, 2023:

	Number of Shares (000's)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (000's)
Outstanding, December 31, 2022		13	$	47.53		1.6	$	—
Granted		24	$	3.32
Outstanding and Vested, September 30, 2023		37	$	18.63		6.3	$	—

The aggregate intrinsic value of options outstanding and vested was calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock as of September 30, 2023. The fair value of the common stock is the closing stock price of the Company's Common Stock.

The following summary information reflects stock options outstanding, vested, and related details as of September 30, 2023:

	Stock Options Outstanding						Stock Options Exercisable
Exercise Price	Number of Shares (000's)		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price		Shares Vested, September 30, 2023 (000,s)		Weighted Average Exercise Price
$3.32		24		9.3	$	3.32		24	$	3.32
$46.80 - $48.72		13		0.9	$	47.42		13	$	47.42
Total		37		6.3	$	18.63		37	$	18.63

Common Stock Warrants

The following summarizes the Company's employee and non-employee common stock warrant activity for the nine months ended September 30, 2023:

	Outstanding and Exercisable
	Number of Shares (000's)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)
Outstanding and Vested, December 31, 2022		35		$	53.31		1.9
Expired		(2	)	$	70.80
Outstanding and Vested, September 30, 2023		33		$	52.38		1.2

The Company has no unrecognized compensation expense related to common stock warrants as of September 30, 2023.

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 11. COMMITMENTS AND CONTINGENCIES

Regulatory Matters

Laws and regulations governing federal Medicare and state Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations can be subject to future governmental review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from certain governmental programs. As of September 30, 2023, all of the Company's facilities operated by Regional or leased and subleased to third-party operators and managed for third-parties are certified by CMS and are operational. See Note 6 - Leases.

Legal Matters

The Company is a party to various legal actions and administrative proceedings and is subject to various claims arising in the ordinary course of business, including claims that the services the Company provided during the time it operated SNFs resulted in injury or death to the patients of the Company's facilities and claims related to professional and general negligence, employment, staffing requirements and commercial matters. Although the Company intends to vigorously defend itself in these matters, there is no assurance that the outcomes of these matters will not have a material adverse effect on the Company's business, results of operations and financial condition.

The Company previously operated, and the Company and its tenants now operate, in an industry that is highly regulated. As such, in the ordinary course of business, the Company and its tenants are continuously subject to state and federal regulatory scrutiny, supervision and control. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition, the Company believes that there has been, and will continue to be, an increase in governmental investigations of long-term care providers, particularly in the area of Medicare and Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in legal proceedings or governmental investigations against or involving the Company or its tenants, whether currently asserted or

arising in the future, could have a material adverse effect on the Company's business, results of operations and financial condition.

Professional and General Liability Claims

Claims on behalf of the Company's Former Patients prior to the Transition

As of September 30, 2023, the Company is a defendant in one professional and general liability action commenced on behalf of one of our former patients who received care at one of our facilities prior to the Transition. The plaintiff in this action alleges negligence due to failure to provide adequate and competent staff resulting in injuries, pain and suffering, mental anguish and malnutrition and seeks unspecified actual and compensatory damages, and unspecified punitive damages. This action is covered by insurance, except that any punitive damages awarded would be excluded from coverage. The case is set to go to trial on October 23, 2023.

Claims on behalf of the Company's Former Patients After the Transition

On May 2, 2023, Plaintiff Danielle Taylor, as Guardian and Conservator of Lynette Taylor filed suit against Tara Operator, LLC alleging negligent care and treatment of Ms. Taylor during her residence at Thunderbolt from June 12, 2021 through September 13, 2021. Specifically, Plaintiff’s claims relate to wound care management Ms. Taylor received while a resident at Thunderbolt. Plaintiff further alleges the Thunderbolt staff failed to develop reasonable interventions for Ms. Taylor’s care after wound development, failed to properly document her wounds, failed to maintain a consistent turning schedule or offloading of pressure, and failed to modify her care plan accordingly. According to Plaintiff, these failures resulted in Ms. Taylor needing bilateral, above the knee amputations of both legs. Plaintiff’s Complaint asserts the following causes of action: failure to exercise a reasonable degree of care and skill and breach of contract. Defendant responded with its Answer on June 28, 2023 and discovery is ongoing.

On July 10, 2023, Plaintiff Sharon Hendricks filed suit against Tara Operator, LLC; ADK Georgia, LLC; Spring Valley, LLC; 3223 Falligant Avenue Associates, LP; Mansell Court Associates, LLC; and Wellington Healthcare Services II, LP alleging negligent care and treatment of Ms. Jones during her residence at Thunderbolt from July 12, 2021 through July 29, 2021. Specifically, Plaintiff’s claims relate to a fall Ms. Jones had on July 17, 2021 while at Thunderbolt. Plaintiff further alleges the Thunderbolt staff failed to administer medications as ordered, failed to initiate appropriate seizure protocols, and failed to properly update Ms. Jones’ care plan after the aforementioned fall. Plaintiff’s Complaint asserts the following causes of action: violation of 42 CFR 483.1; violation of OCGA 31-8-100; violation of federal and state statutes and regulations in the operation of a nursing home; professional negligence, ordinary negligence, negligent management and operation; breach of contract; failure to provide sufficient and properly trained staff; imputed liability; estate tort claims; joint enterprise; wrongful death; and punitive damages.

Claims on behalf of the Company's Prior or Current Tenant's Former Patients after the Transition

As of September 30, 2023, the Company is a defendant in an aggregate of 9 additional professional and general liability actions. These 9 additional professional and general liability actions were commenced on behalf of former patients of our current or prior tenants. These actions generally seek unspecified compensatory and punitive damages for former patients who were allegedly injured or died due to professional negligence or understaffing at the applicable facility operated by our tenants. These actions all relate to events which occurred after the Company transitioned the operations of the facilities in question to a third-party operator (and of which four such actions relate to events which occurred after the Company sold such facilities) and are subject to such operators' indemnification obligations in favor of the Company. There is no assurance that our tenants will have sufficient assets, income, access to financing and insurance coverage to enable them to satisfy their respective indemnification obligations.

During the nine months ended September 30, 2023, the following professional and general liability actions (included in the 10 actions mentioned above) related to our current or former tenant's former patients were filed against the Company.

The resident’s daughter filed suit on behalf of Mr. Shellman on February 14, 2023 asserting claims of professional and ordinary negligence as well the alleged breach of various state and federal regulations. The lawsuit relates to Mr. Shellman’s residence at Glenvue nursing facility which was operated by C.R. of Glenvue, LLC which is also named as a defendant. Plaintiff’s counsel has agreed to extend the deadline for Glenvue H&R Property Holdings, LLC to respond to the lawsuit up to and including May 15, 2023 to enable him to review the response filed by C.R. of Glenvue, LLC and determine whether or not Plaintiff will agree to the dismissal of Glenvue H&R Property Holdings, LLC. If plaintiff does not agree, we intend to serve Plaintiff with a notice

that Glenvue H&R Property Holdings, LLC constitutes an excluded party pursuant to O.C.G.A. 31-7-3.3. Should Plaintiff still not agree to the dismissal of Glenvue H&R Property Holdings, LLC, we will file a motion for summary judgment seeking judgment in its favor. The Court may require Glenvue H&R Property Holdings, LLC to participate in discovery prior to ruling on this motion. In the event that occurs, Glenvue H&R Property Holdings, LLC can seek the recovery of its attorneys fees and expenses pursuant to the above-referenced excluded party statute.

The family of Mable Polite filed suit on March 15, 2023 asserting claims of professional and ordinary negligence as well the alleged breach of various state and federal regulations. The lawsuit relates to Ms. Polite’s residence at the Thunderbolt nursing facility from March 19, 2020 to March 20, 2021. Plaintiff has also asserted claims against 3223 Falligant Avenue Associates, LP and other Wellington related entities. 3223 Falligant Avenue was the operator and licensee of the facility for the first part of Ms. Polite’s residence prior to Tara Operator becoming the operator. Based upon the date the suit was filed, there is an argument that certain claimed acts of negligence are barred by the limitations period. Ms. Polite’s daughter signed an arbitration agreement on her admission to Thunderbolt but we are not in possession of a power of attorney or other documentation authorizing her to execute this agreement. Nonetheless, Tara Operator will file its answer to the Complaint (due April 14) via special appearance to reserve the right to seek arbitration should a power of attorney be located.

Dismissed Claims on behalf of the Company's Prior or Current Tenant's Former Patients after the Transition

In February 2023, the Company was dismissed from the case involving Ronald and Sarah Ross against our prior operator Symmetry Healthcare Management.

The Company established a self-insurance reserve for its professional and general liability claims, included within Accrued expenses on the Company's consolidated balance sheets of $0.1 million and $0.2 million as of September 30, 2023 and December 31, 2022, respectively. Additionally, as of September 30, 2023 and December 31, 2022, $0.1 million and $0.1 million, respectively, was reserved for settlement amounts in Accounts payable on the Company's consolidated balance sheets. For additional information regarding the Company's self-insurance reserve, see Note 13 – Commitments and Contingencies in Part II, Item 8, Financial Statements and Supplementary Data, included in the Annual Report.

XML

Segments Results

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Segments Results

NOTE 12. SEGMENT RESULTS

The Company has two primary reporting segments: (i) Real Estate Services, which consists of the leasing and subleasing of long-term care and senior living facilities to third-party tenants, including the Company's management of three facilities on behalf of third-party owners; and (ii) Healthcare Services, which consists of the operation of the Meadowood and Glenvue facilities.

The Company reports segment information based on the "management approach" defined in ASC 280, Segment Reporting. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments.

The table below presents the results of operations for our reporting segments for the periods presented.

	Three Months Ended September 30,									Three Months Ended September 30,
	2023			2023			2023			2022			2022			2022
(Amounts in 000’s)	Real Estate Services			Healthcare Services			Total			Real Estate Services			Healthcare Services			Total
Revenues:
Patient care revenues	$	—		$	2,136		$	2,136		$	—		$	7,769		$	7,769
Rental revenues		1,739			—			1,739			3,000			—			3,000
Management fees		263			—			263			255			—			255
Other revenues		—			—			—			6			—			6
Total revenues		2,002			2,136			4,138			3,261			7,769			11,030
Expenses:
Patient care expense		—			2,313			2,313			—			7,476			7,476
Facility rent expense		149			—			149			923			528			1,451
Cost of management fees		156			—			156			140			—			140
Depreciation and amortization		472			54			526			590			10			600
General and administrative expense		950			22			972			975			403			1,378
Doubtful accounts expense		—			229			229			1,515			—			1,515
Other operating expenses		54			143			197			(80	)		521			441
Total expenses		1,781			2,761			4,542			4,063			8,938			13,001
Income (loss) from operations		221			(625	)		(404	)		(802	)		(1,169	)		(1,971	)
Other (income) expense:
Interest expense, net		669			39			708			633			(69	)		564
Other (income) expense, net		(541	)		402			(139	)		(2,164	)		—			(2,164	)
Total other (income) expense, net		128			441			569			(1,531	)		(69	)		(1,600	)
Net income (loss)	$	93		$	(1,066	)	$	(973	)	$	729		$	(1,100	)	$	(371	)

	Nine Months Ended September 30,									Nine Months Ended September 30,
	2023			2023			2023			2022			2022			2022
(Amounts in 000’s)	Real Estate Services			Healthcare Services			Total			Real Estate Services			Healthcare Services			Total
Revenues:
Patient care revenues	$	—		$	6,577		$	6,577		$	—		$	14,650		$	14,650
Rental revenues		5,170			—			5,170			10,326			—			10,326
Management fees		788			—			788			774			—			774
Other revenues		107			—			107			20			—			20
Total revenues		6,065			6,577			12,642			11,120			14,650			25,770
Expenses:
Patient care expense		—			7,010			7,010			—			14,040			14,040
Facility rent expense		446			—			446			3,899			826			4,725
Cost of management fees		442			—			442			459			—			459
Depreciation and amortization		1,578			160			1,738			1,796			23			1,819
General and administrative expense		2,970			220			3,190			2,660			772			3,432
Doubtful accounts expense		—			269			269			3,742			—			3,742
Other operating expenses		225			286			511			555			854			1,409
Total expenses		5,661			7,945			13,606			13,111			16,515			29,626
Income (loss) from operations		404			(1,368	)		(964	)		(1,991	)		(1,865	)		(3,856	)
Other (income) expense:
Interest expense, net		1,947			119			2,066			1,898			(43	)		1,855
Other (income) expense, net		—			620			620			(1,088	)		—			(1,088	)
Total other (income) expense, net		1,947			739			2,686			810			(43	)		767
Net income (loss)	$	(1,543	)	$	(2,107	)	$	(3,650	)	$	(2,801	)	$	(1,822	)	$	(4,623	)

Total assets for the Real Estate Services segment and Healthcare Services segment were $57.0 million and $7.0 million, respectively, as of September 30, 2023. Total assets for the Real Estate Services segment and Healthcare Services segment were $63.5 million and $5.6 million, respectively, as of December 31, 2022.

XML

Subsequent Events

9 Months Ended

Sep. 30, 2023

Subsequent Events [Abstract]

Subsequent Events

NOTE 13. SUBSEQUENT EVENTS

We evaluate subsequent events that occur after our consolidated balance sheet date but before our consolidated financial statements are issued. We have evaluated subsequent events occurring after September 30, 2023, and based on our evaluation have identified the subsequent events described below.

On October 13, 2023, the lawsuit against the Company filed by one of our former patients prior to the transition referenced in Note 11 settled for an undisclosed sum within insurance policy limits. In addition, the Company's motion for summary judgment presented on October 23, 2023 was granted, and the Company was dismissed from the lawsuit with prejudice on November 3, 2023.

XML

Organization and Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Description of Business

Description of Business

Regional Health Properties, Inc.'s (the "Company" or "Regional Health") predecessor was incorporated in Ohio on August 14, 1991, under the name Passport Retirement, Inc. In 1995, Passport Retirement, Inc. acquired substantially all of the assets and liabilities of AdCare Health Systems, Inc. and changed its name to AdCare Health Systems, Inc. ("AdCare"). AdCare completed its initial public offering in November 2006, relocated its executive offices and accounting operations to Georgia in 2012, and changed its state of incorporation from Ohio to Georgia in December 2013. Regional Health Properties, Inc. is a self-managed real estate investment company that invests primarily in real estate purposed for long-term care and senior housing. Our business primarily consists of leasing such facilities to third-party tenants, which operate the facilities. The Company has two primary reporting segments: (i) Real Estate Services, which consists of the leasing and subleasing of long-term care and senior living facilities to third-party tenants, including the Company's management of three facilities on behalf of third-party owners; and (ii) Healthcare Services, which consists of the operation of the Meadowood and Glenvue facilities. Effective August 3, 2023, the Company’s 12.5% Series B Cumulative Redeemable Preferred Shares (the “Series B Preferred Stock”) is quoted on the OTC Markets Group, Inc.’s OTCQB Venture Market under the symbol “RHEPB”.

Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles ("GAAP") in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"). The accompanying consolidated financial statements are unaudited and should be read in conjunction with the 2022 audited consolidated financial statements and notes thereto, which are included in our 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on April 14, 2023 ("Annual Report").

In the opinion of management, the unaudited consolidated financial statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company's financial position and the results of its operations and cash flows for such periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.

Reclassifications

Reclassifications

Certain reclassifications have been made to the amounts in prior periods in order to conform to the current period's presentation. A reclassification has been made to the stock balances on the consolidated statement of stockholders’ equity in prior periods in order to conform to the current period's presentation.

Principles of consolidations

Principles of Consolidations

The consolidated financial statements include the Company's majority owned and controlled subsidiaries. All intercompany transactions and balances have been eliminated through consolidation

Variable Interest Entities

Variable Interest Entities

The Company has a loan receivable with Peach Health, a sublessee. Such agreement creates a variable interest in the Peach Health sublessee that may absorb some or all of the expected losses of the entity. The Company does not consolidate the operating activities of the Peach Health sublessee as the Company does not have the power to direct the activities that most significantly impact the entity's economic performance.

Revenue Recognition and Allowances

Revenue Recognition and Allowances

Patient Care Revenue. ASC Topic 606, Revenue from Contracts with Customers requires a company to recognize revenue when the company transfers control of promised goods and services to a customer. Revenue is recognized in an amount that reflects the consideration to which a company expects to receive in exchange for such goods and services. Revenue from our Healthcare Services business segment is derived from services rendered to patients in the Meadowood and Glenvue facilities. The Company receives payments from the following sources for services rendered in our facilities: (i) the federal government under the Medicare program administered by the U.S. Department of Health and Human Services Centers for Medicare and Medicaid Services ("CMS"); (ii) state governments under their respective Medicaid and similar programs; (iii) commercial insurers; and (iv) individual patients and clients. The vast majority of the revenue the Company recognizes is from government sources. The Company determines the transaction price based on established billing rates reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients and other price concessions. Contractual adjustments and discounts are based on contractual agreements, discount policies and historical experience. The Company recognizes revenue at the amount that reflects the consideration the Company expects to receive in exchange for the services provided. These amounts are due from residents or third-party payors and include variable consideration for retroactive adjustments from estimated reimbursements, if any, under reimbursement programs. Performance obligations are determined based on the nature of the services provided. Revenue is recognized as performance obligations are satisfied. Estimated uncollectable amounts due from patients are generally considered implicit price concessions that are a direct reduction to net operating revenues.

Triple-Net Leased Properties. The Company recognizes rental revenue in accordance with ASC 842, Leases. The Company's triple-net leases provide for periodic and determinable increases in rent. The Company recognizes rental revenues under these leases on a straight-line basis over the applicable lease term when collectability is probable. Recognizing rental income on a straight-line basis generally results in recognized revenues during the first half of a lease term exceeding the cash amounts contractually due from our tenants, creating a straight-line rent receivable that is included in the straight-line rent receivable on our consolidated balance sheets. In the event the Company cannot reasonably estimate the future collection of rent from one or more tenant(s) of the Company's facilities, rental income for the affected facilities is recognized only upon cash collection, and any accumulated straight-line rent receivable is expensed in the period in which the Company deems rent collection to no longer be probable.

Management Fee Revenues and Other Revenues. The Company recognizes management fee revenues as services are provided. The Company has one contract to manage three facilities (the "Management Contract"), with payment for each month of service generally received in full on a monthly basis. The maximum penalty for service contract nonperformance under the Management Contract is $50,000 per year, payable after the end of the year. Further, the Company recognizes interest income from loans and investments, using the effective interest method when collectability is probable. The Company applies the effective interest method on a loan-by-loan basis. On June 30, 2023, the Company received a notice of termination, pursuant to which the Management Contract will terminate on December 31, 2023.

Allowances. The Company assesses the collectability of its rent receivables, including straight-line rent receivables, working capital loans to tenants and patient reimbursement. The Company bases its assessment of the collectability of rent receivables and working capital loans to tenants on several factors, including payment history, the financial strength of the tenant and any guarantors, the value of the underlying collateral, and current economic conditions. If the Company's evaluation of these factors indicates it is probable that the Company will be unable to receive the rent payments or payments on a working capital loan, then the Company provides a reserve against the recognized straight-line rent receivable asset or working capital loan for the portion that we estimate may not be recovered. Payments received on impaired loans are applied against the allowance. If the Company changes its assumptions or estimates regarding the collectability of future rent payments, then the Company may adjust its reserve to the rental or interest revenue recognized in the period the Company makes such change. See Note 6 – Leases. Regarding patient reimbursements, the Company assesses the patient receivable based on payor type and age of the receivable amongst several other factors. The Company has reserved for approximately 1.5% of our patient care revenue based on the historical performance and industry practices.

As of September 30, 2023 and December 31, 2022, the Company reserved for approximately $1.6 million and $1.3 million, respectively, of uncollected receivables. Accounts receivable, net of allowance, totaled $2.0 million at September 30, 2023 and $6.3 million at December 31, 2022.

The following table presents the Company's Accounts receivable, net of allowance for the periods presented:

(Amounts in 000’s)	September 30, 2023			December 31, 2022
Gross receivables
Real Estate Services	$	908		$	1,094
Healthcare Services		2,706			6,493
Subtotal		3,614			7,587
Allowance
Real Estate Services		(338	)		(338	)
Healthcare Services		(1,241	)		(960	)
Subtotal		(1,579	)		(1,298	)
Accounts receivable, net of allowance	$	2,035		$	6,289

Prepaid Expenses and Other

Prepaid Expenses and Other

As of September 30, 2023 and December 31, 2022, the Company had approximately $0.9 million and $0.7 million , respectively, in prepaid expenses and other; the $0.2 million increase is related to insurance for the Meadowood and Glenvue facility operations, while the other amounts are predominantly for directors' and officers' insurance, NYSE American annual fees, and mortgage insurance premiums.

Accounts Payable

Accounts Payable

The following table presents the Company's Accounts payable for the periods presented:

(Amounts in 000’s)	September 30, 2023		December 31, 2022
Accounts payable
Real Estate Services	$	1,052	$	797
Healthcare Services		1,731		2,496
Total Accounts payable	$	2,783	$	3,293

Other Expense, Net

Other Expense, net

The Company retained a law firm to evaluate and assist with possible opportunities to improve the Company's capital structure. For the three months ended September 30, 2023 and September 30, 2022, these costs were $0.3 million and $0.2 million, respectively. For the nine months ended September 30, 2023 and September 30, 2022, these costs were $0.8 million and $1.1 million, respectively.

Leases and Leasehold Improvements

Leases and Leasehold Improvements

The Company leases certain facilities and equipment in the normal course of business. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating lease or finance lease. As of September 30, 2023, all of the Company's leased facilities are accounted for as operating leases. For operating leases that contain scheduled rent increases, the Company records rent expense on a straight-line basis over the term of the lease. Leasehold improvements are amortized over the shorter of the useful life of the asset or the lease term.

The Company recognizes both right of use assets and lease liabilities for leases in which we lease land, real property, or other equipment. We assess any new contracts or modification of contracts in accordance with ASC 842, Leases to determine the existence of a lease and its classification.

We report revenues and expenses for real estate taxes and insurance where the lessee has not made those payments directly to a third-party in accordance with its respective leases with us. Additionally, we expense certain leasing costs, other than leasing commissions, as they are incurred. The present value of minimum lease payments was calculated on each lease, using a discount rate that approximated our incremental borrowing rate and the current lease term. See Note 6– Leases for more information on the Company's operating leases.

Insurance

Insurance

We maintain general liability, professional liability, and other insurance policies in amounts and with coverage and deductibles we believe are appropriate, based on the nature and risks of our business, historical experience, availability, and industry standards, including for the operations at the Glenvue and Meadowood facilities. Our current policies provide for deductibles for each claim and contain various exclusions from coverage. The Company has self-insured against professional and general liability claims related to its healthcare operations that were discontinued during 2014 and 2015 in connection with its transition from an owner and operator of healthcare properties to a healthcare property holding and leasing company (the "Transition"). For further information, see Note 11 – Commitments and Contingencies, and Note 13 – Commitments and Contingencies, to the consolidated financial statements for the year ended December 31, 2022 for more information. The Company evaluates quarterly the adequacy of its self-insurance reserve based on a number of factors, including: (i) the number of actions pending and the relief sought; (ii) analyses provided by defense counsel, medical experts or other information which comes to light during discovery; (iii) the legal fees and other expenses anticipated to be incurred in defending the actions; (iv) the status and likely success of any mediation or settlement discussions, including estimated settlement amounts and legal fees and other expenses anticipated to be incurred in such settlement, as applicable; and (v) the venues in which the actions have been filed or will be adjudicated. The Company believes that most of the professional and general liability actions are defensible and intends to defend them through final judgment unless settlement is more advantageous to the Company. Accordingly, the self-insurance reserve reflects the Company's estimate of settlement amounts for the pending actions, if applicable, and legal costs of settling or litigating the pending actions, as applicable. Because the self-insurance reserve is based on estimates, the amount of the self-insurance reserve may not be sufficient to cover the settlement amounts actually incurred in settling the pending actions, or the legal costs actually incurred in settling or litigating the pending actions. See Note 7 – Accrued Expenses. In addition, the Company maintains certain other insurance programs, including commercial general liability, property, casualty, directors' and officers' liability, crime, and employment practices liability.

Discontinued Operations

Discontinued Operations

Prior to December 2015, the Company’s business focused primarily on owning and operating skilled nursing facilities ("SNF") and managing such facilities for unaffiliated owners with whom the Company had management contracts. These operations were discontinued and transitioned to the leasing model of business.

As of September 30, 2023 and December 21, 2022 the Company determined remaining escheatment liabilities for discontinued operations are $0.8 million and are included in accrued expenses.

Net Loss Per Share

Net Loss Per Share

Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the respective period. Diluted earnings per share is similar to basic net loss per share except that the net loss is adjusted by the impact of the weighted-average number of shares of common stock outstanding including potentially dilutive securities (such as options, warrants and non-vested common stock) when such securities are not anti-dilutive. Potentially dilutive securities from options, warrants and unvested restricted shares are calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all options and warrants with exercise prices exceeding the average market value are used to repurchase common stock at market value. The incremental shares remaining after the proceeds are exhausted represent the potentially dilutive effect of the securities.

Securities outstanding that were excluded from the computation, because they would have been anti-dilutive were as follows:

	September 30,
(Share amounts in 000’s)	2023		2022
Stock options		37		13
Warrants - employee		32		34
Warrants - non employee		1		5
Total anti-dilutive securities		70		52

The weighted average contractual terms in years for these securities as of September 30, 2023, with no intrinsic value, are 6.3 years for the stock options and 1.2 years for the warrants.

New Accounting Pronouncements Issued But Not Yet Effective

New Accounting Pronouncements Issued But Not Yet Effective

In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842): Common Control Arrangements (Topic 842) amendments, which requires entities to determine whether related party arrangements between entities under common control are leases. The amendments also address the accounting treatment of leasehold improvements associated with common control leases. They require the lessee to amortize leasehold improvements over the useful life of the improvements to the common control group, regardless of the lease term, as long as the lessee controls the use of the underlying asset. If the lessee no longer controls the use of the asset, the leasehold improvements are accounted for as a transfer between entities under common control through an adjustment to equity. These improvements are also subject to impairment guidance in Topic 360, Property, Plant, and Equipment. The amendment is effective for public entities beginning after December 15, 2023. The Company is currently evaluating the impact of ASU 2023-01 on its financial statements.

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company's financial statements.

XML

Organization and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Company's Accounts Receivable, Net of Allowance

The following table presents the Company's Accounts receivable, net of allowance for the periods presented:

(Amounts in 000’s)	September 30, 2023			December 31, 2022
Gross receivables
Real Estate Services	$	908		$	1,094
Healthcare Services		2,706			6,493
Subtotal		3,614			7,587
Allowance
Real Estate Services		(338	)		(338	)
Healthcare Services		(1,241	)		(960	)
Subtotal		(1,579	)		(1,298	)
Accounts receivable, net of allowance	$	2,035		$	6,289

Company's Accounts Payable

The following table presents the Company's Accounts payable for the periods presented:

(Amounts in 000’s)	September 30, 2023		December 31, 2022
Accounts payable
Real Estate Services	$	1,052	$	797
Healthcare Services		1,731		2,496
Total Accounts payable	$	2,783	$	3,293

Schedule of Securities Outstanding that were Excluded From the Computation, Prior to the Use of the Treasury Stock Method, Because They Would Have Been Anti-dilutive

Securities outstanding that were excluded from the computation, because they would have been anti-dilutive were as follows:

	September 30,
(Share amounts in 000’s)	2023		2022
Stock options		37		13
Warrants - employee		32		34
Warrants - non employee		1		5
Total anti-dilutive securities		70		52

XML

Liquidity (Tables)

9 Months Ended

Sep. 30, 2023

Liquidity [Abstract]

Summary of Lease Terminations

The table below summarizes the lease terminations related to existing properties as of September 30, 2023 since the onset of the COVID-19 pandemic and the Company’s resulting portfolio stabilization measures:

Date	Facility Name	Former Operator	Current Operator
April 2022	Meadowood	C.R. Management	Regional Health (managed by Cavalier Senior Living Operations)
August 2022	Glenvue	C.R. Management	Regional Health

XML

Cash and Restricted Cash (Tables)

9 Months Ended

Sep. 30, 2023

Restricted Cash and Investments [Abstract]

Schedule of Cash and Restricted Cash

The following presents the Company's cash and restricted cash:

(Amounts in 000’s)	September 30, 2023		December 31, 2022
Cash	$	1,427	$	843
Restricted cash:
Cash collateral	$	118	$	135
HUD and other replacement reserves		2,138		2,155
Escrow deposits		635		459
Restricted investments for debt obligations		317		317
Total restricted cash		3,208		3,066
Total cash and restricted cash	$	4,635	$	3,909

XML

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

The following table sets forth the Company's property and equipment:

(Amounts in 000’s)	Estimated Useful Lives (Years)		September 30, 2023			December 31, 2022
Buildings and improvements	5-40		$	64,429		$	63,746
Equipment and computer related	2-10			1,615			1,807
Land (1)		—		2,774			2,774
Property and equipment				68,818			68,327
Less: accumulated depreciation and amortization				(23,012	)		(21,716	)
Property and equipment, net			$	45,806		$	46,611

(1)Includes $0.1 million of land improvements with an average estimated useful remaining life of approximately 5.3 years.

The following table summarizes total depreciation and amortization expense three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Amounts in 000’s)	2023		2022		2023		2022
Depreciation	$	416	$	490	$	1,409	$	1,490
Amortization		110		110		329		329
Total depreciation and amortization expense	$	526	$	600	$	1,738	$	1,819

XML

Intangible Assets and Goodwill (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill

Intangible assets and Goodwill consist of the following:

(Amounts in 000’s)	Bed licenses (included in property and equipment) (1)			Bed Licenses - Separable (2)		Lease Rights			Total			Goodwill (2)
Balances, December 31, 2022
Gross	$	14,276		$	2,471	$	206		$	16,953		$	1,585
Accumulated amortization		(4,583	)		—		(96	)		(4,678	)		—
Net carrying amount	$	9,693		$	2,471	$	110		$	12,275		$	1,585
Balances, September 30, 2023
Gross		14,276			2,471		206			16,953			1,585
Accumulated amortization		(4,894	)		—		(114	)		(5,008	)		—
Net carrying amount	$	9,382		$	2,471	$	92		$	11,945		$	1,585

(1)Non-separable bed licenses are included in property and equipment as is the related accumulated amortization expense (see Note 4 – Property and Equipment).

(2)The Company does not amortize indefinite-lived intangibles, which consist of separable bed licenses and goodwill.

Schedule of Total Amortization Expense

The following table summarizes amortization expense for the three and nine months ended September 30, 2023 and 2022:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Amounts in 000’s)	2023		2022		2023		2022
Bed licenses	$	104	$	104	$	311	$	311
Lease rights		6		6		18		18
Total amortization expense	$	110	$	110	$	329	$	329

Schedule of Estimated Amortization Expense for All Definite Lived Intangibles

Expected amortization expense for the years ending December 31, for all definite-lived intangibles, for each of the next five years and thereafter is as follows:

(Amounts in 000’s)	Bed Licenses		Lease Rights
2023 (3 months remaining)	$	103	$	6
2024		414		24
2025		414		24
2026		414		24
2027		414		14
Thereafter		7,623		-
Total expected amortization expense	$	9,382	$	92

XML

Leases (Tables)

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Schedule of Future Minimum Lease Payments

Future minimum lease payments for the twelve months ending December 31, for each of the next five years and thereafter is as follows:

(Amounts in 000’s)	Future rental payments		Accretion of lease liability (1)			Operating lease obligation
2023 (3 months remaining)	$	156	$	(2	)	$	154
2024		633		(39	)		594
2025		645		(85	)		560
2026		658		(131	)		527
2027		671		(174	)		497
Thereafter		914		(298	)		616
Total	$	3,677	$	(729	)	$	2,948

(1)Weighted average discount rate 3.85%.

Schedule of Future Minimum Lease Receivables

Future minimum lease receivables for the twelve months ending December 31, for each of the next five years and thereafter is as follows:

	(Amounts in 000's)
2023 (3 months remaining)	$	1,577
2024		6,187
2025		6,034
2026		5,362
2027		5,445
Thereafter		11,605
Total	$	36,210

XML

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2023

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consist of the following:

(Amounts in 000’s)	September 30, 2023		December 31, 2022
Accrued employee benefits and payroll-related	$	328	$	539
Real estate and other taxes (1)		2,891		2,428
Self-insured reserve		62		80
Accrued interest		222		210
Unearned rental revenue		-		43
Medicaid overpayment - Healthcare Services		56		169
Insurance escrow		79		—
Other accrued expenses		1,168		1,567
Total accrued expenses	$	4,806	$	5,036

(1)September 30, 2023 includes approximately $2.5 million of franchise tax accruals for the Healthcare Services segment. December 31, 2022 includes approximately $2.2 million of franchise tax accruals for the Healthcare Services segment.

XML

Notes Payable and Other Debt (Tables)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Schedule of Notes Payable and Other Debt

Notes payable and other debt consists of the following:

(Amounts in 000’s)	September 30, 2023			December 31, 2022
Senior debt—guaranteed by HUD	$	29,183		$	29,782
Senior debt—guaranteed by USDA (1)		7,332			7,526
Senior debt—guaranteed by SBA(2)		562			580
Senior debt—bonds		6,117			6,253
Senior debt—other mortgage indebtedness		8,089			8,266
Other debt		1,181			895
Subtotal		52,464			53,302
Deferred financing costs		(971	)		(1,005	)
Unamortized discount on bonds		(115	)		(119	)
Notes payable and other debt	$	51,378		$	52,178

(1)U.S. Department of Agriculture ("USDA")

(2)U.S. Small Business Administration ("SBA")

The following is a detailed listing of the debt facilities that comprise each of the above categories:

(Amounts in 000’s)
Facility	Lender	Maturity	Interest Rate (1)			September 30, 2023		December 31, 2022
Senior debt - guaranteed by HUD (2)
The Pavilion Care Center	Newpoint Capital	12/01/2039	Fixed	3.97	%	$	810	$	835
Hearth and Care of Greenfield	Newpoint Capital	8/01/2050	Fixed	3.97	%		1,919		1,949
Woodland Manor	Newpoint Capital	11/01/2052	Fixed	3.97	%		4,913		4,980
Glenvue	Newpoint Capital	10/01/2044	Fixed	3.75	%		7,134		7,297
Autumn Breeze	KeyBank	01/01/2045	Fixed	3.65	%		6,203		6,344
Georgetown	Newpoint Capital	10/01/2046	Fixed	2.98	%		3,144		3,214
Sumter Valley	KeyBank	01/01/2047	Fixed	3.70	%		5,061		5,163
Total						$	29,184	$	29,782
Senior debt - guaranteed by USDA (3)
Mountain Trace (4)	Community B&T	12/24/2036	Prime + 1.75%	10.00	%	$	3,575	$	3,680
Southland (5)	Cadence Bank, NA	07/27/2036	Prime + 1.50%	9.75	%		3,757		3,846
Total						$	7,332	$	7,526
Senior debt - guaranteed by SBA
Southland(6)	Cadence Bank, NA	07/27/2036	Prime + 2.25%	10.50	%	$	562	$	580
Total						$	562	$	580

(1)Represents cash interest rates as of September 30, 2023 as adjusted for interest rate floor limitations, if applicable. The rates exclude amortization of deferred financing costs, which range from 0.09% to 0.53% per annum.

(2)For the seven SNFs, the Company has term loans with financial institutions that are insured 100% by HUD. The loans are secured by, among other things, an assignment of all rents paid under any existing or future leases and rental agreements with respect to the underlying facility. The loans contain customary events of default, including fraud or material misrepresentations or material omission, the commencement of a forfeiture action or proceeding, failure to make required payments, and failure to perform or comply with certain agreements. Upon the occurrence of certain events of default, the lenders may, after receiving the prior written approval of HUD, terminate the loans and all amounts under the loans will become immediately due and payable. In connection with entering into each loan, the Company entered into a healthcare regulatory agreement and a promissory note, each containing customary terms and conditions. Pursuant to the CARES Act, up to three months of debt service payments for six of the credit facilities can be made from our restricted cash reserves.

(3)For the two SNFs, the Company has term loans with financial institutions that are insured 70% to 80% by the USDA. The loans have an annual renewal fee for the USDA guarantee of 0.25% of the guaranteed portion. The loans had prepayment penalties of 1%, capped at 1% for the remainder of the first 10 years of the term and 0% thereafter.

(4)Pursuant to the CARES Act, the monthly principal and interest payments due May 1, 2020 through August 1, 2020 for the Mountain Trace Facility loan were deferred. Monthly payments that commenced on September 1, 2020 were being applied to current interest, then deferred interest until the deferred interest was paid in full on April 1, 2021. Payments have been re-amortized over the extended term of the loan.

(5)Pursuant to the CARES Act, the monthly principal and interest payments due May 1, 2020 through October 1, 2020 for the loan for that certain 126-bed SNF commonly known as Southland, located in Dublin, Georgia, were deferred as a part of the USDA Payment Program. Monthly payments recommenced on November 1, 2020 with payments through February 2021 being applied to principal and interest. Monthly payments that commenced on March 1, 2021 are being applied to current interest, then deferred interest until the deferred interest is paid in full, payments will be re-amortized over the extended term of the loan.

(6)For the one SNF, commonly known as Southland, the Company has a term loan with a financial institution, which is 75% insured by the SBA. The SBA funded two monthly debt payments during the three months ended March 31, 2021 and six payments commencing on March 1, 2020 and ending on August 1, 2020.

(Amounts in 000’s)
Facility	Lender	Maturity	Interest Rate (1)			September 30, 2023		December 31, 2022
Senior debt - bonds
Eaglewood Bonds Series A	City of Springfield, Ohio	05/01/2042	Fixed	7.65	%	$	6,117	$	6,253

(1)Represents cash interest rates as of September 30, 2023. The rates exclude amortization of deferred financing of approximately 0.1% per annum.

(Amounts in 000’s)
Facility	Lender	Maturity	Interest Rate (1)			September 30, 2023		December 31, 2022
Senior debt - other mortgage indebtedness
Meadowood (2)	Exchange Bank of Alabama	10/01/2026	Fixed	4.50	%	$	3,279	$	3,319
Coosa (3)	Exchange Bank of Alabama	10/10/2026	Fixed	3.95	%		4,810		4,946
Total						$	8,089	$	8,266

(1)Represents cash interest rates as of September 30, 2023 as adjusted for interest rate floor limitations, if applicable. The rates exclude amortization of deferred financing costs of 0.34% per annum.

(2)On October 1, 2021, the Exchange Bank of Alabama and the Company extended the maturity date of the Meadowood Credit Facility which is secured by the Meadowood Facility and the assets of Coosa, and which is guaranteed by Regional Health Properties, Inc., from May 1, 2022 to October 1, 2026.

(3)On September 30, 2021, the Company refinanced the MCB Coosa Loan secured by the Coosa Facility, incurring approximately $0.1 million in new fees. The Coosa Credit Facility, guaranteed by Regional Health Properties, Inc. includes customary terms, including events of default with an associated annual 5% default interest rate, and is secured by the Coosa Facility and the assets of Meadowood. Upon the occurrence of certain events of default, the lenders may terminate the Coosa Credit Facility and the Meadowood Credit Facility and all amounts due under both credit facilities will become immediately due and payable. The Coosa Credit Facility has prepayment penalties of 5% in the first year, 4% in the second year and 1% thereafter.

(Amounts in 000’s)
Lender	Maturity	Interest Rate			September 30, 2023		December 31, 2022
Other debt
First Insurance Funding (1)	Various 2023	Fixed	3.19	%	$	658	$	357
Key Bank (2)	08/25/2025	Fixed	0.00	%		495		495
Marlin Capital Solutions	06/1/2027	Fixed	5.00	%		28		43
Total					$	1,181	$	895

(1)Annual Insurance financing primarily for the Company's directors and officers insurance and professional liability for the facilities where the company is the licensed operator.

(2)On December 30, 2022, Key Bank and the Company extended the maturity date from August 25, 2023 to August 25, 2025.

Summary of the Scheduled Maturities

The schedule below summarizes the scheduled gross maturities as of September 30, 2023 for each of the next five years and thereafter.

For the Twelve Months Ended December 31,	(Amounts in 000’s)
2023 (3 months remaining)	$	660
2024		2,046
2025		2,269
2026		8,746
2027		1,562
Thereafter		37,181
Subtotal	$	52,464
Less: unamortized discounts		(115	)
Less: deferred financing costs, net		(971	)
Total notes and other debt	$	51,378

XML

Stock Based Compensation (Tables)

9 Months Ended

Sep. 30, 2023

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Summary of Recognized Stock Based Compensation

For the three and nine months ended September 30, 2023 and 2022, the Company recognized stock-based compensation expense as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(Amounts in 000’s)	2023		2022		2023		2022
Employee compensation:
Stock compensation expense	$	85	$	58	$	321	$	227
Forfeitures of stock based awards		—		—		—		(54	)
Total employee stock-based compensation expense	$	85	$	58	$	321	$	173

Summary of Company's Restricted Stock Activity

The following table summarizes the Company's restricted stock activity for the nine months ended September 30, 2023:

	Number of Shares (000's)			Weighted Avg. Grant Date (per Share) Fair Value
Unvested, December 31, 2022		51		$	8.99
Granted		99		$	3.61
Vested		(26	)	$	9.06
Unvested, September 30, 2023		124		$	4.68

Summary of Company's Stock Option Activity

The following summarizes the Company's employee and non-employee stock option activity for the nine months ended September 30, 2023:

	Number of Shares (000's)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (000's)
Outstanding, December 31, 2022		13	$	47.53		1.6	$	—
Granted		24	$	3.32
Outstanding and Vested, September 30, 2023		37	$	18.63		6.3	$	—

Schedule of Exercise Price Range

The following summary information reflects stock options outstanding, vested, and related details as of September 30, 2023:

	Stock Options Outstanding						Stock Options Exercisable
Exercise Price	Number of Shares (000's)		Weighted Average Remaining Contractual Term (in years)		Weighted Average Exercise Price		Shares Vested, September 30, 2023 (000,s)		Weighted Average Exercise Price
$3.32		24		9.3	$	3.32		24	$	3.32
$46.80 - $48.72		13		0.9	$	47.42		13	$	47.42
Total		37		6.3	$	18.63		37	$	18.63

Warrants

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Schedule of Common Stock Warrant Activity

The following summarizes the Company's employee and non-employee common stock warrant activity for the nine months ended September 30, 2023:

	Outstanding and Exercisable
	Number of Shares (000's)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)
Outstanding and Vested, December 31, 2022		35		$	53.31		1.9
Expired		(2	)	$	70.80
Outstanding and Vested, September 30, 2023		33		$	52.38		1.2

XML

Segments Results (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Summary of Results of Operations for Reporting Segments

The table below presents the results of operations for our reporting segments for the periods presented.

	Three Months Ended September 30,									Three Months Ended September 30,
	2023			2023			2023			2022			2022			2022
(Amounts in 000’s)	Real Estate Services			Healthcare Services			Total			Real Estate Services			Healthcare Services			Total
Revenues:
Patient care revenues	$	—		$	2,136		$	2,136		$	—		$	7,769		$	7,769
Rental revenues		1,739			—			1,739			3,000			—			3,000
Management fees		263			—			263			255			—			255
Other revenues		—			—			—			6			—			6
Total revenues		2,002			2,136			4,138			3,261			7,769			11,030
Expenses:
Patient care expense		—			2,313			2,313			—			7,476			7,476
Facility rent expense		149			—			149			923			528			1,451
Cost of management fees		156			—			156			140			—			140
Depreciation and amortization		472			54			526			590			10			600
General and administrative expense		950			22			972			975			403			1,378
Doubtful accounts expense		—			229			229			1,515			—			1,515
Other operating expenses		54			143			197			(80	)		521			441
Total expenses		1,781			2,761			4,542			4,063			8,938			13,001
Income (loss) from operations		221			(625	)		(404	)		(802	)		(1,169	)		(1,971	)
Other (income) expense:
Interest expense, net		669			39			708			633			(69	)		564
Other (income) expense, net		(541	)		402			(139	)		(2,164	)		—			(2,164	)
Total other (income) expense, net		128			441			569			(1,531	)		(69	)		(1,600	)
Net income (loss)	$	93		$	(1,066	)	$	(973	)	$	729		$	(1,100	)	$	(371	)

	Nine Months Ended September 30,									Nine Months Ended September 30,
	2023			2023			2023			2022			2022			2022
(Amounts in 000’s)	Real Estate Services			Healthcare Services			Total			Real Estate Services			Healthcare Services			Total
Revenues:
Patient care revenues	$	—		$	6,577		$	6,577		$	—		$	14,650		$	14,650
Rental revenues		5,170			—			5,170			10,326			—			10,326
Management fees		788			—			788			774			—			774
Other revenues		107			—			107			20			—			20
Total revenues		6,065			6,577			12,642			11,120			14,650			25,770
Expenses:
Patient care expense		—			7,010			7,010			—			14,040			14,040
Facility rent expense		446			—			446			3,899			826			4,725
Cost of management fees		442			—			442			459			—			459
Depreciation and amortization		1,578			160			1,738			1,796			23			1,819
General and administrative expense		2,970			220			3,190			2,660			772			3,432
Doubtful accounts expense		—			269			269			3,742			—			3,742
Other operating expenses		225			286			511			555			854			1,409
Total expenses		5,661			7,945			13,606			13,111			16,515			29,626
Income (loss) from operations		404			(1,368	)		(964	)		(1,991	)		(1,865	)		(3,856	)
Other (income) expense:
Interest expense, net		1,947			119			2,066			1,898			(43	)		1,855
Other (income) expense, net		—			620			620			(1,088	)		—			(1,088	)
Total other (income) expense, net		1,947			739			2,686			810			(43	)		767
Net income (loss)	$	(1,543	)	$	(2,107	)	$	(3,650	)	$	(2,801	)	$	(1,822	)	$	(4,623	)

XML

Organization and Significant Accounting Policies - Additional Information (Details)		3 Months Ended		9 Months Ended
	Aug. 03, 2023	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) Segment	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Finite Lived Intangible Assets [Line Items]
Maximum penalty for service contract nonperformance		$ 50,000		$ 50,000
Percentage of reserve for patient care revenue		1.50%		1.50%
Number of primary reporting segments | Segment				2
Receivables, estimated allowance for uncollectible accounts		$ 1,579,000		$ 1,579,000		$ 1,298,000
Accounts receivable, net of allowance		2,035,000		2,035,000		6,289,000
Prepaid expenses and other		900,000		900,000		700,000
Other expense, net		300,000	$ 200,000	800,000	$ 1,100,000
Increase in prepaid expenses and other				200,000
Other liabilities		1,707,000		1,707,000		1,131,000
Intrinsic Value		0		$ 0
Number of reportable segments | Segment				2
Accrued Expenses
Finite Lived Intangible Assets [Line Items]
Escheatment liabilities		800,000		$ 800,000		800,000
Stock options
Finite Lived Intangible Assets [Line Items]
Weighted average contractual terms				6 years 3 months 18 days
Warrants
Finite Lived Intangible Assets [Line Items]
Weighted average contractual terms				1 year 2 months 12 days
Wellington Lease Termination
Finite Lived Intangible Assets [Line Items]
Receivables, estimated allowance for uncollectible accounts		$ 1,600,000		$ 1,600,000		$ 1,300,000
Series B Cumulative Redeemable Preferred Shares
Finite Lived Intangible Assets [Line Items]
Preferred stock, fixed interest rate (percentage)	12.50%

XML

Organization and Significant Accounting Policies - Company's Accounts Receivable, Net of Allowance (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounts Notes And Loans Receivable [Line Items]
Gross receivables	$ 3,614	$ 7,587
Allowance	(1,579)	(1,298)
Accounts receivable, net of allowance	2,035	6,289
Real Estate Services
Accounts Notes And Loans Receivable [Line Items]
Gross receivables	908	1,094
Allowance	(338)	(338)
Healthcare Services
Accounts Notes And Loans Receivable [Line Items]
Gross receivables	2,706	6,493
Allowance	$ (1,241)	$ (960)

XML

Organization and Significant Accounting Policies - Company's Accounts Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounts Payable [Line Items]
Accounts payable	$ 2,783	$ 3,293
Real Estate Services
Accounts Payable [Line Items]
Accounts payable	1,052	797
Healthcare Services
Accounts Payable [Line Items]
Accounts payable	$ 1,731	$ 2,496

XML

Organization and Significant Accounting Policies - Anti-dilutive Securities (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Anti-dilutive securities outstanding that were excluded from the computation
Antidilutive securities	70	52
Stock options
Anti-dilutive securities outstanding that were excluded from the computation
Antidilutive securities	37	13
Warrants - employee
Anti-dilutive securities outstanding that were excluded from the computation
Antidilutive securities	32	34
Warrants - non employee
Anti-dilutive securities outstanding that were excluded from the computation
Antidilutive securities	1	5

XML

Liquidity - Additional Information (Details) - USD ($) $ in Thousands				9 Months Ended		12 Months Ended
	Oct. 21, 2022	Aug. 17, 2021	Aug. 16, 2021	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Aug. 11, 2023	Dec. 30, 2022
Management's plan for increasing liquidity
Unrestricted cash				$ 1,400
Cash flow from operations				3,460	$ (2,171)
Total indebtedness				51,378
Net of deferred financing costs and unamortized discounts, in indebtedness				1,100
Debt repayments of principal in next 12 months, amortization				2,300
Prepayment penalty				17
Deferred financing fees				1,100
Accounts payable				2,783		$ 3,293
Accumulated and unpaid dividends on series A preferred stock				50,400
Healthcare Services [Member]
Management's plan for increasing liquidity
Accounts Receivable				1,800
Accounts payable				1,731		2,496
Accounts payable				1,700
Key Bank Exit Notes
Management's plan for increasing liquidity
Debt instrument								$ 500
Maturity date		Aug. 25, 2025	Aug. 25, 2023
Routine debt
Management's plan for increasing liquidity
Debt repayments of principal in next 12 months, amortization				1,500
Insurance Financing Amortization
Management's plan for increasing liquidity
Debt repayments of principal in next 12 months, amortization				700
Bond Debt
Management's plan for increasing liquidity
Debt repayments of principal in next 12 months, amortization				$ 100
Promissory Note
Management's plan for increasing liquidity
Interest rate							8.00%
HUD Notes
Management's plan for increasing liquidity
Net of deferred financing costs and unamortized discounts, in indebtedness						200
Debt instrument	$ 7,600
Interest rate	3.97%
Net loss on extinguishment of debt						400
Prepayment penalty						200
Deferred financing fees						$ 200
HUD Notes | Northwood HUD Note
Management's plan for increasing liquidity
Debt instrument	$ 4,900
Maturity date	Nov. 01, 2052
HUD Notes | Greenfield HUD Note
Management's plan for increasing liquidity
Debt instrument	$ 1,900
Maturity date	Nov. 01, 2050
HUD Notes | Pavilion HUD Note
Management's plan for increasing liquidity
Debt instrument	$ 800
Maturity date	Dec. 01, 2039

XML

Liquidity - Summary of Lease Terminations (Details)	9 Months Ended
	Sep. 30, 2023
Meadowood
Liquidity [Line Items]
Date	2022-04
Former Operator	C.R. Management
Current Operator	Regional Health (managed by Cavalier Senior Living Operations)
Glenvue
Liquidity [Line Items]
Date	2022-08
Former Operator	C.R. Management
Current Operator	Regional Health

XML

Cash and Restricted Cash - Schedule of Cash and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Restricted Cash And Investments [Line Items]
Cash	$ 1,427	$ 843
Restricted cash:
HUD and other replacement reserves	2,138	2,155
Escrow deposits	635	459
Restricted investments for debt obligations	317	317
Total restricted cash	3,208	3,066
Total cash and restricted cash	4,635	3,909	$ 5,397	$ 9,848
Asset Pledged as Collateral without Right
Restricted cash:
Cash collateral	$ 118	$ 135

XML

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment	$ 68,818	$ 68,327
Less: accumulated depreciation and amortization	(23,012)	(21,716)
Property and equipment, net	45,806	46,611
Buildings and Improvements
Property, Plant and Equipment [Line Items]
Property and equipment	$ 64,429	63,746
Buildings and Improvements | Minimum
Property, Plant and Equipment [Line Items]
Useful lives	5 years
Buildings and Improvements | Maximum
Property, Plant and Equipment [Line Items]
Useful lives	40 years
Equipment and Computer Related
Property, Plant and Equipment [Line Items]
Property and equipment	$ 1,615	1,807
Equipment and Computer Related | Minimum
Property, Plant and Equipment [Line Items]
Useful lives	2 years
Equipment and Computer Related | Maximum
Property, Plant and Equipment [Line Items]
Useful lives	10 years
Land
Property, Plant and Equipment [Line Items]
Property and equipment	$ 2,774	$ 2,774

XML

Property and Equipment - Schedule of Property and Equipment (Parenthetical) (Details) $ in Millions	Sep. 30, 2023 USD ($)
Property, Plant and Equipment [Line Items]
Land improvements	$ 0.1
Land Improvements
Property, Plant and Equipment [Line Items]
Useful lives	5 years 3 months 18 days

XML

Property and Equipment - Schedule of Total Depreciation and Amortization Expense of Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 416	$ 490	$ 1,409	$ 1,490
Amortization	110	110	329	329
Total depreciation and amortization expense	$ 526	$ 600	$ 1,738	$ 1,819

XML

Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands		Sep. 30, 2023	Dec. 31, 2022
Intangible assets net excluding goodwill
Finite and indefinite lived intangible assets, gross		$ 16,953	$ 16,953
Finite and indefinite lived intangible assets, accumulated amortization		(5,008)	(4,678)
Intangible assets, net carrying amount		11,945	12,275
Goodwill Roll Forward
Goodwill, Gross		1,585	1,585
Goodwill, net carrying amount		1,585	1,585
Bed Licenses Separable
Intangible assets net excluding goodwill
Finite and indefinite lived intangible assets, gross	[1]	2,471	2,471
Intangible assets, net carrying amount	[1]	2,471	2,471
Bed Licenses Included in Property and Equipment
Intangible assets net excluding goodwill
Finite and indefinite lived intangible assets, gross	[2]	14,276	14,276
Finite and indefinite lived intangible assets, accumulated amortization	[2]	(4,894)	(4,583)
Intangible assets, net carrying amount	[2]	9,382	9,693
Lease Rights
Intangible assets net excluding goodwill
Finite and indefinite lived intangible assets, gross		206	206
Finite and indefinite lived intangible assets, accumulated amortization		(114)	(96)
Intangible assets, net carrying amount		$ 92	$ 110

[1] The Company does not amortize indefinite-lived intangibles, which consist of separable bed licenses and goodwill

[2] Non-separable bed licenses are included in property and equipment as is the related accumulated amortization expense (see Note 4 – Property and Equipment).

XML

Intangible Assets and Goodwill - Schedule of Total Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Finite Lived Intangible Assets [Line Items]
Amortization	$ 110	$ 110	$ 329	$ 329
Bed Licenses Included in Property and Equipment
Finite Lived Intangible Assets [Line Items]
Amortization	104	104	311	311
Lease Rights
Finite Lived Intangible Assets [Line Items]
Amortization	$ 6	$ 6	$ 18	$ 18

XML

Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense for All Definite Lived Intangibles (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Bed Licenses Included in Property and Equipment
Finite Lived Intangible Assets [Line Items]
2023 (6 months remaining)	$ 103
2024	414
2025	414
2026	414
2027	414
Thereafter	7,623
Total expected amortization expense	9,382
Lease Rights
Finite Lived Intangible Assets [Line Items]
2023 (6 months remaining)	6
2024	24
2025	24
2026	24
2027	14
Total expected amortization expense	$ 92

XML

Leases - Operating Leases - Additional Information (Details)	9 Months Ended
	Sep. 30, 2023 ft² Facility
Operating Leased Assets [Line Items]
Number of SNFs under non-cancelable operating leases | Facility	1
Lease termination , descreption	The Company also leased certain office space located in Suwanee, Georgia through the termination date of June 30, 2023.
Facility
Operating Leased Assets [Line Items]
Weighted average remaining lease term	5 years 7 months 6 days
Office lease
Operating Leased Assets [Line Items]
Weighted average remaining lease term	1 year 9 months 18 days
GEORGIA
Operating Leased Assets [Line Items]
Office space subleased | ft²	2,000
Sublease expiration date	Jul. 31, 2025

XML

Leases - Schedule of Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Future Rental Payments [Abstract]
2023 (3 months remaining)	$ 156
2024	633
2025	645
2026	658
2027	671
Thereafter	914
Total	3,677
Accretion of Lease Liability [Abstract]
2023 (3 months remaining)	(2)	[1]
2024	(39)	[1]
2025	(85)	[1]
2026	(131)	[1]
2027	(174)	[1]
Thereafter	(298)	[1]
Total	(729)	[1]
Operating Lease Obligation [Abstract]
2023 (3 months remaining)	154
2024	594
2025	560
2026	527
2027	497
Thereafter	616
Total	$ 2,948

[1] Weighted average discount rate 3.85%.

XML

Leases - Schedule of Future Minimum Lease Payments (Parenthetical) (Details)	Sep. 30, 2023
Leases [Abstract]
Weighted average discount rate	3.85%

XML

Leases - Facilities Lessor - Additional Information (Details)		9 Months Ended
	Aug. 11, 2023 USD ($)	Sep. 30, 2023 USD ($) Facility
Lessor, Lease, Description [Line Items]
Lease amendment, decrease in monthly rent | $	$ 43,000
Lease amendment, included promissory note | $	$ 312,000	$ 0
Lease expiration date	Oct. 31, 2024
Number of owned facilities | Facility		11
Number of owned facilities, Lessor | Facility		9
Number of owned facilities, Sub lessor | Facility		1
Weighted average remaining sublease term, Facilities lessor		5 years 6 months
Promissory Note
Lessor, Lease, Description [Line Items]
Interest rate principal sum plus all accrued interest	8.00%
Promissory Note | Minimum
Lessor, Lease, Description [Line Items]
Minimum monthly payments of principal and interest | $	$ 18,353

XML

Leases - Schedule of Future Minimum Lease Receivables from Company's Facilities Leased and Subleased to Third Party Tenants (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Operating Leases, Future Minimum Payments Receivable [Abstract]
2023 (3 months remaining)	$ 1,577
2024	6,187
2025	6,034
2026	5,362
2027	5,445
Thereafter	11,605
Total	$ 36,210

XML

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands		Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued employee benefits and payroll-related		$ 328	$ 539
Real estate and other taxes	[1]	2,891	2,428
Self-insured reserve		62	80
Accrued interest		222	210
Unearned rental revenue			43
Medicaid overpayment - Healthcare Services		56	169
Insurance escrow		79
Other accrued expenses		1,168	1,567
Total accrued expenses		$ 4,806	$ 5,036

[1] September 30, 2023 includes approximately $2.5 million of franchise tax accruals for the Healthcare Services segment. December 31, 2022 includes approximately $2.2 million of franchise tax accruals for the Healthcare Services segment.

XML

Accrued Expenses - Schedule of Accrued Expenses (Parenthetical) (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Healthcare Services Segment
Payables And Accruals [Line Items]
Franchise Tax	$ 2.5	$ 2.2

XML

Notes Payable and Other Debt - Summary of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Debt instrument, outstanding amount	$ 52,464	$ 53,302
Deferred financing costs	(971)	(1,005)
Unamortized discount on bonds	(115)	(119)
Notes payable and other debt	51,378	52,178
Senior debt - guaranteed by HUD
Debt Instrument [Line Items]
Debt instrument, outstanding amount	29,183	29,782
Senior debt - guaranteed by USDA
Debt Instrument [Line Items]
Debt instrument, outstanding amount	7,332	7,526
Senior debt - guaranteed by SBA
Debt Instrument [Line Items]
Debt instrument, outstanding amount	562	580
Senior debt Bonds, net of discount
Debt Instrument [Line Items]
Debt instrument, outstanding amount	6,117	6,253
Senior debt - other mortgage indebtedness
Debt Instrument [Line Items]
Debt instrument, outstanding amount	8,089	8,266
Other Debt
Debt Instrument [Line Items]
Debt instrument, outstanding amount	$ 1,181	$ 895

XML

Notes Payable and Other Debt - Details of Long-term Debt (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Debt instrument, outstanding amount	$ 52,464	$ 53,302
Senior debt - guaranteed by HUD
Debt Instrument [Line Items]
Debt instrument, outstanding amount	29,183	29,782
Senior debt - guaranteed by USDA
Debt Instrument [Line Items]
Debt instrument, outstanding amount	7,332	7,526
Senior debt - guaranteed by SBA
Debt Instrument [Line Items]
Debt instrument, outstanding amount	562	580
Senior Debt Other Mortgage Indebtedness
Debt Instrument [Line Items]
Debt instrument, outstanding amount	8,089	8,266
Senior Debt Obligations | Senior debt - guaranteed by HUD
Debt Instrument [Line Items]
Debt instrument, outstanding amount	29,184	29,782
Senior Debt Obligations | Senior debt - guaranteed by USDA
Debt Instrument [Line Items]
Debt instrument, outstanding amount	7,332	7,526
Senior Debt Obligations | Senior debt - guaranteed by SBA
Debt Instrument [Line Items]
Debt instrument, outstanding amount	562	580
Other Debt
Debt Instrument [Line Items]
Debt instrument, outstanding amount	$ 1,181	895
Newpoint Capital | The Pavilion Care Center | Senior Debt Obligations | Senior debt - guaranteed by HUD
Debt Instrument [Line Items]
Maturity date	Dec. 01, 2039
Interest rate	3.97%
Debt instrument, outstanding amount	$ 810	835
Newpoint Capital | Hearth And Care Of Greenfield | Senior Debt Obligations | Senior debt - guaranteed by HUD
Debt Instrument [Line Items]
Maturity date	Aug. 01, 2050
Interest rate	3.97%
Debt instrument, outstanding amount	$ 1,919	1,949
Newpoint Capital | Woodland Manor | Senior Debt Obligations | Senior debt - guaranteed by HUD
Debt Instrument [Line Items]
Maturity date	Nov. 01, 2052
Interest rate	3.97%
Debt instrument, outstanding amount	$ 4,913	4,980
Newpoint Capital | Glenvue H&R | Senior Debt Obligations | Senior debt - guaranteed by HUD
Debt Instrument [Line Items]
Maturity date	Oct. 01, 2044
Interest rate	3.75%
Debt instrument, outstanding amount	$ 7,134	7,297
Newpoint Capital | Georgetown Health | Senior Debt Obligations | Senior debt - guaranteed by HUD
Debt Instrument [Line Items]
Maturity date	Oct. 01, 2046
Interest rate	2.98%
Debt instrument, outstanding amount	$ 3,144	3,214
KeyBank | Other Debt
Debt Instrument [Line Items]
Maturity date	Aug. 25, 2025
Interest rate	0.00%
Debt instrument, outstanding amount	$ 495	495
KeyBank | Autumn Breeze | Senior Debt Obligations | Senior debt - guaranteed by HUD
Debt Instrument [Line Items]
Maturity date	Jan. 01, 2045
Interest rate	3.65%
Debt instrument, outstanding amount	$ 6,203	6,344
KeyBank | Sumter Valley | Senior Debt Obligations | Senior debt - guaranteed by HUD
Debt Instrument [Line Items]
Maturity date	Jan. 01, 2047
Interest rate	3.70%
Debt instrument, outstanding amount	$ 5,061	5,163
Marlin Capital Solutions | Other Debt
Debt Instrument [Line Items]
Maturity date	Jun. 01, 2027
Interest rate	5.00%
Debt instrument, outstanding amount	$ 28	43
Community Bank | Mountain Trace Rehab | Senior Debt Obligations | Senior debt - guaranteed by USDA
Debt Instrument [Line Items]
Maturity date	Dec. 24, 2036
Debt instrument, outstanding amount	$ 3,575	3,680
Effective interest rate (as a percent)	10.00%
Community Bank | Mountain Trace Rehab | Senior Debt Obligations | Senior debt - guaranteed by USDA | Prime Rate
Debt Instrument [Line Items]
Basis spread	1.75%
Cadence Bank N A | Southland Healthcare | Senior Debt Obligations | Senior debt - guaranteed by USDA
Debt Instrument [Line Items]
Maturity date	Jul. 27, 2036
Debt instrument, outstanding amount	$ 3,757	3,846
Effective interest rate (as a percent)	9.75%
Cadence Bank N A | Southland Healthcare | Senior Debt Obligations | Senior debt - guaranteed by USDA | Prime Rate
Debt Instrument [Line Items]
Basis spread	1.50%
Cadence Bank N A | Southland Healthcare | Senior Debt Obligations | Senior debt - guaranteed by SBA
Debt Instrument [Line Items]
Maturity date	Jul. 27, 2036
Debt instrument, outstanding amount	$ 562	580
Effective interest rate (as a percent)	10.50%
Cadence Bank N A | Southland Healthcare | Senior Debt Obligations | Senior debt - guaranteed by SBA | Prime Rate
Debt Instrument [Line Items]
Basis spread	2.25%
City of Springfield | Eaglewood Care Center | Bonds | Bonds Series A
Debt Instrument [Line Items]
Maturity date	May 01, 2042
Interest rate	7.65%
Debt instrument, outstanding amount	$ 6,117	6,253
Exchange Bank Of Alabama | Meadowood Facility
Debt Instrument [Line Items]
Maturity date	Oct. 01, 2026
Effective interest rate (as a percent)	4.50%
Exchange Bank Of Alabama | Meadowood Facility | Senior Debt Other Mortgage Indebtedness
Debt Instrument [Line Items]
Debt instrument, outstanding amount	$ 3,279	3,319
Exchange Bank Of Alabama | Coosa Valley Health Care
Debt Instrument [Line Items]
Maturity date	Oct. 10, 2026
Effective interest rate (as a percent)	3.95%
Exchange Bank Of Alabama | Coosa Valley Health Care | Senior Debt Other Mortgage Indebtedness
Debt Instrument [Line Items]
Debt instrument, outstanding amount	$ 4,810	4,946
First Insurance Funding | Other Debt
Debt Instrument [Line Items]
Maturity date	Various 2023
Interest rate	3.19%
Debt instrument, outstanding amount	$ 658	$ 357

XML

Notes Payable and Other Debt - Details of Long-term Debt (Parenthetical) (Details) $ in Millions			9 Months Ended
	Dec. 30, 2022	Oct. 01, 2021	Sep. 30, 2023 Facility Bed	Sep. 30, 2021 USD ($)
Meadowood Facility
Debt Instrument [Line Items]
Debt instrument maturity date start range		May 01, 2022
Debt instrument maturity date end range		Oct. 01, 2026
Coosa Valley Health Care
Debt Instrument [Line Items]
Prepayment penalties capped percentage				5.00%
Prepayment penalties percentage capped thereafter				1.00%
New fees amount | $				$ 0.1
Default interest rate				5.00%
Prepayment penalties capped percentage in second year				4.00%
KeyBank
Debt Instrument [Line Items]
Debt instrument maturity date start range	Aug. 25, 2023
Debt instrument maturity date end range	Aug. 25, 2025
Senior debt - guaranteed by HUD
Debt Instrument [Line Items]
Number of skilled nursing facilities			7
Percentage of debt insured			100.00%
Senior debt - guaranteed by USDA
Debt Instrument [Line Items]
Number of skilled nursing facilities			2
Annual renewal fee for the USDA guarantee (as a percent)			0.25%
Debt Instrument Prepayment Penalties Percentage			1.00%
Prepayment penalties capped percentage			1.00%
Prepayment penalties percentage capped, period			10 years
Prepayment penalties percentage capped thereafter			0.00%
Senior debt - guaranteed by SBA
Debt Instrument [Line Items]
Number of skilled nursing facilities			1
Percentage of debt insured			75.00%
Number of licensed beds | Bed			126
Senior debt Bonds, net of discount
Debt Instrument [Line Items]
Amortization of deferred financing costs (in percentage)			0.10%
Senior debt - other mortgage indebtedness
Debt Instrument [Line Items]
Amortization of deferred financing costs (in percentage)			0.34%
Minimum
Debt Instrument [Line Items]
Amortization of deferred financing costs (in percentage)			0.09%
Minimum | Senior debt - guaranteed by USDA
Debt Instrument [Line Items]
Percentage of debt insured			70.00%
Maximum
Debt Instrument [Line Items]
Amortization of deferred financing costs (in percentage)			0.53%
Maximum | Senior debt - guaranteed by USDA
Debt Instrument [Line Items]
Percentage of debt insured			80.00%

XML

Notes Payable and Other Debt - Additional Information (Details)	Sep. 30, 2023 Credit_instrument
Debt Disclosure [Abstract]
Number of credit related instruments	16

XML

Notes Payable and Other Debt - Summary of the Scheduled Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
2023 (3 months remaining)	$ 660
2024	2,046
2025	2,269
2026	8,746
2027	1,562
Thereafter	37,181
Subtotal	52,464	$ 53,302
Less: unamortized discounts	(115)	(119)
Less: deferred financing costs, net	(971)	$ (1,005)
Total notes and other debt	$ 51,378

XML

Common and Preferred Stock - Additional Information (Details) - USD ($)			3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 27, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Class of Stock [Line Items]
Common stock, shares authorized			55,000,000		55,000,000		55,000,000
Common stock, shares issued			1,894,000		1,894,000		1,793,000
Common stock, shares outstanding			1,883,028		1,883,028		1,784,000
Gain on extinguishment of preferred stock					$ 43,395,000
Subsequent Amendment of Prior Charter
Class of Stock [Line Items]
Preferred stock, shares authorized		5,000,000
Common stock, shares authorized		55,000,000
Subsequent Amendment of Prior Charter | Maximum
Class of Stock [Line Items]
Shares authorized		60,000,000
Certain Amendments to Prior Charter
Class of Stock [Line Items]
Preferred stock, shares authorized		6,000,000
Common stock, shares authorized		55,000,000
Certain Amendments to Prior Charter | Maximum
Class of Stock [Line Items]
Shares authorized		61,000,000
Series A Preferred Stock
Class of Stock [Line Items]
Preferred stock, fixed interest rate (percentage)		10.875%
Preferred stock, shares outstanding			560,000		560,000		2,812,000
Percentage of outstanding preferred stock tendered	80.10%
Preferred stock, shares issued	560,000		560,000		560,000		2,812,000
Preferred stock, shares tendered	2,252,272
Preferred stock, shares authorized			560,000		560,000		5,000,000
Preferred stock, redemption price per share		$ 5
Preferred stock terms					Series A Preferred Stock when voting as a single class with any other class or series of stock to one vote per $5.00 liquidation preference
Stock retired and exchanged					2,252,272
Dividends paid, preferred stock			$ 0	$ 0	$ 0	$ 0
Unpaid dividends forteited			50,400,000		50,400,000
Stated liquidation preference		5
Gain on extinguishment of preferred stock					$ 43,400,000
Fair value of the preferred stock per share					$ 0.76
Redemption price per share		$ 5
Preferred stock, redemption amount			$ 426,000		$ 426,000		$ 70,288,000
Series A Preferred Stock | Temporary Amendment of Prior Charter | Maximum
Class of Stock [Line Items]
Preferred stock, shares authorized		6,000,000
Series A Preferred Stock | Subsequent Amendment of Prior Charter | Maximum
Class of Stock [Line Items]
Preferred stock, shares authorized		5,000,000
Series B Preferred Stock
Class of Stock [Line Items]
Preferred stock, fixed interest rate (percentage)					12.50%
Preferred stock, shares outstanding			2,252,272		2,252,272		0
Preferred stock, shares issued	2,252,272		2,252,272		2,252,272		0
Preferred stock, shares authorized			2,812,000		2,812,000		0
Dividend period commencing date						Jul. 01, 2027
Stock retired and exchanged					2,252,272
Dividends paid, preferred stock			$ 0	0	$ 0	$ 0
Stated liquidation preference			$ 10		$ 10
Preferred stock liquidation preference reduced per share					5
Preferred stock liquidation preference increase over time					25
Fair value of the preferred stock per share					$ 8.26
Preferred stock, redemption amount			$ 18,602,000		$ 18,602,000
Series B Preferred Stock | Maximum
Class of Stock [Line Items]
Preferred stock, shares outstanding			200,000		200,000
Series E Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding			0		0
Preferred stock, shares issued			0		0
Dividends payable date declared					Feb. 13, 2023
Dividends payable, date of record					Feb. 27, 2023
Dividends payable, date to be paid					Feb. 28, 2023
Terms of dividend payment					On February 13, 2023, the Board declared a dividend of one one-thousandth of a share of Series E Preferred Stock for each outstanding share of common stock, payable on February 28, 2023 to shareholders of record at 5:00 p.m. Eastern Time on February 27, 2023 (the “Dividend Record Date”).
Common Stock
Class of Stock [Line Items]
Common stock, shares authorized			55,000,000		55,000,000
Common stock, shares issued			1,893,908		1,893,908
Dividends paid, common stock			$ 0	$ 0	$ 0	$ 0
Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding			2,811,535		2,811,535
Preferred stock, shares issued			2,811,535		2,811,535
Preferred stock, shares authorized			5,000,000		5,000,000

XML

Stock Based Compensation - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 15, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 300,000
Employee | Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	0
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 300,000
Period of recognition of compensation expense	2 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, granted during the period	24,000
2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards made under employee stock option plan	0
Incentive stock options may be granted after 10th anniversary of date of Board approval	0
Number of securities remaining available for future issuance	52,805
2011 plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares of the company's stock that may be issued		168,950
Additional award granted	0
Maximum | 2020 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares of the company's stock that may be issued	250,000

XML

Stock Based Compensation - Summary of Recognized Stock Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 85	$ 58	$ 321	$ 173
Employee | Stock compensation expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	85	58	321	227
Employee | Forfeitures of Stock Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 0	$ 0	$ 0	$ (54)

XML

Stock Based Compensation - Summary of Company's Restricted Stock Activity (Details) - Restricted Stock shares in Thousands	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Number of Shares (000's)
Unvested at the beginning of the period (in shares) | shares	51
Granted (in shares) | shares	99
Vested (in shares) | shares	(26)
Unvested at the end of the period (in shares) | shares	124
Weighted Average Grant Date Fair Value
Unvested at the beginning of the period (in dollars per share) | $ / shares	$ 8.99
Granted (in dollars per share) | $ / shares	3.61
Vested (in dollars per share) | $ / shares	9.06
Unvested at the ending of the period (in dollars per share) | $ / shares	$ 4.68

XML

Stock Based Compensation - Summary of Company's Stock Option Activity (Details) - Stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (shares)	13
Granted, number of shares	24
Ending balance (shares)	37	13
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning balance (USD per share)	$ 47.53
Granted, weighted average exercise price	3.32
Ending balance (USD per share)	$ 18.63	$ 47.53
Additional disclosures
Outstanding and vested - weighted average remaining contractual life	6 years 3 months 18 days	1 year 7 months 6 days
Outstanding and vested, aggregate intrinsic value	$ 0	$ 0

XML

Stock Based Compensation - Schedule of Exercise Price Range (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding, number (shares) | shares	37
Stock options outstanding, weighted average remaining contractual term (in years)	6 years 3 months 18 days
Stock options outstanding, weighted average exercise price (USD per share) | $ / shares	$ 18.63
Stock options exercisable, shares vested and exercisable (shares) | shares	37
Stock options exercisable, weighted average exercise price (USD per share) | $ / shares	$ 18.63
$3.32
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding, number (shares) | shares	24
Stock options outstanding, weighted average remaining contractual term (in years)	9 years 3 months 18 days
Stock options outstanding, weighted average exercise price (USD per share) | $ / shares	$ 3.32
Stock options exercisable, shares vested and exercisable (shares) | shares	24
Stock options exercisable, weighted average exercise price (USD per share) | $ / shares	$ 3.32
$46.80 - $48.72
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding, number (shares) | shares	13
Stock options outstanding, weighted average remaining contractual term (in years)	10 months 24 days
Stock options outstanding, weighted average exercise price (USD per share) | $ / shares	$ 47.42
Stock options exercisable, shares vested and exercisable (shares) | shares	13
Stock options exercisable, weighted average exercise price (USD per share) | $ / shares	$ 47.42

XML

Stock Based Compensation - Schedule of Exercise Price Range (Parenthetical) (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares
$3.32
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price, (USD per share)	$ 3.32
$46.80 - $48.72
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price, minimum (USD per share)	46.8
Exercise price, maximum (USD per share)	$ 48.72

XML

Stock Based Compensation - Schedule of Common Stock Warrant Activity (Details) - Warrants - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding and vested at the beginning of the period (in shares)	35
Expired (in shares)	(2)
Outstanding and vested at the ending of the period (in shares)	33	35
Outstanding and vested at the beginning of the period (in dollars per share)	$ 53.31
Expired (in dollars per share)	70.8
Outstanding and vested at the ending of the period (in dollars per share)	$ 52.38	$ 53.31
Weighted average remaining contractual term (in years)	1 year 2 months 12 days	1 year 10 months 24 days

XML

Commitments and Contingencies - Additional Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) Case	Dec. 31, 2022 USD ($)
Loss Contingencies [Line Items]
Pending litigation	10
Self-insured reserve | $	$ 62	$ 80
Accounts Payable
Loss Contingencies [Line Items]
Self-insured reserve | $	100	100
Accrued Expenses
Loss Contingencies [Line Items]
Self-insured reserve | $	$ 100	$ 200
Professional and General Liability Actions
Loss Contingencies [Line Items]
Pending litigation	9
Professional and General Liability Actions | Patient Care that Current or Prior Tenants Provided to their Patients
Loss Contingencies [Line Items]
Pending litigation	9
ARKANSAS | Pending Litigation
Loss Contingencies [Line Items]
Loss contingency claims after disposal of facilities	4

XML

Segment Results - Additional Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) Segment	Dec. 31, 2022 USD ($)
Segment Reporting Information [Line Items]
Number of primary reporting segments | Segment	2
Description of primary reporting segments	(i) Real Estate Services, which consists of the leasing and subleasing of long-term care and senior living facilities to third-party tenants, including the Company's management of three facilities on behalf of third-party owners; and (ii) Healthcare Services, which consists of the operation of the Meadowood and Glenvue facilities.
Assets	$ 64,009	$ 68,580
Real Estate Services
Segment Reporting Information [Line Items]
Assets	57,000	63,500
Healthcare Services Segment
Segment Reporting Information [Line Items]
Assets	$ 7,000	$ 5,600

XML

Segment Results - Summary of Results of Operations for Reporting Segments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Total revenues	$ 4,138	$ 11,030	$ 12,642	$ 25,770
Rental revenues	1,739	3,000	5,170	10,326
Expenses:
Patient care expense	2,313	7,476	7,010	14,040
Facility rent expense	149	1,451	446	4,725
Cost of management fees	156	140	442	459
Depreciation and amortization	526	600	1,738	1,819
General and administrative expense	972	1,378	3,190	3,432
Doubtful accounts expense	229	1,515	269	3,742
Other operating expenses	197	441	511	1,409
Total expenses	4,542	13,001	13,606	29,626
Loss from operations	(404)	(1,971)	(964)	(3,856)
Other (income) expense:
Interest expense, net	708	564	2,066	1,855
Other (income) expense, net	(139)	(2,164)	620	(1,088)
Total other (income) expense, net	569	(1,600)	2,686	767
Net loss	(973)	(371)	(3,650)	(4,623)
Patient Care Revenues
Revenues:
Total revenues	2,136	7,769	6,577	14,650
Management Fees
Revenues:
Total revenues	263	255	788	774
Other Revenues
Revenues:
Total revenues	0	6	107	20
Real Estate Services
Revenues:
Total revenues	2,002	3,261	6,065	11,120
Rental revenues	1,739	3,000	5,170	10,326
Expenses:
Facility rent expense	149	923	446	3,899
Cost of management fees	156	140	442	459
Depreciation and amortization	472	590	1,578	1,796
General and administrative expense	950	975	2,970	2,660
Doubtful accounts expense		1,515		3,742
Other operating expenses	54	(80)	225	555
Total expenses	1,781	4,063	5,661	13,111
Loss from operations	221	(802)	404	(1,991)
Other (income) expense:
Interest expense, net	669	633	1,947	1,898
Other (income) expense, net	(541)	(2,164)		(1,088)
Total other (income) expense, net	128	(1,531)	1,947	810
Net loss	93	(729)	(1,543)	(2,801)
Real Estate Services | Management Fees
Revenues:
Total revenues	263	255	788	774
Real Estate Services | Other Revenues
Revenues:
Total revenues	0	6	107	20
Healthcare Services Segment
Revenues:
Total revenues	2,136	7,769	6,577	14,650
Expenses:
Patient care expense	2,313	7,476	7,010	14,040
Facility rent expense		528		826
Depreciation and amortization	54	10	160	23
General and administrative expense	22	403	220	772
Doubtful accounts expense	229		269
Other operating expenses	143	521	286	854
Total expenses	2,761	8,938	7,945	16,515
Loss from operations	(625)	(1,169)	(1,368)	(1,865)
Other (income) expense:
Interest expense, net	39	(69)	119	(43)
Other (income) expense, net	402		620
Total other (income) expense, net	441	(69)	739	(43)
Net loss	(1,066)	(1,100)	(2,107)	(1,822)
Healthcare Services Segment | Patient Care Revenues
Revenues:
Total revenues	$ 2,136	$ 7,769	$ 6,577	$ 14,650